ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

Committee Members
Thomas J. Ryan, MD, FACC, Chair; Elliott M. Antman, MD, FACC; Neil H. Brooks, MD, FAAFP.; Robert M. Califf, MD, FACC; L. David Hillis, MD, FACC; Loren F. Hiratzka, MD, FACC; Elliot Rapaport, MD, FACC; Barbara Riegel, DNSc, FAAN; Richard O. Russell, MD, FACC; Earl E. Smith III, MD, FACEP; W. Douglas Weaver, MD, FACC

Task Force Members
Raymond J. Gibbons, MD, FACC, Chair; Jospeh S. Alpert, MD, FACC; Kim A. Eagle, MD, FACC; Gabriel Gregoratos, MD, FACC; Timothy J. Gardner, MD, FACC; Arthur Garson, Jr, MD, MPH, FACC; Richard O. Russell, MD, FACC; Thomas J. Ryan, MD, FACC; Sidney C. Smith, Jr, MD, FACC

The "1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction" was approved by the American College of Cardiology Board of Trustees in June 1999 and the American Heart Association Science Advisory and Coordinating Committee in June 1999.


© 1999 by The American College of Cardiology and the American Heart Association, Inc.
ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction

These guidelines have been reviewed over the course of the past 2 and 1/2 years since their initial publication in the Journal of the American College of Cardiology, (J Am Coll Cardiol 1996;28:1328-428). This update is based on what the committee believes are the most relevant and significant advances established for the management of patients with acute myocardial infarction made during that time frame. The guidelines are available on the Web sites of both the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). Deleted text is indicated by strikeout, and revised text is presented in red. Reprints of the 1996 document as published in the Journal of the American College of Cardiology with the revised sections appended are available on request from both organizations.

Contents

I. Preamble and Introduction

II. Prehospital Issues
   Recommendations
   Recognition and Management
      Intervention Strategies
      Emergency Medical Systems
      Prehospital-Initiated Thrombolysis

III. Initial Recognition and Management in the Emergency Department
   Recommendation
   Detection/Quantification and Risk Assessment
   Serum Cardiac Markers
   Routine Measures (Oxygen, Nitroglycerin, Aspirin)
      Recommendations
      Oxygen
         Recommendations
      Nitroglycerin
         Recommendations for Intravenous Nitroglycerin
      Analgesia
      Aspirin
         Recommendations

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Atropine

Recommendations
Side Effects
Risk Stratification and Management of ST-Segment Elevation/Bundle Branch Block Cohort

Newer Concepts
Noninvasive Imaging in the Emergency Department
Thrombolysis
Recommendations
Risk of Stroke
Net Clinical Benefit
Contraindications/Cautions

Primary Percutaneous Transluminal Coronary Angioplasty
Recommendations
Recommendations for Early Coronary Angiography in the ST-Segment Elevation or Bundle Branch Block Cohort Not Undergoing
Primary Percutaneous Transluminal Coronary Angioplasty
Recommendations for Emergency or Urgent Coronary Artery Bypass Graft Surgery

Risk Stratification and Management in Non-ST-Segment Elevation Cohort

Recommendations for Early Coronary Angiography and/or Interventional Therapy
Patient Characteristics
Pharmacological Therapy in Patients in the Non-ST-Segment Elevation Cohort
Antithrombotic Therapy
Glycoprotein IIb/IIIa Inhibitors
Low-Molecular Weight Heparin and Direct Antithrombins
Interventional Therapy
Glucose-Insulin-Potassium Infusion

IV. Hospital Management
Early, General Measures
Recommendations
Monitoring for Adverse Events
Level of Activity
Proper Analgesia (Use of Morphine, Anxiolytics, and the Role of Education)
Treatment of Adverse Events
Identification and Treatment of the Patient at Low Risk
Triage of Patients With Acute Myocardial Infarction and Other Coronary Syndromes
Summary of Identification and Treatment of the Patient at Low Risk
Identification and Treatment of the Patient at High Risk
Recommendations for Management of Recurrent
Chest Discomfort
Recurrent Chest Pain in the Post-MI Patient:
Pericarditis and Ischemia
Heart Failure and Low-Output Syndromes
  Left Ventricular Dysfunction
  Right Ventricular Infarction and Dysfunction
  Anatomic and Pathophysiological Considerations
  Clinical Diagnosis
  Management of Right Ventricular Ischemia/Infarction
  Prognosis
Hemodynamic Monitoring
  Recommendations for Balloon Flotation
  Right-Heart Catheter Monitoring
  Recommendations for Intra-arterial Pressure Monitoring
  Recommendations for Intra-aortic Balloon Counterpulsation
Rhythm Disturbances
  Atrial Fibrillation
    Recommendations
  Ventricular Tachycardia/Ventricular Fibrillation
    Recommendations
    Ventricular Fibrillation-Background
    Management Strategies for Ventricular Fibrillation
    Ventricular Tachycardia-Background
    Management Strategies for Ventricular Tachycardia
Bradyarrhythmias and Heart Block
  Background, Epidemiology, and Importance
  Prognosis
  Treatment
  Recommendations for Atropine
Temporary Pacing
  Recommendations for Placement of Transcutaneous Patches and Active (Demand) Transcutaneous acing
  Recommendations for Temporary Transvenous Pacing
Permanent Pacing After Acute Myocardial Infarction
  Recommendations

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Other Surgical Interventions
Recommendations for Emergency or Urgent Cardiac Repair of Mechanical Defects
Clinical Situations Leading to Coronary Artery Bypass Graft Surgery
Evolving Myocardial Infarction
Failed Percutaneous Transluminal Coronary Angioplasty
Postthrombolytic Therapy
Recurrence Ischemia
Elective Coronary Artery Bypass Graft Surgery
Surgery After Acute Myocardial Infarction
Ventricular Tachyarrhythmias
Patients With Prior Coronary Artery Bypass Graft Surgery
Patients Undergoing Cardiopulmonary Resuscitation
Intraoperative Myocardial Protection in the Acutely Injured Heart
Management of Mechanical Defects After Acute Myocardial Infarction
Diagnosis
Acute Mitral Valve Regurgitation
Postinfarction Ventricular Septal Defect
Left Ventricular Free Wall Rupture
Left Ventricular Aneurysm
Mechanical Support of the Failing Heart
Transplantation After Acute Myocardial Infarction
Relation Between Volume of Surgery and Outcome
Minimum Operative Caseload
Case Selection Concerns

V. Rationale and Approach to Pharmacotherapy
Nitroglycerin
Mechanism of Action
Pharmacokinetics and Dosage
Limitations and Adverse Effects
Clinical Trials
Aspirin and Other Platelet-Active Drugs
Mechanism of Action of Aspirin
Aspirin in Prevention of Thrombotic Complications of Atherosclerosis
Aspirin: Risk of Hemorrhagic Stroke
Aspirin: Side Effects and Dosage
Ticlopidine and Clopidogrel
Rationale for Thrombolytic Therapy
Background
Thrombolytic Agents: General Mechanisms of
Action and Pharmacological Properties
Efficacy of Intravenous Thrombolytic Therapy in Acute Myocardial Infarction
Benefits of Thrombolytic Therapy in Specific Patient Subgroups
Comparative Thrombolytic Efficacy
Considerations in Selecting Thrombolytic Regimens
Current Use Rates for Thrombolytic Therapy
Antithrombotics/Anticoagulants
Unfractionated Heparin
Low-Molecular-Weight Heparins Antiarrhythmics
Lidocaine
Bretylium
Procaainamide
β-Adrenoceptor Blockers
Amiodarone
β-Adrenoceptor Blocking Agents
  Recommendations for Early Therapy and Discussion
Contraindications
Angiotensin Converting Enzyme Inhibitors
  Recommendations and Discussion
Calcium Channel Blockers
  Recommendations
Nifedipine
Verapamil
Diltiazem
  Summary of Calcium Channel Blockers
Magnesium
  Recommendations
  Background
Inotropic Agents
  Digitalis
VI. Preparation for Discharge From the Hospital

Noninvasive Evaluation of Low-Risk Patients

Recommendations
- Role of Exercise Testing
- Supplemental Imaging
  - Exercise Myocardial Perfusion Imaging
- Role of Echocardiography
  - Risk Stratification After Myocardial Infarction
  - Myocardial Viability
- Left Ventricular Function
- Radionuclide Testing for the Diagnosis of Acute Myocardial Infarction
- Measurement of Infarct Size
- Summary of Stress Testing After Acute Myocardial Infarction
- Ambulatory Electrocardiographic Monitoring for Ischemia
- Assessment of Ventricular Arrhythmia
  - (Signal-Averaged Electrocardiography, Ambulatory [Holter] Monitoring, Heart Rate Variability)
  - Recommendations for Routine Testing and Discussion

Summary/Conclusions

Invasive Evaluation
- Coronary Angiography and Possible Percutaneous Transluminal Coronary Angioplasty

Recommendations
- Coronary Angiography in the Survivor of Myocardial Infarction Not Receiving Thrombolytic Therapy
- Coronary Angiography and Possible Percutaneous Transluminal Coronary Angioplasty After Thrombolytic Therapy
- Adjuvant Percutaneous Transluminal Coronary Angioplasty
  - Immediately After Failed Thrombolysis
  - Hours to Days After Failed Thrombolysis
- Routine Coronary Angiography and Percutaneous Transluminal Coronary Angioplasty After Successful Thrombolytic Therapy
  - Recommendations
    - Immediately After Successful Thrombolysis
    - Hours to Days After Successful Thrombolysis
    - Days to Weeks After Successful Thrombolysis
- Periprocedural Myocardial Infarction
Secondary Prevention
  Management of Lipids
  Recommendations and Discussion
Smoking Cessation
Long-Term Use of Aspirin
Angiotensin Converting Enzyme Inhibitors
β-Adrenoceptor Blockers
  Recommendations for Long-Term Therapy in Survivors of Myocardial Infarction
Antioxidants
Anticoagulants
  Recommendations for Long-Term Anticoagulation After Acute Myocardial Infarction
Calcium Channel Blockers
Estrogen Replacement Therapy and Myocardial Infarction
  Recommendation
Antiarrhythmic Agents

VII. Long-Term Management
  Cardiac Rehabilitation
  Return to Prior Levels of Activity

Tables and Figures

References
Preamble

It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies in the management or prevention of disease. Rigorous and expert analysis of the available data documenting relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and impact the overall cost of care favorably by focusing resources on the most effective strategies.

The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the preparation of such guidelines in the area of cardiovascular disease since 1980. This effort is directed by the ACC/AHA Task Force on Practice Guidelines, which is charged with developing and revising practice guidelines for important cardiovascular diseases and procedures. Experts in the subject under consideration are selected from both organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other medical provider and specialty groups when appropriate. Writing groups are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes in areas where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, along with frequency of follow-up and cost-effectiveness.

These practice guidelines are intended to assist physicians and other healthcare providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment regarding care of a particular patient must be made by the physician and patient in light of circumstances specific to that patient.

These guidelines have been officially endorsed by the American Society of Echocardiography, the American College of Emergency Physicians, and the American Association of Critical-Care Nurses.

Raymond J. Gibbons, MD, FACC Chair, ACC/AHA Task Force on Practice Guidelines
I. Introduction
The current committee was convened by the ACC/AHA Task Force on Practice Guidelines and charged at its first meeting, held November 12, 1994, “to review a critical body of knowledge that has accumulated since the 1990 publication of the ACC/AHA Guidelines on Acute Myocardial Infarction (1) and recommend whatever changes or revisions of the original guidelines that seem appropriate.” The committee held 7 2-day meetings, convened 11 conference calls, and concluded its business at a final meeting held March 24, 1996. Pertinent medical literature in the English language was identified by a search of standard library databases for the 5 years preceding guideline development. An estimated 5000 publications were reviewed by committee members during the course of their deliberations. The committee reviewed many documents on the management or aspects of management of patients with AMI published by other organizations, such as the American College of Chest Physicians, the American College of Physicians, the Canadian Cardiovascular Society, and the European Society of Cardiology; in addition, the committee made every effort to adhere to well-established guidelines such as those for advanced cardiac life support (ACLS) and use of automatic defibrillation. The resulting report was published in the Journal of the American College of Cardiology in November 1996. The committee has continuously monitored the literature since the 1996 report to ensure relevancy of its recommendations. The guidelines have been updated in 1999 via the ACC and AHA websites to include the most significant advances that have occurred in the management of patients with AMI since publication in 1996. A summary of the new text is published in the September 1, 1999 issue of Journal of the American College of Cardiology. A list of updated recommendations is published in the August 28, 1999 issue of Circulation.

The final recommendations for indications for a diagnostic procedure, a particular therapy, or an intervention summarize both the evidence and expert opinion and are expressed in the ACC/AHA format as follows:

**Class I:** Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.

**Class II:** Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.

**Class IIa:** Weight of evidence/opinion is in favor of usefulness/efficacy.

**Class IIb:** Usefulness/efficacy is less well established by evidence/opinion.

**Class III:** Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.

Literature citations were generally restricted to published manuscripts appearing in journals listed in Index Medicus. Because of the scope and importance of certain ongoing clinical trials and other emerging information, published abstracts (previously refereed) were cited when they were the
only published information available. Several new references have been incorporated into the text since the original publication of these guidelines in 1996. The new references are numbered 788-849 and are listed together at the end of the reference list.

The emphasis of the committee's review reflected the current trend in the practice of medicine, which is making a transition from practice patterns driven by pathophysiological and nonquantitative reasoning to a broad belief in "evidence-based medicine." Nowhere has this concept been more firmly embraced than in the treatment of cardiovascular disease, and it was greatly influenced by the recent demonstration in clinical trials that concepts seemingly quite rational and widely accepted have been associated with substantial adverse effects on mortality (2). Despite the recognized importance of empirical evidence to guide therapeutic decisions, it has been only since the advent of computers that computational and organizational capabilities have begun to meet the need. As a consequence, the medical community is in the rapid growth phase of learning how to assimilate and interpret clinical trials and observational databases.

Although these guidelines have been shaped largely within the context of evidence-based medical practice, the committee clearly understands that variations in inclusion and exclusion criteria from one randomized trial to another impose some limitation on the generalizability of their findings. Likewise, in its efforts to reconcile conflicting data, the committee emphasized the importance of properly characterizing the population under study. Not all patients diagnosed with AMI are alike. For example, those diagnosed with AMI on entry into the medical care system differ considerably from those whose diagnosis becomes evident late after admission and appears not as the admission diagnosis but only as the discharge diagnosis. In the former, thrombolytic therapy is feasible, whereas in the latter it is not. Studies examining "processes of care" in AMI will be greatly influenced by such considerations.

In the first half of this decade rapid changes in the natural history of patients with AMI have continued, and the committee recognizes the establishment of the reperfusion era. In this era a constellation of therapies in the management of patients with AMI has been introduced, and therapy is not limited just to the widespread use of thrombolytic agents, percutaneous transluminal coronary angioplasty (PTCA), and emergency coronary artery bypass graft (CABG) surgery in suitable patients. The reperfusion era also embraces the extensive use of aspirin, β-adrenoceptor blocking agents, vasodilator therapy, and the common use of angiotensin-converting enzyme (ACE) inhibitors. In addition, this era has witnessed far more aggressive use of cardiac catheterization and revascularization techniques in patients with clinical markers of a poor prognosis (eg, hypotension, congestive heart failure [CHF], and continuing ischemia). The combined use of all these therapies has resulted in an impressive reduction in early and 1-year mortality for patients with AMI.

As a consequence of this improved survival rate, patients now under observation, such as those enrolled in recent thrombolysis trials, have low rates for subsequent cardiac events. This substantially reduces the predictive accuracy of many tests previously used in risk stratification. Therefore, many gains have resulted in the need to rethink some diagnostic and therapeutic

©1999 by the American College of Cardiology and the American Heart Association, Inc.
It is the aim of these revised guidelines to reflect what the committee has identified as the most important changes to be made in thinking about patients with AMI. Many therapies and procedures in current use are not based on sound scientific evidence. The committee proposes the abandonment of such therapies and procedures that can be identified with confidence. On the other hand, new information suggests that a practical division of all patients with AMI is to classify them as those with ST-segment elevation and those without it. Evidence now shows a distinction in pathoanatomy between the two that demands different therapeutic approaches. Ample evidence exists that persons with suspected MI and ST-segment elevation or bundle-branch block (BBB) should undergo immediate reperfusion, and those without these findings should not.

Committee members were selected from cardiovascular specialists with broad geographical representation and combined involvement in academic medicine and primary practice. The Committee on Management of Acute Myocardial Infarction was also broadened by members of the American Academy of Family Physicians, the American College of Emergency Physicians, the AHA Council on Cardiovascular Nursing, and the American Association of Critical-Care Nurses.

The committee was chaired by Thomas J. Ryan, MD, and included the following members: Elliott M. Antman, MD; Neil H. Brooks, MD; Robert M. Califf, MD; L. David Hillis, MD; Loren F. Hiratzka, MD; Elliot Rapaport, MD; Barbara Riegel, DNSc; Richard O. Russell, MD; Earl E. Smith III, MD; and W. Douglas Weaver, MD.

This document was reviewed by 3 outside reviewers nominated by the American College of Cardiology and 3 outside reviewers nominated by the American Heart Association, as well as individuals from the American Academy of Family Physicians, the American College of Emergency Physicians, the American Association of Critical-Care Nurses, the AHA Council on Cardiovascular Nursing, the American Society of Echocardiography, and the American Society of Nuclear Cardiology. "ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction" was approved for publication by the governing bodies of the American College of Cardiology and the American Heart Association.
II. Prehospital Issues
Recommendations

Class I
1. Availability of 911 access.
2. Availability of an emergency medical services (EMS) system staffed by persons trained to treat cardiac arrest with defibrillation if indicated and to triage patients with ischemic-type chest discomfort.

Class IIa
1. Availability of a first-responder defibrillation program in a tiered response system.
2. Healthcare providers educate patients/families about signs and symptoms of AMI, accessing EMS, and medications.

Class IIb
1. Twelve-lead telemetry.
2. Prehospital thrombolysis in special circumstances (eg, transport time >90 minutes).

Each year 900,000-800,000 persons in the United States experience AMI, and 225,000 of them die. At least one half of these persons die within 1 hour of onset of symptoms and before reaching a hospital emergency department (3,4). It has been recognized for >3 decades that the majority of these sudden cardiac deaths are the result of fatal arrhythmias that often can be stopped by emergency cardiopulmonary resuscitation (CPR), defibrillation, and prompt ACLS. More recent data regarding the time-dependent benefits of thrombolytic therapy provide added stimulus to develop more effective means of expediting delivery of medical care to persons with AMI. It has been shown that early treatment results in reductions in mortality, infarct size, and improved LV function (5-7). Clearly, delay in treating patients with suspected AMI is a critical factor in decreasing the overall survival rate. For these reasons the National Heart, Lung, and Blood Institute (NHLBI) has initiated the National Heart Attack Alert Program (NHAAP), a coordinated national program that extends the ACC/AHA recommendations promoting rapid identification and treatment of patients with AMI. (8,9)

Recognition and Management
It has been demonstrated that most patients do not seek medical care for ≥2 hours after symptom onset. A sizable proportion wait ≥12 hours. In general, reperfusion therapy beyond 12 hours may offer little benefit (8,9). The components of delay from symptom onset to treatment are (1) patient related (ie, failure to recognize the seriousness of the problem and delay in seeking emergency care); (2) prehospital evaluation, treatment, and transport times; and (3) time required for diagnosis and initiation of treatment in the hospital. In most cases, patient-related delay is the longest, but each component moves the patient further away from the golden first hour to a time when the effect of treatment is lessened. Effective early intervention cannot occur without appropriate patient and family action early after symptom onset.

Intervention Strategies
Interventions to minimize patient delay are primarily educational in nature and focus on what to do when ischemic-type chest discomfort occurs. Patients with known heart disease or those at high risk of AMI should be educated by physicians, nurses, and staff about common symptoms of AMI and appropriate actions to take after symptom onset. Patients should be given an action plan that covers (1) prompt use of aspirin and nitroglycerin if available, (2) how to access EMS, and (3) location of the nearest hospital that offers 24-hour emergency cardiac care. Ideally, patients should be given a copy of their resting ECG as a baseline to aid physicians in the emergency department. Because chest discomfort is the most common symptom of infarction (10), patients need simple instructions to respond effectively. In addition to being made aware that chest discomfort may be more of a pressure sensation than actual pain, they should understand that the discomfort can be referred to the arm, throat, and lower jaw and can be accompanied by breathing difficulty, diaphoresis, or a feeling of impending doom(11,12).

Reviewing the description of possible symptoms and the action plan in simple, understandable terms at each visit is extremely important, because studies have indicated that many patients minimize the importance of their symptoms or deny the possibility of AMI(12,13). Discussions with patients should emphasize the importance of acting promptly. Family members should be included in these discussions and enlisted as advocates for action when symptoms of infarction are apparent (8,11).

The role of medications to be taken at onset of symptoms must be tailored to each individual. Current advice is to take 1 nitroglycerin tablet sublingually at the onset of ischemic-type chest discomfort and another every 5 minutes for a total of 3 doses. If symptoms persist, the patient should call 911 emergency services or obtain other emergency transportation to the hospital—not the physician's office. The hospital should be staffed round-the-clock by physicians and nurses competent in (1) performing an initial evaluation, including an ECG, (2) providing cardiac monitoring and ACLS, and (3) providing reperfusion therapy. Patients who can be identified in the field as being at high risk with signs of shock, pulmonary congestion, heart rate >100 beats per minute (bpm), and systolic blood pressure <100 mm Hg ideally should be triaged to facilities capable of cardiac catheterization and revascularization. Although it has not yet been demonstrated that initial triage of such patients to tertiary centers results in improved outcome compared with initial management in primary facilities, this approach has the desirable effect of obviating the need of emergency transfer of a critically ill patient from one hospital to another, interrupting intensive nursing care and possibly delaying diagnosis and treatment.

Use of the EMS system almost always decreases delays in initiation of definitive care(8). Accordingly, the physician should discuss the use of 911 or other local emergency numbers with the patient and should also be aware of the nature and capability of the care that will be rendered. The physician should know whether or not the local EMS system can provide defibrillation and other lifesaving care and should also be familiar with the triage strategy for patients with suspected MI.

**Emergency Medical Services Systems**
Each community prehospital EMS system should develop a plan to triage and provide rapid
initial medical care to patients with ischemic-type chest discomfort. In most cities in the United States, trained emergency medical technicians (EMTs) work in several different healthcare settings: (1) the emergency medical section of the fire department, (2) hospital-based ambulance systems, and (3) department of health services. To minimize time to treatment, particularly for cardiopulmonary arrest, many systems incorporate professional first responders to provide CPR and defibrillation. Ideally, there should be a sufficient number of trained personnel so that a first responder can be at the victim's side within 5 minutes. Public service personnel such as police, firefighters, public works employees, and other first-aid providers have frequently been trained successfully as first responders. A sense of urgency in managing patients with ischemic-type chest discomfort must be imparted to EMS personnel. Rapid identification and treatment of the AMI patient is imperative.

Early access to EMS is promoted by a 911 system currently available to 80% of the US population (8,9). Enhanced 911 systems provide the caller's location, permitting rapid dispatch of prehospital personnel to locations even if the caller is not capable of verbalizing or the dispatcher cannot understand the location of the emergency. Unfortunately, the capabilities of EMS systems vary considerably among communities, some providing little beyond first aid, whereas others have formal, advanced protocols for the management of patients with suspected MI or ischemic-type chest discomfort. The latter offers promise in favorably influencing outcomes in such patients. Because patients with AMI are at relatively high risk of sudden death during the first hour after onset of symptoms, a prehospital EMS system that can provide defibrillation is mandatory (8,14). The survival of patients who develop ischemia-induced ventricular fibrillation (VF) depends on rapid deployment of defibrillation. The survival rate of prehospital treatment for all patients with cardiac arrest (those with and without AMI) varies from 1% to 25% (15-19). If VF occurs under observation and immediate defibrillation is successful, almost all such patients survive and recover completely (20). Therefore, the AHA has recommended that every ambulance that transports cardiac arrest victims should be equipped with a defibrillator (21). However, this goal is yet to be realized.

Automated external defibrillators (AEDs) have been shown to be effective and safe (18,19,21-23). They can be used by first responders with a minimum of training to quickly and accurately analyze rhythms and deliver defibrillation shocks to patients in VF. Systems that incorporate AEDs to shorten response times are highly desirable. Prehospital providers trained and capable of providing ACLS with drugs, intubation, and other therapy further improve the patient's chances for survival.

Undirected prehospital assessments of patients with ischemic-type chest discomfort can lead to excessive evaluation times and can impede rapid delivery of appropriate therapy (24). Procedures need to be in place for each EMS system so that a targeted history, physical examination, prehospital ECG, and initial treatment take place in \( \leq 20 \) minutes. Recently, highly skilled prehospital healthcare providers have been trained and equipped to evaluate patients with ischemic-type chest discomfort by using a checklist and performing 12-lead ECGs in the prehospital setting (Table 1). The checklist should be designed to determine the likelihood of MI
and the presence or absence of comorbid conditions and underlying conditions in which thrombolytic therapy may be hazardous. The checklist should facilitate detection of patients with suspected MI who are at especially high risk, including those with tachycardia (≥100 bpm), hypotension (≤100 mm Hg), or signs of shock or pulmonary edema. If available, prehospital electrocardiograms (ECGs) should be obtained in all patients with ischemic-type chest discomfort and transmitted to the emergency department (ED) physician for interpretation and instructions. Such advances accelerate the initial diagnosis and administration of thrombolytic agents after the patient's arrival in the ED (5,25,26). Active involvement of local healthcare providers—particularly cardiologists and emergency physicians—is needed to formulate local EMS protocols for patients with suspected MI, provide training, and secure equipment. Virtually all states have regulations and standards for emergency personnel, training, and equipment. It is useful for those involved in the emergency care of patients with AMI to be familiar with these regulations.

<table>
<thead>
<tr>
<th>Table 1. Chest Pain Checklist for Use by EMT/Paramedic for Diagnosis of Acute Myocardial Infarction and Thrombolytic Therapy Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Check each finding below. If all [yes] boxes are checked and ECG indicates ST elevation or new BBB, reperfusion therapy with thrombolysis or primary PTCA may be indicated. Thrombolysis is generally not indicated unless all [no] boxes are checked and BP ≤180/110 mm Hg.</td>
</tr>
<tr>
<td>Ongoing chest discomfort (≥20 min and &lt;12 h)</td>
</tr>
<tr>
<td>Oriented, can cooperate</td>
</tr>
<tr>
<td>Age ≥35 y (&lt;40 if female)</td>
</tr>
<tr>
<td>History of stroke or TIA</td>
</tr>
<tr>
<td>Known bleeding disorder</td>
</tr>
<tr>
<td>Active internal bleeding in past 2 weeks</td>
</tr>
<tr>
<td>Surgery or trauma in past 2 weeks</td>
</tr>
<tr>
<td>Terminal illness</td>
</tr>
<tr>
<td>Jaundice, hepatitis, kidney failure</td>
</tr>
<tr>
<td>Use of anticoagulants</td>
</tr>
<tr>
<td>Systolic/diastolic blood pressure</td>
</tr>
<tr>
<td>Right arm: <em><strong>/</strong></em></td>
</tr>
<tr>
<td>Left arm: <em><strong>/</strong></em></td>
</tr>
<tr>
<td>ECG done</td>
</tr>
<tr>
<td>High-risk profile*</td>
</tr>
<tr>
<td>Heart rate ≥100 bpm</td>
</tr>
<tr>
<td>BP ≤100 mm Hg</td>
</tr>
<tr>
<td>Pulmonary edema (rales greater than one half way up)</td>
</tr>
<tr>
<td>Shock</td>
</tr>
</tbody>
</table>

*Transport to hospital capable of angiography and revascularization if needed.

EMT indicates emergency medical technician; ECG, electrocardiogram; BBB, bundle branch block; PTCA, percutaneous transluminal coronary angioplasty; BP, blood pressure; TIA, transient ischemic attack. Adapted from the Seattle/King County EMS Medical Record.
Prehospital-Initiated Thrombolysis
Randomized controlled trials of fibrinolytic therapy have demonstrated the benefit of initiating thrombolytic therapy as early as possible after onset of ischemic-type chest discomfort (27-29). It seems rational therefore to expect that if thrombolytic therapy could be started at the time of prehospital evaluation, a greater number of lives could be saved. The value of reducing delay until treatment depends not only on the amount of time saved but when it occurs. Available data suggest that time saved within the first 1 to 2 hours has greater biological importance than time saved during the later stages of AMI (5,7,27,28,30). Several randomized trials of prehospital-initiated thrombolysis have advanced our understanding of the impact of early treatment(5,31-34). Acquisition of ECGs in the field and use of a chest-pain checklist (Table 1) leads to more rapid prehospital and hospital care (5,26). Although none of the individual trials showed a reduction in mortality with prehospital-initiated thrombolytic therapy, a meta-analysis of all available trials demonstrated a 17% relative improvement in outcome associated with prehospital therapy (95% confidence interval [CI], 2% to 29%)(34). The greatest improvement in outcome is observed when treatment can be initiated in the field 60 to 90 minutes earlier than in the hospital (5,33-35).

Although prehospital-initiated thrombolytic therapy results in earlier treatment, the time savings can be offset in most cases by an improved hospital triage with resultant "door-to-needle time" reduced to ≤30 minutes (4). However, only a small percentage (5% to 10%) of patients with chest pain in the prehospital setting have AMI and are eligible for thrombolytic therapy (5,25,36). Ensuring proper selection of patients for therapy can be difficult, and avoiding therapy when it is contraindicated has important medical, legal, and economic implications. For these reasons, a general national policy of prehospital thrombolytic therapy cannot currently be advocated. However, in special settings in which physicians are present in the ambulance or prehospital transport times are ≥90 minutes, this therapeutic strategy should be considered. Observations from prehospital trials suggest that prehospital systems should focus on early diagnosis (a relatively minor augmentation in prehospital services) instead of delivery of therapy.
III. Initial Recognition and Management in the Emergency Department

Recommendation

Class I
1. Emergency department AMI protocol that yields a targeted clinical examination and a 12-lead ECG within 10 minutes and a door-to-needle time that is <30 minutes.

Detection/Quantification and Risk Assessment
Physicians evaluating patients in the ED for possible admission to the coronary care unit (CCU) face the difficult task of avoiding unnecessary admissions but also minimizing the number of patients discharged home inappropriately. Certain subgroups of patients are known to present with unusual symptoms of AMI. Women often experience atypical ischemic-type chest discomfort (37), while the elderly may complain of shortness of breath more frequently than ischemic-type chest discomfort (25). In addition, with the advent of reperfusion therapy and the desire to minimize door-to-needle time for administration of thrombolytic agents or rapid triage to the catheterization laboratory for primary PTCA, there is a clear need for better methods of prompt identification of patients experiencing a true AMI as accurately and as soon as possible. The ECG and a history of ischemic-type chest discomfort remain the primary methods for screening patients for myocardial ischemia and infarction. The 12-lead ECG in the ED is at the center of the decision pathway because of the strong evidence that ST-segment elevation identifies patients who benefit from reperfusion therapy. In patients with ischemic-type chest discomfort, ST-segment elevation on the ECG has a specificity of 91% and a sensitivity of 46% for diagnosing AMI (38). Mortality increases with the number of ECG leads showing ST elevation (39). Current data do not support administration of thrombolytic agents to patients without ST elevation or BBB, and the benefit of primary PTCA remains uncertain in this population. However, it remains important to admit such patients to the hospital for medical therapy and possible cardiac catheterization (Figure 1).
Initial errors in ECG interpretation can result in up to 12% of patients being categorized inappropriately (ST elevation versus no elevation), demonstrating a potential benefit of accurate computer-interpreted electrocardiography and facsimile transmission to an expert. Other decision aids such as high-risk clinical indicators (40,41), rapid determination of cardiac serum markers (42,43), 2-dimensional echocardiographic screening for regional wall motion abnormalities (44), myocardial perfusion imaging (45), and computer-based diagnostic aids (46,47) are of greatest importance in patients in whom the ECG is nondiagnostic. Two-dimensional echocardiography (transthoracic and transesophageal) is of particular value for rapid triage decisions in patients.
suspected of having an aortic dissection. Because lethal ventricular arrhythmias may develop abruptly in patients with an acute coronary syndrome, all patients should be monitored electrocardiographically on arrival in the ED. It is important to examine serial tracings during evaluation in the ED for development of ST elevation, an event that may be detected by intermittent visual inspection of the oscilloscope or auditory alarms in systems with continuous ST-monitoring capability.

All patients with complicated infarctions (eg, cardiogenic shock) and/or those requiring sophisticated, labor-intensive treatments (eg, intra-aortic balloon counterpulsation) should be admitted to the CCU. In many hospitals, physicians admit low-risk MI patients to a coronary observation unit or telemetry unit where electrocardiographic monitoring and defibrillation equipment are available, but other forms of monitoring are not, and staffing is reduced.

According to the World Health Organization (WHO) definition, the diagnosis of MI is based on the presence of $\geq 2$ of the following 3 criteria: (1) a clinical history of ischemic-type chest discomfort, (2) changes on serially obtained electrocardiographic tracings, and (3) a rise and fall in serum cardiac markers (10,48). Approximately 70% to 80% of patients with MI present with ischemic-type chest discomfort (49,50). Conversely, <25% of patients admitted to the hospital with ischemic-type chest discomfort are subsequently diagnosed as having had an AMI (51,52). Although ST-segment elevation and/or Q waves on the ECG are highly indicative of MI, $\approx 50\%$ of patients with MI do not exhibit ST elevation (53) but display other or nondiagnostic ECG changes (54). Thus, for the majority of patients, the laboratory plays an essential role in establishing the diagnosis of MI (Figure 2).

Figure 2. Patients with ischemic discomfort may present with or without ST-segment elevation on the electrocardiogram. The majority (large arrow) of patients with ST-segment elevation ultimately develop a Q-wave acute myocardial infarction (AMI), whereas a minority (small arrow) develop a non-Q-wave AMI. Of patients who present without ST-segment elevation, the majority (large arrows) are ultimately diagnosed as having either unstable angina or non-Q-wave AMI based on the presence or absence of a cardiac marker such as CK-MB detected in the serum; a minority of such patients ultimately develop a Q-wave AMI. The spectrum of clinical conditions ranging from unstable angina to non-Q-wave AMI and Q-wave AMI is referred to as acute coronary syndromes. AMI=acute myocardial infarction.
An ideal serum marker of MI should be present early and in high concentration in the myocardium and should be absent from nonmyocardial tissue and serum. It should be rapidly released into the blood after myocardial injury, and there should be a stoichiometric relation between the plasma level of the marker and the extent of myocardial injury. The marker should persist in blood for a sufficient length of time to provide a convenient diagnostic time window. Finally, measurement should be easy, inexpensive, and rapid.

Creatine kinase-MB (CK-MB) is the current standard laboratory test for confirmation of MI, although it is by no means perfect. Its drawbacks include lack of specificity for cardiac muscle, resulting in false positive results and inability to detect MI with sufficient sensitivity in the first 6 to 8 hours. There is also uncertainty regarding the meaning of increased levels of CK-MB in the presence of normal total CK levels. In addition, CK-MB is excreted rapidly and usually does not remain elevated in the blood more than 72 hours.

CK-MB exists in only one form in myocardial tissue but in different isoforms (or subforms) in the plasma. An absolute level of CK-MB2 greater than 1 U/L or a ratio of CK-MB2 to CK-MB1 of 1.5 has improved sensitivity and specificity for diagnosis of MI within the first 6 hours as compared with conventional assays for CK-MB. Cardiac specific troponin T (cTnT) and I (cTnI) are new markers for AMI. Rapid whole blood bedside assays are now available, and increases in serum levels of cTnT and cTnI may therefore occur relatively early after muscle damage and may be present for several days after MI (up to 7 days for cTnI and up to 10 to 14 days for cTnT). An elevated cTnT level (greater than 0.1 ng/mL) on admission in a patient with an acute coronary syndrome is an important indicator of subsequent cardiac events. Myoglobin, a low molecular weight heme protein found in cardiac and skeletal muscle, is released more rapidly from infarcted myocardium than CK-MB but is also excreted rapidly by renal clearance. Although myoglobin elevations may be seen as early as 2 hours after infarction, the lack of cardiac specificity suggests a need for confirmation of the cardiac source of myoglobin by supplementary tests such as CK-MB or cardiac specific troponin (Table 2).

Assays for biochemical markers of myocardial necrosis must be interpreted in the context of the time-dependent process of MI. Some markers may be more efficient at detecting MI in patients presenting early (e.g., myoglobin), while others are useful for detecting patients who present late (e.g., cardiac specific troponin T and troponin I). A major difficulty in interpreting the results of clinical trials with biochemical markers is the lack of a clear gold standard. The WHO criteria are inadequate for many cases of MI, especially when CK and CK-MB values are only minimally elevated above the normal range.

Serum Cardiac Markers
When myocytes become necrotic, they lose membrane integrity, and intracellular macromolecules diffuse into the cardiac interstitium and ultimately into the cardiac microvasculature and lymphatics (55). Eventually, these macromolecules are detectable in the peripheral circulation. The term currently used to collectively describe these macromolecules is serum cardiac markers. An ideal serum cardiac marker of MI should be present early and in high concentration in the myocardium and should be absent from nonmyocardial tissue and serum (55-57). It should be rapidly released into the blood at the time of the myocardial injury, and there should be a stoichiometric relation between the plasma level and the extent of myocardial injury. The marker should persist in blood for a sufficient length of time to provide a convenient diagnostic time window. Finally, measurement of the marker should be easy, inexpensive, and rapid.

The nomenclature of the acute coronary syndromes (ACS) is illustrated in revised Figure 2. The central position of the 12-lead electrocardiogram (ECG) and initial triage of patients are emphasized. Listed at the bottom of the figure is the information sought by clinicians when measuring serum cardiac marker levels in patients at different ends of the ACS spectrum. Serum cardiac markers are useful for confirming the diagnosis of MI when patients present without ST-segment elevation, when the diagnosis may be unclear, and when clinicians must distinguish patients with unstable angina from those with a non–Q-wave MI. Serum cardiac markers also provide valuable prognostic information. For patients with ST-segment elevation, the diagnosis of MI is secure; clinicians are interested in prognostic information as well as a noninvasive assessment of the likelihood that the patient has undergone successful reperfusion when thrombolytic therapy is administered.

Because the conventional serum cardiac marker, creatine kinase (CK) and its MB isoenzyme (CK-MB) lack sufficient sensitivity and specificity, there is a need for more sensitive and cardiac-specific markers of myocardial necrosis (792-794). The troponin complex consists of 3 subunits: troponin T, troponin I, and troponin C (795). The ternary troponin complex is a calcium-sensitive molecular apparatus that regulates the interaction of actin and myosin. Troponin T binds the troponin complex to tropomyosin, and troponin I binds to actin and inhibits interactions between actin and myosin. Troponin C is responsive to changes in intracellular calcium concentration. Amino acid sequences of the skeletal and cardiac isoforms of troponin I and troponin T have sufficient dissimilarity that monoclonal antibody-based immunoassays have been developed to detect cardiac-specific troponin T (cTnT) and cardiac-specific troponin I (cTnI). Because the amino acid sequence of troponin C is the same in cardiac and skeletal muscle, no immunoassays of troponin C have been developed for clinical purposes.

Because CK-MB is found in the skeletal muscle and blood of healthy subjects, the cutoff value for an elevated CK-MB level is typically set a few units above the upper end of the reference (normal) range. In contrast, because cardiac troponin I and cardiac troponin T are not normally detected in the blood of healthy people, the cutoff value for elevated cTnI and cTnT levels may be set only slightly above the noise level of the assay, permitting clinicians to diagnose lesser degrees of myocardial necrosis (ie, increased sensitivity) (796). Because CK and CK-MB are characteristically used as the gold standard for diagnosing MI, investigators may face a dilemma...
when a new diagnostic test is more sensitive than the gold standard, particularly for identifying episodes of minor myocardial cell necrosis. Case reports confirm histologic evidence of focal myocyte necrosis in patients with elevated cardiac troponin levels and normal CK values (796). It is estimated that ≈30% of patients presenting without ST-segment elevation who would otherwise be diagnosed with unstable angina are actually experiencing a non-Q-wave MI when assessed with cardiac-specific troponin assays (797). Furthermore, numerous investigators have now reported that elevated levels of cTnI or cTnT provide more prognostic information than that supplied by the patient's demographic characteristics or the ECG at presentation (798,799). Elevated cTnI or cTnT levels, even in the presence of normal CK-MB levels, identify patients without ST-segment elevation who are at an increased risk of death. Finally, patients presenting without ST-segment elevation who are characterized as high risk because of elevated cardiac-specific troponin levels demonstrate a greater benefit from treatment with new therapies such as glycoprotein (GP) IIb/IIIa inhibitors than patients without elevated cardiac-specific troponin levels who receive such new pharmacotherapeutic interventions (800).

CK-MB isoforms are another new serum cardiac marker that may be useful for evaluating patients with an acute coronary syndrome. CK-MB exists in only 1 form in myocardial tissue but in different isoforms (or subforms) in the plasma. An absolute level of CK-MB2 >1 U/L or a ratio of CK-MB2 to CK-MB1 of 1.5 has improved sensitivity and specificity for diagnosis of MI within the first 6 hours compared with conventional assays for CK-MB (59). Myoglobin, a low-molecular-weight heme protein found in cardiac and skeletal muscle, is not cardiac specific but is released more rapidly from infarcted myocardium than CK-MB and may be detected as early as 2 hours after MI. The diagnostic sensitivity and specificity for MI were compared for total CK-MB (activity and mass), CK-MB subforms, myoglobin, cTnI, and cTnT in the Diagnostic Marker Cooperative Study (DMCS) (801). The DMCS was a large, prospective, multicenter, double-blind study of patients presenting in the emergency department (ED) with chest pain. CK-MB subforms were most efficient for early diagnosis (within 6 hours) of MI, whereas cTnI and cTnT were highly cardiac specific and particularly efficient for late diagnosis of MI. The DMCS investigators concluded that either a single assay (CK-MB subforms) or a select combination (CK-MB subform and a cardiac-specific troponin) reliably triages patients with chest pain and could potentially lead to improved therapy and reduced cost of care of ACS patients. It should be noted that serum levels of cTnT and cTnI may be present for several days after MI (up to 7 days for cTnI and up to 10 to 14 days for cTnT). Therefore, the ability to diagnose recurrent infarction is significantly compromised if the clinician relies solely on cardiac-specific troponins and fails to obtain a concomitant CK or CK-MB measurement within the first 12 to 24 hours of admission of an MI patient. Thus, although CK and CK-MB are not as cardiac specific as the troponins, they will return to normal levels within the first 24 to 36 hours, making it more likely that a reelevation is associated with recurrent myocardial necrosis. For patients presenting within the first two or three hours of symptom onset, the two markers most appropriate for the early diagnosis of AMI are myoglobin and CK-MB subforms.

In patients presenting with ST-segment elevation, clinicians usually use peak CK as a rough estimate of the magnitude of the infarct and assessment of the patient’s prognosis. Release of
cardiac-specific troponins is stoichiometrically correlated with the amount of myocardial necrosis, and the new serum cardiac markers can also be used to estimate infarct size and prognosis (58). Cardiac-specific troponins may not be detectable for up to 6 hours after onset of chest pain. Thus, when cTnI and cTnT levels are elevated early after onset of discomfort in patients with ST-segment elevation MI, clinicians should suspect that an antecedent episode of unstable angina was in fact MI and the patient is exhibiting a stuttering course of occlusion and release of the infarct-related artery. Data from the Global Utilization of Streptokinase and TPA for Occluded Arteries (GUSTO) III Study suggest that patients with elevated cardiac troponin T levels and who are <6 hours from the onset of discomfort have an increased mortality risk (802).

In addition to monitoring the patient for resolution of ischemic-type chest discomfort and regression of the magnitude of ST-segment elevation on the ECG, clinicians can obtain serial measurements of serum cardiac markers to buttress the noninvasive diagnosis of reperfusion of the infarct-related artery after thrombolytic therapy (65,803). Because of its rapid-release kinetics, myoglobin is a particularly attractive marker for the early diagnosis of reperfusion.

**Bedside Testing for Serum Cardiac Markers**

Handheld rapid bedside assays are clinically available for measuring cTnI, cTnT, myoglobin, and CK-MB. Small desktop rapid analyzers are also available for the same purpose. A rapid, high-voltage electrophoretic system is available for measuring CK-MB isoforms. When using a handheld rapid bedside assay for a serum cardiac marker, the clinician places a small aliquot of the patient’s blood or serum in the specimen well and observes the development of a colored line in the read zone of the device. It should be noted that the time to development of the colored line and the intensity of the color are related to the concentration of the serum cardiac marker in the specimen. For example, when a handheld bedside immunoassay is used to test the blood of patients with high cTnT levels, a red line quickly appears; such patients are at increased mortality risk (804). Careful attention to the timing of the appearance of a positive bedside assay result may provide clinicians with a tool for a semiquantitative estimate of a serum cardiac marker level at the patient’s bedside. A positive bedside test however should be confirmed by a conventional quantitative test.

**Routine Measures (Oxygen, Nitroglycerin, Aspirin)**

**Class I**

1. Supplemental oxygen, intravenous access, and continuous electrocardiographic monitoring should be established in all patients with acute ischemic-type chest discomfort.

2. An ECG should be obtained and interpreted within 10 minutes of arrival in the ED in all patients with suspected acute ischemic-type chest discomfort.

Although the specific diagnosis of AMI can be made with absolute certainty only occasionally at
the time of a patient's entry into the healthcare system, the immediate management of all acute coronary syndromes is generally the same. All patients suspected of having an AMI should have a clinical and electrocardiographic evaluation that is prompt and targeted to estimate the likelihood that the presenting condition is an AMI as opposed to one of its potentially lethal mimics: aortic dissection, acute pericarditis, acute myocarditis, spontaneous pneumothorax, or pulmonary embolism.

Although local settings vary widely, the entry process should be completed by a health team member (or members) with the competency to make such an assessment within a very short time of the patient's presentation, ideally within the first 10 minutes and certainly not >20 minutes from presentation. Only then should specific procedures or therapies be given, except for securing peripheral venous access. At this entry stage it is important that all members of the healthcare team interact with the patient and family in a warm and caring fashion while projecting professionalism and confidence.

**Oxygen Recommendations**

**Class I**
1. Overt pulmonary congestion.
2. Arterial oxygen desaturation (SaO2 <90%).

**Class IIa**
1. Routine administration to all patients with uncomplicated MI during the first 2 to 3 hours.

**Class IIb**
1. Routine administration of supplemental oxygen to patients with uncomplicated MI beyond 3 to 6 hours.

It has become universal practice to administer oxygen, usually by nasal prongs, to virtually all patients suspected of having acute ischemic-type chest discomfort, although it is not known whether this therapy limits myocardial damage or reduces morbidity or mortality. If oxygen saturation monitoring is used, therapy with supplemental oxygen is indicated if the saturation is <90%. Experimental results indicate that breathing oxygen may limit ischemic myocardial injury (66), and there is evidence that oxygen administration reduces ST-segment elevation in patients with MI as well (67). The rationale for use of oxygen is based on the observation that even with uncomplicated MI, some patients are modestly hypoxemic initially, presumably because of ventilation-perfusion mismatch and excessive lung water (68).

In patients with severe CHF, pulmonary edema, or a mechanical complication of AMI, significant hypoxemia may not be corrected with supplemental oxygen alone. Continuous positive-pressure breathing or endotracheal intubation and mechanical ventilation are often required in such cases and should not be unnecessarily delayed (69). A variety of mechanical ventilators are available, and multiple modes are possible. For patients who do not have a depressed sensorium and are capable of initiating spontaneous ventilation, the preferred modes to
use include intermittent mandatory ventilation, assist control, or pressure-support ventilation.(70)

For patients without complications, it should be recalled that excess administration of oxygen can lead to systemic vasoconstriction, and high flow rates can be harmful to patients with chronic obstructive airway disease. On the other hand, because administration of nitroglycerin dilates the pulmonary vascular bed and increases ventilation-perfusion abnormalities, it is reasonable to provide supplemental oxygen, at least in the initial hours, to all patients suspected of having an AMI. In the absence of compelling evidence for established benefit in uncomplicated cases and in view of its expense, there appears to be little justification for continuing its routine use beyond 2 to 3 hours.

Nitroglycerin
Recommendations for Intravenous Nitroglycerin

**Class I**
1. For the first 24 to 48 hours in patients with AMI and CHF, large anterior infarction, persistent ischemia, or hypertension.
2. Continued use (>48 hours) in patients with recurrent angina or persistent pulmonary congestion.

**Class IIa**
None.

**Class IIb**
1. For the first 24 to 48 hours in all patients with AMI who do not have hypotension, bradycardia, or tachycardia.
2. Continued use (>48 hours)* in patients with a large or complicated infarction.

**Class III**
1. Patients with systolic pressure <90 mm Hg or severe bradycardia (<50 bpm).

*Oral or topical preparations may be substituted.

Considering that the use of nitrates in AMI was believed to be contraindicated until the early 1970s (71), it is rather striking that today, with the exception of hypotensive patients, virtually all patients with acute ischemic syndromes will receive ≥1 sublingual nitroglycerin tablet before admission to the hospital. Aside from its known clinical benefit in alleviating ischemic myocardial pain, nitroglycerin is now appreciated as having a dilatory effect on the vascular smooth muscle in vessels throughout the body. Thus, vasodilation of the coronary arteries themselves (especially at or adjacent to sites of recent plaque disruption), the peripheral arteries, and the venous capacitance vessels is particularly beneficial to the patient with acute infarction. However, inadvertent systemic hypotension with resulting worsening of myocardial ischemia is the most serious potential complication of nitroglycerin therapy. Thus, patients with ischemic-type chest discomfort should receive sublingual nitroglycerin unless the initial systolic blood pressure is <90 mm Hg. It should be avoided in the presence of marked bradycardia (<50 bpm) or tachycardia (72) and used with extreme caution, if at all, in patients with suspected right ventricular infarction. Patients with right ventricular infarction are especially dependent on
adequate right ventricular preload to maintain cardiac output and can experience profound hypotension during administration of nitrates(73).

Long-acting oral nitrate preparations should be avoided in the early management of AMI. Sublingual or transdermal nitroglycerin can be used, but intravenous infusion of nitroglycerin allows for more precise minute-to-minute control of this agent. Intravenous nitroglycerin can be successfully titrated by frequent measurement of cuff blood pressure and heart rate. Although invasive hemodynamic monitoring is not mandatory, it may be preferable if high doses of vasodilating agents are required, blood pressure instability ensues, or there is clinical doubt about the adequacy of LV filling pressure. Although quite effective in relieving ischemic-type chest discomfort due to acute coronary syndromes, nitroglycerin should not be used as a substitute for narcotic analgesia that is usually required to manage pain associated with AMI. For a detailed discussion of the pharmacotherapy and relevant clinical studies pertaining to the use of nitroglycerin in AMI, see "Rationale and Approach to Pharmacotherapy."

**Analgesia**

The clinical observation of rapid and complete relief of pain after early reperfusion with thrombolytic therapy reinforces the concept that the pain of AMI is due to continuing ischemia of viable but jeopardized myocardium rather than the effects of completed myocardial necrosis. Efforts to control pain therefore may reasonably involve use of anti-ischemic interventions, including, in addition to reperfusion, oxygen, nitrates, β-adrenoceptor blocking agents, and, in some circumstances, intra-aortic balloon counterpulsation. Effective analgesia (eg, intravenous morphine) should be administered promptly at the time of diagnosis and should not be delayed on the premise that to do so will obscure ability to evaluate the results of anti-ischemic therapy. See "Hospital Management" for more detailed discussion of proper analgesia.

**Aspirin**

**Recommendations**

**Class I**

1. A dose of 160 to 325 mg should be given on day 1 of AMI and continued indefinitely on a daily basis thereafter.

**Class IIb**

1. Other antiplatelet agents such as dipyridamole, ticlopidine or clopidogrel may be substituted if true aspirin allergy is present or if the patient is unresponsive to aspirin.

The Second International Study of Infarct Survival (ISIS-2) has shown conclusively the efficacy of aspirin alone for treatment of evolving AMI with a 35-day mortality reduction of 23% (29) When combined with streptokinase, the reduction in mortality was 42%. A meta-analysis demonstrated that aspirin reduced coronary reocclusion and recurrent ischemic events after thrombolytic therapy with either streptokinase or alteplase (74) In a dose ≥160 mg, aspirin produces a rapid clinical antithrombotic effect caused by immediate and near-total inhibition of thromboxane A2 production. Accordingly, aspirin now forms part of the early management of all
patients with suspected AMI and should be given promptly and certainly within the first 24 hours at a dose between 160 and 325 mg and continued daily indefinitely. Unlike fibrinolytic agents, there is little evidence for a time-dependent effect of aspirin on early mortality. However, data do support the contention that a chewable aspirin is absorbed more quickly than one swallowed in the early hours after infarction, particularly after opiate therapy. The use of aspirin is contraindicated in those with a hypersensitivity to salicylate and should be used with caution in patients with active ulcer disease. Aspirin suppositories (325 mg) can be used safely and are the recommended route of administration for patients with severe nausea and vomiting or known upper-gastrointestinal disorders. There is currently no evidence that other antiplatelet agents such as dipyridamole, ticlopidine, or sulfinpyrazone have any advantage over aspirin for mortality reduction after AMI. See "Rationale and Approach to Pharmacotherapy" for additional discussion on the use of aspirin in the management of AMI, and "Preparation for Discharge From the Hospital."

Atropine

Recommendations

The following recommendations are applicable from early after onset of AMI to 6 to 8 hours afterward:

**Class I**

1. Sinus bradycardia with evidence of low cardiac output and peripheral hypoperfusion or frequent premature ventricular complexes at onset of symptoms of AMI.
2. Acute inferior infarction with type I second- or third-degree atrioventricular (AV) block associated with symptoms of hypotension, ischemic discomfort, or ventricular arrhythmias.
3. Sustained bradycardia and hypotension after administration of nitroglycerin.
4. For nausea and vomiting associated with administration of morphine.
5. Ventricular asystole.

**Class IIa**

1. Symptomatic patients with inferior infarction and type I second- or third-degree heart block at the level of the AV node (ie, with narrow QRS complex or with known existing BBB).

**Class IIb**

1. Administration concomitant with (before or after) administration of morphine in the presence of sinus bradycardia.
2. Asymptomatic patients with inferior infarction and type I second-degree heart block or third-degree heart block at the level of the AV node.
3. Second- or third-degree AV block of uncertain mechanism when pacing is not available.

**Class III**

1. Sinus bradycardia >40 bpm without signs or symptoms of hypoperfusion or frequent premature ventricular contractions.
2. Type II AV block and third-degree AV block and third-degree AV block with new
wide QRS complex presumed due to AMI.

By its parasympatholytic (anticholinergic) activity, atropine sulfate reduces vagal tone, enhances the rate of discharge of the sinus node, and facilitates AV conduction (75). It may be given as an adjunct to morphine administration when nausea and vomiting occur. During the early moments to hours of acute ischemia or AMI, atropine is particularly useful in treating sinus bradycardia associated with reduced cardiac output and signs of peripheral hypoperfusion, including arterial hypotension, confusion, faintness, or frequent premature ventricular complexes (76). In this setting, leg elevation and intravenous administration of atropine may be lifesaving.

**Atropine for Atrioventricular Block, Sinus Bradycardia, or Ventricular Asystole**

Atropine is the drug of choice for the occasional treatment of type I second-degree AV block, especially when complicating inferior MI. It is occasionally useful in third-degree AV block at the AV node level in either restoring AV conduction or enhancing the junctional response. When AV block or sinus bradycardia is associated with CHF, hypotension, or frequent and complex ventricular arrhythmias, atropine may improve AV conduction, increase the sinus rate, and avoid the need for immediate insertion of a transvenous pacemaker (77). As a rule, however, in the absence of hemodynamic compromise, treatment of sinus bradycardia or first- or second-degree AV block is not indicated. Similarly, atropine is rarely, if ever, the drug of choice for management of type II second-degree AV block. On occasion, while failing to improve AV block, atropine may increase the sinus rate, and, in fact, enhance the block.

The recommended dosage of atropine for bradycardia is 0.5 to 1.0 mg intravenously (IV), repeated if needed every 3 to 5 minutes to a total dose ≤2.5 mg (0.03 to 0.04 mg/kg), the amount that produces complete vagal blockade. Atropine may also be therapeutic in ventricular asystole, for which the recommended dose is 1 mg IV, to be repeated every 3 to 5 minutes (while CPR continues) if asystole persists. The total cumulative dose should not exceed 2.5 mg over 2.5 hours. The peak action of atropine given intravenously is observed within 3 minutes (1)

**Side Effects**

When administered in doses of <0.5 mg or other than intravenously, atropine may produce a paradoxical effect (namely, bradycardia and depression of AV conduction) (78), which is due either to central reflex stimulation of the vagus or a peripheral parasympathomimetic effect on the heart. Urinary retention is not uncommon following administration of atropine and can be deleterious to the patient with AMI. Repeated administration of atropine may produce adverse central nervous system effects, including hallucinations and fever. Careful dosing and observation after administration of atropine is necessary because the sinus tachycardia that follows may increase ischemia. Rarely, ventricular tachycardia and fibrillation occur after intravenous administration of atropine (79).

Pacing is the treatment of choice for symptomatic bradycardia not responding promptly to atropine administration.
Risk Stratification and Management of ST-Segment Elevation/Bundle Branch Block Cohort

Newer Concepts

The spectrum of myocardial ischemia consists of patients with clinical presentations that cover the following range of diagnoses: stable angina, unstable angina, MI without ST elevation, and MI with ST elevation. Clinical discrimination among unstable angina, Q wave, and non-Q-wave MI can only be made retrospectively after serial ECGs and serum cardiac markers have been obtained (Figure 2). Patients with ST-segment elevation have a high likelihood of a coronary thrombus occluding the infarct-related artery (80,81). However, not every ST-elevation MI evolves into a Q-wave MI. Angiographic evidence of occlusive coronary thrombus formation may be seen in >90% of patients with ST-elevation MI but in only 1% of patients with stable angina and ≈35% to 75% of patients with unstable angina or non-Q-wave MI (80-83). Commonly indicated treatment regimens for all acute coronary ischemic syndromes include aspirin, heparin, \( \beta \)-adrenoceptor blockers, and nitrates. Thrombolytic therapy is highly effective in patients with ST elevation or presumably new left BBB (LBBB) (which obscures the electrocardiographic diagnosis of MI) (27) (Figure 3).

![Figure 3. Recommendations for management of patients with ST elevation. All patients with ST-segment elevation on the electrocardiogram should receive aspirin (ASA), \( \beta \)-adrenoceptor blockers (in the absence of contraindications), and an antithrombolytic (particularly if tissue-type plasminogen activator [t-PA] is used for thrombolytic therapy). Whether heparin is required in patients receiving streptokinase (SK) remains a matter of controversy; the small additional risk for intracranial hemorrhage may not offset the survival benefit afforded by adding heparin to SK therapy. Patients treated within 12 hours who are eligible for thrombolysis should expeditiously receive either frontloaded tPA or SK or be considered for primary percutaneous transliminal coronary angioplasty (PTCA). Primary PTCA is also to be considered when thrombolytic therapy is absolutely contraindicated. Coronary artery bypass graft (CABG) may be considered if the patient is less than 6 hours from onset of symptoms. Individual treated after 12 hours should receive the initial medical therapy noted above and, on an individual basis, may be candidates for reperfusion therapy or angiotensin-converting enzyme (ACE) inhibitors (particularly if left ventricular function is impaired). Modified from Antman EM. Medical therapy for acute coronary syndromes: an overview. In: Califf RM, ed. Atlas of Heart Disease. VIII. Philadelphia, Pa: Current Medicine; 1996.](image-url)
At the same time, evidence now suggests that thrombolytic therapy is ineffective (for normal or nonspecific electrocardiographic presentations) and possibly even harmful (for ST-depression presentation) in unstable angina and non-ST-elevation MI subgroups (27,84) Figure 4 presents a suggested schema for management of AMI without ST-segment elevation.
Figure 4. All patients without ST elevation should be treated with an antithrombin and aspirin (ASA). Nitrates should be administered for recurrent episodes of angina. Adequate b-adrenoceptor blockade should then be established; when this is not possible or contraindications exist, a calcium antagonist can be considered. Current data indicate that either an invasive or non-invasive treatment strategy is suitable for non-ST-elevation AMI patients. AMI= acute myocardial infarction, CABG=coronary artery bypass graft, ECG=electrocardiographic, GpIIb/GpIIIa= Glyco protein IIb/IIIa receptor for platelet aggregation, LMWH= low-molecular-weight heparin, LV=left ventricular, PTCA=percutaneous transluminal coronary angioplasty; Modified from Antman EM. Medical therapy for acute coronary syndromes: an overview. In Califf RM, editor. Atlas of Heart Diseases, VIII. Philadelphia, PA: Current Medicine; 1996.
Noninvasive Imaging in the Emergency Department
Screening patients who present with ischemic-type chest discomfort in the ED is an area of clinical and economic importance. Because ≤25% of patients admitted to the hospital to "rule out" MI actually suffer an MI, accurate screening techniques to identify patients with ongoing necrosis is an important goal. The usefulness of echocardiography in the ED as a means of screening for MI has been validated, but small areas of infarction can be missed, and the age of a regional wall motion abnormality cannot be determined (85-87a). Thallium and sestamibi imaging in the ED are both very good radioisotope screening techniques (85,88,89) and appear to be quite sensitive. However, their use in the ED is still viewed as experimental and is not recommended. In time, the value of noninvasive imaging may further diminish as rapid assays of specific, earlier, and more sensitive serum markers of myocardial necrosis are developed(56,58,60,61).

Thrombolysis Recommendations
The constellation of clinical features that must be present (although not necessarily at the same time) to serve as standard indications for administration of thrombolytic therapy to patients with AMI are as follows (selection of specific thrombolytic agents or regimens is discussed in "Rationale and Approach to Pharmacotherapy") :

Class I
1. ST elevation (>0.1 mV, ≥2 contiguous leads), * time to therapy ≤12 hours, † age <75 years.
2. Bundle-branch block (obscuring ST-segment analysis) and history suggesting AMI.

Comment: Treatment benefit is present regardless of gender, presence of diabetes, blood pressure (if < 180 mm Hg systolic), heart rate, or history of previous MI.(27) Benefit is greater in the setting of anterior MI, diabetes, low blood pressure (<100 mm Hg systolic), or high heart rate (>100 bpm). The earlier therapy begins, the better the outcome, with the greatest benefit decidedly occurring when therapy is given within the first 3 hours; proven benefit occurs, however, up to at least within 12 hours of the onset of symptoms. Benefit is less with inferior AMI, except for the subgroup with associated right ventricular infarction (ST-elevation RV-4) or anterior-segment depression indicative of a posterior current of injury as often occurs with occlusion of a large circumflex coronary artery.

Class IIa
1. ST elevation,* age ≥75 years old.

Comment: In persons ≥75 years old, the overall risk of mortality from infarction is high without and with therapy. Although the proportionate reduction in mortality is less than in patients ≤75, the absolute reduction results in 10 lives saved per 1000 patients treated in those > 75. The relative benefit of therapy is reduced (27).

Class IIb
1. ST elevation,* time to therapy >12 to 24 hours.†
2. Blood pressure on presentation >180 mm Hg systolic and/or >110 mm Hg diastolic associated with high-risk MI.

©1999 by the American College of Cardiology and the American Heart Association, Inc.
**Comment:** Generally there is only a small trend for benefit of therapy after a delay >12 to 24 hours, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation. Risk of intracranial hemorrhage (ICH) is greater when presenting blood pressure is >180/110 mm Hg, and in this situation the potential benefit of therapy must be weighed carefully against the risk of hemorrhagic stroke. Risk of cardiac rupture appeared to increase with prolonged time to therapy in an earlier meta-analysis (90) but was not associated with increased risk of rupture in a later, larger study (91). Generally patients presenting >12 hours after symptom onset were excluded from some but not all trials. An attempt to lower blood pressure first (with nitrates, β-adrenoceptor blockers, etc) is recommended but is not of proven benefit in lowering the risk of ICH. Primary PTCA or CABG may be considered if available.

**Class III**

1. ST elevation,* time to therapy >24 hours, † ischemic pain resolved.

   **Comment:** In the absence of ST elevation, there is no evidence of benefit for patients with normal electrocardiographic or nonspecific changes, and, using current thrombolytic regimens, there is some suggestion of harm (including increased bleeding risk) for patients with ST-segment depression only (27,92). When marked ST-segment depression is confined to leads V1 through V4, there is a likelihood that this reflects a posterior current of injury and suggests a circumflex artery occlusion for which thrombolytic therapy would be considered appropriate. Retrospective analysis of the Late Assessment of Thrombolytic Efficacy (LATE) Trial (93,94) also casts some uncertainties about withholding thrombolytic therapy from this heterogenous group of patients.

   *Repeat ECGs recommended during medical observation in suggestive clinical settings when initial ECG is nondiagnostic of ST elevation.

†Time of symptom onset is defined as the beginning of continuous, persistent discomfort that brought the patient to the hospital.

A collaborative overview from 9 trials of thrombolytic therapy (versus control) for AMI has shown a highly significant (*P*<0.00001) 18% proportional reduction in 35-day mortality (9.6% fibrinolysis versus 11.5% control) corresponding to a reduction of 18 deaths per 1000 patients treated when data from all patient groups are pooled (27). In patients with ST elevation, a proportional mortality reduction of 21% occurred. It is now known that this survival benefit can be maintained long term (6 months to ≥4 years) (27,95).
Figure 5 summarizes the number of lives saved per 1000 patients treated based on the presenting ECG pattern (96). In general, thrombolytic agents should be administered only to patients with ST-segment elevation >0.1 mV or presumably new LBBB on the ECG (27,97). However, in the very early phase of acute infarction, giant, hyperacute T waves may be present with no ST-segment elevation. Similarly, direct posterior infarction can result in ST-segment depressions in leads V1 through V4, and in both situations it is appropriate to administer thrombolytic therapy. Thus, it should be clear that certain cases require experienced interpretation of the ECG before withholding reperfusion therapy. Unquestionably, patients with LBBB and anterior ST elevation are at greater inherent risk from MI but also achieve greater benefit with thrombolytic therapy. Although 1 study (39) suggested that the amount of ST elevation might also predict greater inherent risk and therefore greater benefit, it did not take into account the increased amount of ST elevation seen in patients with anterior infarction. Other factors such as collateral flow (98) clearly influence the amount of ST elevation, which may limit its value for predicting therapeutic benefit.

Additional factors that influence the decision to administer thrombolytic therapy include time since onset of symptoms, patient's age, hemodynamic status, and coexisting medical illnesses (Figures 6 and 7). Myocardial salvage increases with progressively earlier administration of thrombolytic therapy, although a reduction in mortality may still be seen in patients treated up to at least 12 hours from onset of definitive symptoms(27,99,100). Some patients presenting at >12 to 24 hours with persistent ischemic symptoms and ST elevation also may benefit from treatment. Although younger patients achieve a greater relative reduction in mortality compared with older patients, the increasing absolute mortality rates with advancing age result in
progressively greater absolute mortality reductions up to age 75. Benefit may also be achieved after age 75 but is less certain than at younger ages (27,101). Advanced age does increase risk of stroke after AMI, both without and with thrombolytic therapy. Given the much greater mortality risk of MI, the elderly should be considered candidates for thrombolytic therapy after careful screening for exclusions. Patients should be considered at higher risk if they have any of the following: female gender, advanced age (>70 years), history of previous infarction, atrial fibrillation, anterior infarction, rales in more than one third of the lung fields, hypotension, and sinus tachycardia or diabetes mellitus (27,102). Indeed, certain subgroups of patients with an especially high likelihood of benefiting from successful reperfusion include those with hypotension, tachycardia, and a history of diabetes mellitus or prior MI.

Early placebo-controlled trials of thrombolysis for MI raised concern about a paradoxical increase in mortality during the first 24 hours after thrombolysis that was later offset by a greater reduction in mortality in the thrombolytic groups (27). More recently conducted thrombolytic trials have confirmed a "high density" of mortality in the first 24 hours but suggest that this may be attributed primarily to pump failure from unsuccessful reperfusion rather than an early hazard of thrombolysis (103).
**Risk of Stroke**

Thrombolytic therapy is associated with a slight but definite excess risk of stroke that occurs predominantly within the first day of therapy (27). Clinical variables that can be ascertained in the ED that predict an increased risk of ICH are advanced age (>65 years, OR 2.2, 95% CI, 1.4 to 3.5), low body weight (<70 kg, OR 2.1, CI 1.3 to 3.2), hypertension on presentation (OR 2.0, CI 1.2 to 3.2), and use of alteplase (OR 1.6, CI 1.0 to 2.5) (104-106). The number of risk factors at presentation may be used to estimate the probability of ICH and is shown in Figure 8. Although no firm guidelines have been established, ICH rates <1% have generally been regarded as acceptable in clinical trials, considering the overall favorable benefit-risk profiles, whereas rates >1.5% or higher have been viewed as unacceptably high (107).

![Figure 8. Risk of intracranial hemorrhage (ICH) during thrombolytic therapy.](image)

More recent trials show that as use of thrombolysis has increased, a greater proportion of patients who are >75 years old or female are now included. This change has been associated with a higher rate of ICH than that seen in earlier studies. For example, the rate of ICH after administration of alteplase was ≈0.7%; in more recent studies, it is 0.8% to 0.9% (Table 2.1). It should be noted that the streptokinase without heparin administration regimen has the lowest rate of ICH.

*To reduce risk, the dose of 90-minute alteplase should be adjusted downward for low body weight (<67 kg). Similarly, the 180-minute regimen should be adjusted downward for patients who weigh <65 kg.*
Net Clinical Benefit

Clinicians must carefully weigh the risk-benefit ratio of thrombolysis for individual patients. Hesitancy to prescribe thrombolytic therapy arises from concern about intracranial bleeding and uncertainty about eligibility criteria. The generally higher mortality rate among MI patients who do not undergo thrombolysis underscores the need for heightened awareness of current indications for thrombolysis through such projects as the NHAAP (108). Decision analysis methods suggest that appropriate use of thrombolytic therapy in eligible patients would save many additional lives annually in the United States (109).

Contraindications/Cautions

Hemorrhage represents the most important risk of thrombolytic therapy, especially ICH, which may be fatal in one half to two thirds of patients. Contraindications and cautions to thrombolytic use are given in Table 3.
Table 3. Contraindications and Cautions for Thrombolytic Use in Myocardial Infarction*

Contraindications
- Previous hemorrhagic stroke at any time; other strokes or cerebrovascular events within 1 year
- Known intracranial neoplasm
- Active internal bleeding (does not include menses)
- Suspected aortic dissection
Cautions/relative contraindications
- Severe uncontrolled hypertension on presentation (blood pressure >180/110 mm Hg)†
- History of prior cerebrovascular accident or known intracerebral pathology not covered in contraindications
- Current use of anticoagulants in therapeutic doses (INR ≥2-3); known bleeding diathesis
- Recent trauma (within 2-4 weeks), including head trauma or traumatic or prolonged (>10 min) CPR or major surgery (<3 wk)
- Noncompressible vascular punctures
- Recent (within 2-4 weeks) internal bleeding
- For streptokinase/ alteplase: prior exposure (especially within 5 d-2 y) or prior allergic reaction
- Pregnancy
- Active peptic ulcer
- History of chronic severe hypertension

INR indicates International Normalized Ratio; CPR, cardiopulmonary resuscitation. *Viewed as advisory for clinical decision making and may not be all-inclusive or definitive. †Could be an absolute contraindication in low-risk patients with myocardial infarction (see text).

Summary of Initial Diagnostic and Treatment Strategy
A summary of initial diagnostic and treatment strategies for patients with AMI with ST elevation or BBB, focusing on emergency management, is provided in Table 4.
Table 4. Diagnostic and Treatment Measures in Patients With ST Elevation or Bundle Branch Block

Initial diagnostic measures
1. Use continuous ECG, automated BP, HR monitoring
2. Take targeted history (for AMI inclusions, thrombolysis exclusions), check vital signs, perform focused examination
3. Start IV(s), draw blood for serum cardiac markers, hematology, chemistry, lipid profile
4. Obtain 12-lead ECG
5. Obtain chest x-ray (preferably upright)

General treatment measures
1. Aspirin, 160-325 mg (chew and swallow)
2. Nitroglycerin, sublingual: test for Prinzmetal's angina, reversible spasm; anti-ischemic, antihypertensive effects
3. Oxygen: sparse data; probably indicated, first 2-3 h in all; continue if low arterial oxygen saturation (<90%).
4. Adequate analgesia: small doses of morphine (2-4 mg) as needed

Specific treatment measures
1. Reperfusion therapy: goal—door-to-needle time <30 min; door-to-dilatation time <60 min
2. Conjugate antithrombotics: aspirin, heparin (especially with TPA)
3. Adjunctive therapies: β-adrenergicceptor blockade if eligible, intravenous nitroglycerin (for anti-ischemic or antihypertensive effects), ACE inhibitor (especially with large or anterior AMI, heart failure without hypotension [SBP >100 mm Hg], previous MI).

ECG indicates electrocardiogram; BP, blood pressure; HR, heart rate; AMI, acute myocardial infarction; IVs, intravenous administrations; TPA, tissue plasminogen activator; ACE, angiotensin converting enzyme; SBP, systolic blood pressure.

Primary Percutaneous Transluminal Coronary Angioplasty

Recommendations

1. As an alternative to thrombolytic therapy in patients with AMI and ST-segment elevation or new or presumed new LBBB who can undergo angioplasty of the infarct artery within 12 hours of onset of symptoms or >12 hours if ischemic symptoms persist, if performed in a timely fashion by individuals persons skilled in the procedure and supported by experienced personnel in high-volume centers in an appropriate laboratory environment.

2. In patients who are within 36 hours of an acute ST-elevation/Q-wave or new LBBB MI who develop cardiogenic shock, are <75 years of age, and revascularization can be performed within 18 hours of onset of shock.

Class IIa

1. As a reperfusion strategy in patients who are candidates for reperfusion but who have a risk of bleeding contraindication to thrombolytic therapy (Table 3).

2. Patients in cardiogenic shock.

1. As a reperfusion strategy in candidates for reperfusion who have a contraindication to thrombolytic therapy (Table 3).
Class IIb
1. As a reperfusion strategy in patients who fail to qualify for thrombolytic therapy for reasons other than a risk of bleeding contraindication.
   1. In patients with AMI who do not present with ST elevation but who have reduced (less than TIMI [Thrombolysis in Myocardial Infarction] grade 2) flow of the infarct-related artery and when angioplasty can be performed within 12 hours of onset of symptoms.

Class III
This classification applies to patients with AMI who

1. Undergo elective angioplasty of a non–infarct-related artery at the time of AMI
2. Are >12 hours after onset of symptoms and have no evidence of myocardial ischemia
3. Have received fibrinolytic therapy and have no symptoms of myocardial ischemia
4. Are eligible for thrombolysis and are undergoing primary angioplasty performed by a low volume operator in a laboratory without surgical capability

Comment: There is serious concern that a routine policy of primary PTCA for patients with AMI will result in unacceptable delays in achieving reperfusion in a substantial number of cases and less than optimal outcomes if performed by less experienced operators. Strict performance criteria must be mandated for primary angioplasty programs so that such delays in revascularization and performance by low-volume operators/centers do not occur. Interventional cardiologists and centers must operate within a specified "corridor of outcomes" to include (1) balloon dilation within 90 (±30) minutes of admission and diagnosis of AMI; (2) a documented clinical success rate with TIMI-II through III flow attained in >90% of patients without emergency CABG, stroke, or death; (3) emergency CABG rate <5% among all patients undergoing the procedure; (4) actual performance of angioplasty in a high percentage of patients (85%) brought to the laboratory; and (5) mortality rate <12.10%. Otherwise, the focus of treatment should be the early use of thrombolytic therapy.

*Performance standard: balloon inflation within 90 (±30) minutes of admission.
†Persons who perform >75 PTCA procedures per year (110).
‡Centers that perform >200 PTCA procedures per year and have cardiac surgical capability (110).

Since publication of the original report of primary (direct) PTCA as an alternative to thrombolytic therapy in patients with AMI (111), its merits have been debated (112,113). There are no randomized controlled trials of primary PTCA versus no reperfusion. Thus, the recommendations are based on findings from small and moderately sized comparative trials of primary PTCA and thrombolysis and from indirect evidence.

Initial assessments showed that PTCA restored antegrade flow in the occluded infarct-related
artery in >90% of patients and was associated with a 1-year survival rate of 90% to 96% (114-117). Subsequently several randomized trials compared PTCA and thrombolytic therapy in patients with AMI (118-120). In these studies PTCA was reported to successfully restore antegrade coronary flow in ≈88% to 95% of attempts. In the study of Zijlstra et al (118), follow-up angiography weeks after infarction showed that the infarct-related artery was patent in 91% of those who had primary PTCA (studied on average 3 months after the procedure) and in 68% of those who received streptokinase ($P=0.001$) (studied 3 weeks later). The residual infarct-related artery stenosis was less in those who underwent PTCA. Those in whom primary PTCA was performed also had fewer in-hospital adverse events (nonfatal reinfarction or death) and were less likely to have recurrent ischemia or to require coronary revascularization over the period of follow-up.

Similarly, Gibbons et al (119) found that those who underwent primary PTCA were less likely to require coronary revascularization for recurrent ischemia over a 6-month follow-up period than those treated with alteplase. In this study the 2 groups had similar myocardial salvage (the primary end point), left ventricular (LV) ejection fraction, incidence of recurrent MI, and survival. The Primary Angioplasty in Myocardial Infarction (PAMI) Investigators (120) found a significant difference in their primary end point (combined death and nonfatal reinfarction) between patients receiving PTCA (5.1%) or alteplase (12.0%, $P = 0.02$) but no significant differences in LV function or mortality. In a post hoc analysis of high-risk patients (ie, >70 years, with anterior infarction or tachycardia on presentation), mortality was only 2% for those who had primary PTCA and 10% for those who received thrombolysis ($P=0.01$). The survival benefit of PTCA was at least partly due to the fact that those who received thrombolytic therapy had an excessive incidence of cerebrovascular hemorrhage with death; in fact, cardiac-related deaths were similar in the 2 groups.

In the GUSTO-IIb trial (805), 1138 patients with evolving ST-segment elevation MI within 12 hours of onset of chest pain were randomly assigned to receive PTCA (n=565) or accelerated tissue plasminogen activator (tPA) (n=573). Thirty days after enrollment, the incidence of death, recurrent MI, or disabling stroke was 9.6% in those who underwent PTCA and 13.6% in those who received tPA ($P=0.033$). However, 6 months after enrollment the difference between the 2 treatments did not reach statistical significance; the incidence of the composite adverse outcome was 13.3% in the PTCA group and 15.7% in the tPA group ($P=ns$).

Recently published data from the Second National Registry of Myocardial Infarction (NRMI-2) (124) suggest that primary PTCA and thrombolytic therapy offer similar efficacy. Over 17 months, 4939 subjects with evolving ST-segment elevation MI received primary PTCA, and 24705 received alteplase. For patients without cardiogenic shock, the in-hospital mortality rate was similar (5.4% for the alteplase group, 5.2% for the PTCA group), and this was true even when the data from certain "high-risk" subgroups, such as those >75 years old and those with anterior MI, were analyzed.

Among the most important contributions to these revised guidelines are the data in the
preliminary report of the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock? (SHOCK) Trial, presented by Dr Judith Hochman on March 7, 1999, at the 48th Scientific Sessions of the American College of Cardiology, held in New Orleans, La and to be published in the August 26, 1999 issue of the *New England Journal of Medicine* (805a). When this multicenter study was designed in 1992, it was postulated that emergency revascularization (ERV) of cardiogenic shock due to an ST-elevation/Q-wave or new LBBB MI would result in a 20% (absolute) reduction in the primary end point, all-cause 30 day mortality compared with initial medical stabilization (IMS), and delayed revascularization as clinically determined.

In this study, 152 patients were randomly assigned to the ERV strategy, and 150 patients were assigned to a strategy of IMS. The 30-day mortality rate for ERV patients was 46.7% versus 56.0% for IMS patients (95% CI, −20.5 to +1.9%, *P* =0.11), a nonsignificant trend. However, the mortality rate at 6 months (a secondary end point) was significantly lower in the ERV group (50.3% versus 63.1%, *P* =0.27). The prespecified subgroup analysis of patients <75 years old showed a 15.4% reduction in the primary end point (IMS group, 56.8%, versus ERV group, 41.4%, *P* <0.01), whereas outcome in patients >75 years old was worse for the ERV group. Intra-aortic balloon pump (IABP) support was used in 86% of both groups; 63% of the IMS group received thrombolytic agents, and 25% underwent delayed revascularization. Of the ERV group of patients who underwent emergency early revascularization, >60% received PTCA, and 40% had CABG; the 30-day mortality rate was 45% and 42%, respectively.

A meta-analysis suggests that, in comparison with thrombolytic therapy, primary PTCA reduces the incidence of subsequent hospital morbidity, readmission, and follow-up costs largely by reducing recurrent ischemia following intervention. However, this benefit comes at the cost of performing PTCA on all patients presenting with infarction (rather than the 20% to 40% who require revascularization for clinical indications following thrombolytic therapy in these trials).

An early meta-analysis of the randomized clinical trials that compared primary PTCA with thrombolytic therapy was reported in early 1995 (121) and included data on in-hospital or 6-week mortality and nonfatal MI for all 7 trials reported to that time. The combined data showed a mortality rate at 6 weeks of 3.7% in the PTCA group and 6.4% in the thrombolysis group (OR, 0.56; 95% CI, 0.33 to 0.94). In the combined outcome of short-term mortality and nonfatal reinfarction, the event rate was 6.1% for the PTCA group and 11.0% for the thrombolytic therapy group (OR, 0.53; 95% CI, 0.35 to 0.80). By 1 year, however, none of these end point differences were statistically significant. The analyses showed that >30% of the thrombolytic therapy patients underwent PTCA sometime during hospitalization or within the first 6 weeks of infarction. Therefore, the contrast in the proportions of patients receiving any PTCA versus patients receiving no PTCA was substantial (64%). The authors conclude that the data on primary PTCA appear promising but should be interpreted with caution and viewed as a strong impetus for the conduction of larger trials in a more diverse range of hospitals, with clinical outcomes being the primary end points of interest.
A more recent meta-analysis by Weaver et al (806) provides a quantitative review of the treatment effects of primary coronary angioplasty versus intravenous thrombolysis for AMI from 10 randomized trials that involved 2606 patients. When the results of all studies were combined, the mortality rate at ≤30 days was 4.4% for the 1290 patients treated with primary angioplasty, compared with 6.5% for the 1316 patients treated with thrombolysis (34% reduction; OR, 0.66%; 95% CI, 0.46 to 0.94; \( P = 0.02 \)). The pooled rate of death or nonfatal reinfarction was also lower in patients treated with primary PTCA than in those treated with thrombolytic therapy, from 11.9% to 7.2%, respectively (OR, 0.58; 95% CI, 0.44 to 0.76). Angioplasty was associated with a significant reduction in total stroke (9/1290, 0.7%; versus 26/1390, 2%; \( P = 0.007 \)) and hemorrhagic strokes as well (0.1% versus 1.1%; \( P < 0.001 \)). On the basis of outcomes at hospital discharge or 30 days, this analysis concluded that “primary PTCA appears to be superior to thrombolytic therapy for treatment of patients with AMI, with the proviso that success rates for PTCA are as good as those achieved in these trials. Data evaluating longer-term outcome, operator expertise, and time delays before treatment are needed before primary PTCA can be recommended universally as the preferred treatment.”

Before selecting PTCA as the preferred therapy for AMI, several caveats should be kept in mind. Because only >20% of hospitals in the United States have cardiac catheterization laboratories and even fewer have the capability of performing emergency PTCA, the applicability of PTCA as a primary therapy for AMI is limited. Although transfer of the patient with MI to a facility that can perform PTCA is possible, the necessary time delay in achieving reperfusion may outweigh any added benefit.

The excellent results attained in the limited number of patients studied in the randomized trials to date can be attributed to several factors, including (1) the extensive experience of these investigators in performing PTCA in the setting of AMI; (2) their enthusiastic commitment to all details of the protocol; (3) the resulting dedication of their institutions and support personnel to the project; and (4) the capability to perform PTCA within a short time frame (by 60 to 90 minutes of arrival at hospital) (118, 120). These important considerations may not be reproducible in the community setting and for all AMI patients not enrolled in specific protocols.

Recently Brodie et al (788) pointed out that patients who underwent angioplasty within 2 hours of onset of symptoms showed a striking 53% relative reduction in 30-day mortality compared with those who underwent angioplasty >2 to 6 hours (4.3% versus 9.2%; \( P < 0.04 \)). Because their data failed to show an important time-dependent worsening of mortality beyond 2 hours, it has been suggested that the time delay in transferring patients with AMI to tertiary centers for primary PTCA may be permissible if the procedure cannot be done within the first 2 hours of symptom onset. Clearly, it becomes critical to measure the outcomes of larger numbers of
patients stratified by time to answer this important question. On the other hand, if a time dependent worsening of mortality does exist for patients undergoing angioplasty (as seems likely since it does so for patients reperfused with fibrinolytic therapy) it seems reasonable to explore the theoretical advantage of combining the administration of smaller doses of fibrinolytic agents on presentation at the community hospital (for early patency) with prompt transfer to a tertiary center for PCI (sustained patency). The safety of such an approach has been reported by Dr. Allan Ross for the PACT Trial at the 71st Scientific Sessions of the American Heart Association, in Dallas, Texas on November 10, 1998.

In the recently completed GUSTO-IIb trial results presented at the 45th Annual Scientific Session of the American College of Cardiology, held in Orlando, Fla, in March 1996, 1138 patients were randomly selected to receive either direct angioplasty or thrombolytic therapy with accelerated alteplase. Although the mortality (5.7% versus 7.0%) and the composite of death, reinfarction, and disabling stroke (9.6% versus 13.1%) showed a trend toward favoring direct angioplasty, the magnitude of the effect was less than that observed in the previous small trials, and the cost of each therapy was within several hundred dollars of the other.

It is also important to recognize that the results of the randomized trials were achieved only in patients who were eligible for thrombolytic therapy, and the findings do not necessarily apply to persons who are not eligible. In addition, 2% to 5% of patients initially referred for PTCA will require emergency CABG surgery, because either the artery is not suitable for PTCA or failed angioplasty requires further surgical intervention. Accordingly, primary PTCA should be performed in centers with cardiac surgical capability or in those institutions with a proven plan for rapid access to cardiac surgery in a nearby facility. Until more data have more reliably quantified a benefit of primary PTCA over thrombolytic therapy in the community setting, it seems prudent to suggest that institutions that do not have the capability of offering primary PTCA should not feel compelled to develop such services at this time (121,807).

The most recent developments in acute reperfusion by mechanical interventions in the management of patients with AMI are the emerging reports of randomized comparisons between primary PTCA and routine deployment of stents (127,808). The Amsterdam group (127) published a randomized comparison of coronary stenting with balloon angioplasty in selected patients with AMI that showed that primary stenting can be used safely and effectively, resulting in a lower incidence of recurrent infarction and a significant reduction in the need for subsequent target-vessel revascularization compared with balloon angioplasty. These data support the concept that with improved stent technique and use of more effective antiplatelet regimens, including ticlopidine, the thrombus-laden lesion no longer represents a strict contraindication to stenting. An appropriate note of caution has been made about interpreting these data (809), pointing out the highly selective nature of the study population. Only 50% of patients with AMI who underwent primary PTCA were considered eligible for this study, raising serious questions about the generalizability of the results.

The STENT PAMI (Stents-Primary Angioplasty in Acute MI) Trial reported the results of
randomly assigning 900 AMI patients to PTCA or PTCA with deployment of a heparin-coated stent at the 71st Scientific Sessions of the American Heart Association held in Dallas in November 1998. The primary end point was the incidence of the combination of death, reinfarction, disabling stroke, or ischemic-driven, target-vessel revascularization at 6 months. Although there was a statistically significant difference in the combined end point that favored stent placement compared with PTCA alone (12.4% versus 20.1%, \( P<0.01 \)), this was determined solely by the incidence of target-vessel revascularization at 6 months (7.5% versus 17%, \( P<0.0001 \), respectively). Unfortunately, there were more deaths in the stent placement arm (4.2%) than in the PTCA arm (2.7%), although the difference was not statistically significant in this trial, which had a total of only 31 deaths.

Recommendations for Early Coronary Angiography in the ST-Segment Elevation or Bundle Branch Block Cohort Not Undergoing Primary Percutaneous Transluminal Coronary Angioplasty

**Class I**
None.

**Class IIa**
1. Patients with cardiogenic shock or persistent hemodynamic instability.

**Class IIb**
1. Patients with evolving large or anterior infarcts treated with thrombolytic agents in whom it is believed that the artery is not patent and adjuvant PTCA is planned.

**Class III**
1. Routine use of angiography and subsequent PTCA within 24 hours of administration of thrombolytic agents.

Recommendations for Emergency or Urgent Coronary Artery Bypass Graft Surgery

**Class I**
1. Failed angioplasty with persistent pain or hemodynamic instability in patients with coronary anatomy suitable for surgery.
2. AMI with persistent or recurrent ischemia refractory to medical therapy in patients with coronary anatomy suitable for surgery who are not candidates for catheter intervention.
3. At the time of surgical repair of postinfarction ventricular septal defect (VSD) or mitral valve insufficiency.

**Class IIa**

**Class IIb**
1. Failed PTCA and small area of myocardium at risk; hemodynamically stable.

**Class III**
1. When the expected surgical mortality rate equals or exceeds the mortality rate associated with appropriate medical therapy.

Comment: These recommendations are supplementary to those published in a more complete set of general guidelines and indications for CABG by another ACC/AHA subcommittee (128) and
are restricted in general to patients with AMI and associated complications. The basis for recommending surgery in emergency circumstances is based on the documented benefits of CABG for severe multivessel disease or left main coronary artery stenosis, particularly with reduced LV function (128-131). with the realization that risk of emergency CABG is greater than that for elective operation.

Previous studies (132-134) suggested that emergency CABG improved survival and salvaged more myocardium than matched retrospective control groups developed before the widespread use of thrombolytic therapy and primary PTCA. More recently, emergency CABG has been used for AMI patients when other interventional therapies have failed or have not been indicated.

Risk Stratification and Management in Non-ST-Segment Elevation Cohort

Recommendations for Early Coronary Angiography and/or Intervventional Therapy

Class I
1. Patients with recurrent (stuttering) episodes of spontaneous or induced ischemia or evidence of shock, pulmonary congestion, or LV dysfunction.

1. Patients with persistent or recurrent (stuttering) episodes of symptomatic ischemia, spontaneous or induced, with or without associated ECG changes.

2. Presence of shock, severe pulmonary congestion, or continuing hypotension.

Class IIa
1. Patients with persistent ischemic-type discomfort despite medical therapy and an abnormal ECG or two or more risk factors for coronary artery disease. 2. Patients with chest discomfort, hemodynamic instability, and an abnormal ECG.

Class IIb
1. Patients with chest discomfort and an unchanged ECG. 2. Patients with ischemic-type chest discomfort and a normal ECG and more than two risk factors for coronary artery disease.

Class IIa
None.

Class IIb
None.

Patient Characteristics

Ischemic-type chest discomfort in the setting of nondiagnostic electrocardiographic findings (no ST-elevation) represents a continuum between chronic stable angina and typical acute MI. Unstable angina and MI without ST elevation represent two of the most common cardiac emergencies requiring hospitalization and account for over 650,000 discharges per year in the United States. While the optimal treatment regimen or strategy for such patients is under investigation, a proposed schema is presented in Fig 4.

It is believed that acute MI accompanied by nondiagnostic ECG changes is related to acute disruption of an atherosclerotic plaque.82,135-137 Although there are few angiographic and clinical correlations with the syndrome, studies to date have suggested that, unlike MI with ST
In the setting of nondiagnostic ECG findings (non-ST elevation), ACS represents a continuum between chronic stable angina and AMI with ST-segment elevation. Although the prognosis of the patient with chronic stable angina can be stratified and the emergency situation engendered by ST-elevation MI is readily evident, patients with acute symptoms but nondiagnostic ECG findings range from those with noncardiac chest pain to very high-risk MI with multivessel disease. Unstable angina and MI without ST elevation represent 2 of the most common cardiac emergencies requiring hospitalization and account for >650,000 discharges per year in the United States. Although the optimal treatment regimen or strategies for such patients is under investigation, a proposed diagnostic schema is presented in Figure 2 and a therapeutic approach is depicted in revised Figure 4.
AMI accompanied by nondiagnostic ECG changes is believed to be related to acute disruption of an atherosclerotic plaque in the setting of chronic inflammatory infiltration of its fibrous cap; this underlying pathophysiology is not thought to differ from AMI accompanied by ST-segment elevation. As more angiographic and clinical correlation studies are done, it is becoming clear that total occlusion of the culprit vessel is much less common in AMI without ST-segment elevation than in MI with ST elevation (82,138-140). Furthermore, patients without ST-segment elevation are more likely to have multivessel disease and prior MIs than are those with ST-elevation MI (810). In the clinical history, patients with MI without ST-segment elevation are more likely than those with ST elevation to have a history of diabetes, hypertension, heart failure, and peripheral vascular disease but less likely to be smokers or to have hyperlipidemia (810). Importantly, the
The elderly are less likely to have ST-segment elevation with MI, probably because of the more common presence of prior myocardial damage and multivessel disease (25,149).

Thus, during initial evaluation of the patient with acute ischemic-type chest discomfort, the clinician should classify patients as those with ST elevation or LBBB (acute reperfusion indicated) and those with nondiagnostic ECGs. The nondiagnostic ECG group will include patients with noncardiac symptoms, those with unstable angina and no myocardial necrosis, those with small MIs, those with direct posterior infarctions caused by circumflex artery occlusion, and those at very high risk with multivessel coronary disease and significant left ventricular dysfunction. Studies with different mixes of these subgroups have reported different morbidity and mortality rates for the population as a whole.

The initial importance of classifying patients on the basis of the ECG should not be confused with the question of whether the patient has a Q-wave or a non–Q-wave MI. This classification can be made only after 24 hours, well beyond the point at which critical decisions about treatment must be made. Whether or not the patient initially has ST elevation, those with a normal QRS complex who do not develop Q waves with MI have a low in-hospital mortality rate, but recurrent ischemia, recurrent MI, and death in the weeks after discharge occur frequently. In contrast, patients with a significant QRS abnormality who do not develop new Q waves with a new MI are at high risk of both early and later death. The overall incidence of non–Q-wave MI may be increasing with the advancing age of the population and the greater use of thrombolytic therapy, aspirin, and β-adrenoreceptor blockers.

Most randomized trials in patients with MI have been conducted in those with ST-segment elevation, although a few early studies were less restrictive and provide some insight into the effect of thrombolysis on outcome in patients with nondiagnostic electrocardiographic changes. In the first GISSI study (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) of streptokinase for AMI, no benefit was associated with thrombolytic therapy in patients with ST-segment depression at the time of admission. Mortality rates in patients with ST-segment depression were in fact higher in those treated with streptokinase (20.5% versus 16.2% in the control group) (28). Patients with less abnormal or undefined electrocardiographic abnormalities had a lower overall mortality rate, averaging ≈8%. Again, there was no treatment benefit of thrombolytic therapy (28). It is important to realize, however, that only ≈10% of all patients randomly assigned in the trial had nondiagnostic electrocardiographic findings. Thus, they likely represent a very select group of patients with nondiagnostic electrocardiographic changes who were deemed eligible and appropriate for thrombolytic therapy. In the ISIS-2 trial there was a relatively high mortality rate in patients with MI and ST-segment depression and no treatment benefit from thrombolytic therapy (29). In patients with MI who had only T-wave abnormalities, mortality rates were low (≈5%); in patients with normal ECGs, the mortality rate was 1% to 2%. In a recent overview of the early, large randomized placebo-controlled trials of thrombolytic therapy, 3.6% of the entire group had ST-segment depression (27). The mortality rate for those receiving thrombolysis was 15.2%, compared with 13.8% for control subjects, a
higher rate than in those with ST elevation. Furthermore, 2 randomized trials of thrombolytic therapy in patients with unstable angina or MI with nondiagnostic electrocardiographic findings showed no benefit of alteplase compared with treatment with aspirin and heparin alone (92,150)

In summary, the available data do not support the routine use of thrombolytic therapy as a form of reperfusion in patients admitted with ischemic-type chest discomfort and nondiagnostic ECGs.

It should be recognized that relatively few patients with nondiagnostic electrocardiographic findings have been studied to date, and the possibility of benefit, particularly in some subsets of patients, cannot be excluded on the basis of the available data. In the retrospective subgroup analysis of patients enrolled in the LATE study (93), 1-year mortality was significantly reduced by alteplase in patients presenting initially with ST depression >2 mm (20.1% versus 31.9%, P=0.006). Thus, although the available data do not support the routine use of thrombolytic therapy in patients with ischemic-type chest discomfort and nondiagnostic ECGs, future prospective trials are warranted to better define the role of thrombolytic therapy in such patients (94).

Although few patients with nondiagnostic electrocardiographic findings have been treated in trials, it is important to realize that this presentation is not unusual. It was estimated in 1 consecutive series of patients that almost half of patients with MI were ineligible for acute reperfusion because of a nondiagnostic ECG at the time of admission, yet the mortality rate for this subset was high (14%) (84,151).

Pharmacological Therapy in Patients in the Non-ST-Segment Elevation Cohort

Despite the recent realization that at least half of patients with enzymatic evidence of myocardial necrosis do not have ST-segment elevation on the ECG, little is known about the specific response of these patients to pharmacological therapy other than their lack of mortality reduction with thrombolytic therapy as discussed above. On presentation these patients cannot be distinguished from those with unstable angina without myocardial necrosis. The initial pharmacological therapy, other than avoidance of thrombolytic therapy, is the same as for all patients with unstable angina or infarction with ST-segment elevation (Figure 2). It is important to recognize, however, that these recommendations are made in the absence of information specific to this very large group of patients. In patients with recurrent episodes of pain, serial ECGs should be repeated frequently. The development of sustained ST elevation is an indication for thrombolysis or primary PTCA. If the ECG remains nondiagnostic but stuttering symptoms continue, urgent angiography is recommended.

Antithrombotic Therapy

Thousands of patients with ACS without ST-segment elevation have now been randomly assigned to treatment with various antithrombotic regimens. In these trials, approximately half the patients had enzymes positive for myocardial necrosis on the first measurement, indicating that they were having an MI without ST-segment elevation at the time of randomization. Patients
with positive enzymes on the first draw not only had a higher mortality rate than patients without positive enzymes, but they also had a higher risk of repeat MI, hemodynamic complications, and arrhythmias. Fortunately, the response to newer antithrombotic agents has been homogeneous in patients with ACS without ST elevation, whether or not they had positive enzymes at the time of admission.

**Glycoprotein IIb/IIIa Inhibitors**

Class IIa

1. For use in patients having an MI without ST-segment elevation who have some high risk features and/or refractory ischemia provided they don’t have a major contraindication due to a bleeding risk.

The glycoprotein (GP) IIb/IIIa receptor is a member of the integrin family of receptors that is found in the membrane of platelets (811). When platelets are activated by a variety of stimuli, including thrombin, collagen, adenosine diphosphate (ADP), and epinephrine, the GP IIb/IIIa receptor changes conformation to be receptive to one end of a fibrinogen dimer. Occupancy of a GP IIb/IIIa receptor by the other end of the dimer provides the basis for platelet aggregation. Thus, the GP IIb/IIIa receptor is considered the final common pathway of platelet aggregation (812). Multiple therapeutic agents have now been developed to block the receptor.

More than 30,000 patients with ACS without ST-segment elevation have now been randomly assigned into trials comparing GP IIb/IIIa inhibitors with placebo in addition to treatment with aspirin and unfractionated heparin (UFH). A systematic overview has demonstrated a definite reduction in the composite end point of death and MI and in the composite end point of death, MI, and the need for revascularization procedures (813). A slight trend toward a reduction in mortality may exist but does not reach statistical significance. The reduction in events is present while patients are treated with active drug, and the difference in event rates does not change after that point. When treatment is discontinued, no further effect, either beneficial or detrimental, is seen. Thus, intravenous GP IIb/IIIa inhibitors may be considered as a method to reduce acute events and stabilize patients in the acute phase of MI without ST-segment elevation. Direct comparisons of the agents are not available, so the specific choice of which agent to use is speculative.

Three agents are available for clinical practice:

1. Abciximab is a chimeric Fab fragment of a monoclonal antibody to the GP IIb/IIIa receptor. Although multiple clinical trials have documented the reduction in the composite of death and nonfatal MI with abciximab in the setting of percutaneous intervention, (814–817), only 1 trial (Chimeric 7E3 Antiplatelet in Unstable Angina Refractory to Standard Treatment [CAPTURE]) (814) has been completed in the setting of non–ST-elevation ACS.

2. Eptifibatide is a cyclical heptapeptide, which binds to the receptor with a short half-life (818). It has been evaluated in a trial of 11,000 patients with non–ST-elevation ACS, 45% of whom had
enzymes positive for myocardial necrosis on admission.

3. Tirofiban is a small nonpeptide compound that also has a short half-life. It has been evaluated in 5147 patients in 2 randomized trials of non-ST-elevation ACS (819,820). In the PRISM-PLUS Study (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) (820), 45% of patients also had positive enzymes for myocardial necrosis.

**Low-Molecular-Weight Heparin and Direct Antithrombins**

Low-molecular-weight heparin (LMWH) is a subfraction of standard heparin with a greater degree of inhibition of factor Xa relative to thrombin when compared with standard UFH. In addition to its convenience—it can be administered subcutaneously with high bioavailability—LMWH has a number of theoretical benefits over UFH. These include the potential to prevent thrombin generation as well as inhibit thrombin, the lack of a need to monitor with coagulation testing, and a lower rate of heparin-associated thrombocytopenia. Four trials have compared the use of LMWH and UFH for non-ST-elevation ACS (507,838-840). In 2 trials, a clear benefit of LMWH was observed (839,840), whereas in another, LMWH was superior to placebo (507). The fourth trial did not show a clear difference in outcomes (838).

Direct-thrombin inhibitors are now available for use in heparin-induced thrombocytopenia and deep venous thrombosis, but they have not been approved for treatment of ACS. Hirudin, a recombinant protein that is an important component of leech saliva, has been studied in many thousands of patients; the results show a consistent reduction in the composite of death and nonfatal MI. Hirulog, a synthetic direct thrombin inhibitor, has been studied in only limited populations.

**Interventional Therapy**

There is considerable variation in the use of acute catheterization, angiography, and catheter or surgical interventions in the management of patients with suspected AMI and nondiagnostic ECGs. The approach of acute catheterization has been promoted to quickly identify the problem, offer reperfusion therapy, and expedite hospital discharge. Although PTCA for non-Q wave MI has been shown to have high success rates and improve myocardial function within the infarct zone, few data exist regarding its effect on clinical outcome (92,152) To elucidate this issue, the TIMI-IIIB study was undertaken.

TIMI-IIIB was the largest (1473 patients) randomized, controlled trial of early intervention versus a conservative strategy in patients with unstable angina/MI and nondiagnostic electrocardiographic changes (92). Results showed no significant difference in the primary outcome (death, MI, or a positive exercise test at 42 days) in patients receiving early angiography and revascularization versus the conservative approach (16.2% versus 18.1%),92 although the trend favored PTCA. Hospital mortality rates in the population selected for this trial were low (<3%) and considerably lower than the rate observed for patients with nondiagnostic
electrocardiographic changes in the large trials. The rate of death and recurrent MI in patients with documented MI and nondiagnostic ECGs treated by early intervention versus conservative therapy was 7.2% versus 9.9%. Similarly, in the subset of patients with unstable angina, these event rates (7.2% versus 6.9%) were not significantly different. In those with ST-segment depression, death and MI occurred in 10.5% in the early intervention group versus 11.8% in the conservative group. All patients were treated with β-adrenoceptor blockers, calcium channel blockers, nitrates, heparin, and aspirin. By 42 days, 64% of the conservative-treatment group had received coronary angiography because of either spontaneous or induced ischemia on provocative testing. Fifty-five percent of the angiograms were done before hospital discharge. The greatest difference between the 2 treatment strategies was the need for readmission, which was less in patients undergoing early intervention (7.8% versus 14.1%, respectively). The initial hospitalization was statistically shorter, but the average time saved was only 15 hours and the lengths of hospital stay were much longer than the national average (10 days). There were no economic comparisons of the 2 strategies, and thus it is not known whether the cost of routine angiography and intervention was offset by the reduced need for readmission.

Many physicians in hospitals with full cardiac facilities routinely perform delayed coronary angiography within 2 to 3 days of admission and then revascularization if appropriate, even if the patient remains asymptomatic (153). Other physicians treat such patients conservatively and perform angiography and revascularization only in those with spontaneous or induced ischemia during provocative testing in the recovery phase of hospitalization. Proponents for the routine use of coronary angiography soon after admission for patients with suspected MI and nondiagnostic electrocardiographic findings argue that (1) a definitive anatomic diagnosis can be made and prognosis can be stratified, based on the extent of coronary disease and LV dysfunction; (2) a therapeutic plan can be executed early in the hospital, possibly reducing length of stay; and (3) patients with critical coronary obstructions can undergo revascularization in the hope that outcome improves and the subsequent need for antianginal medications lessens.(153) However, there are no trials or empiric data substantiating better outcome using this approach. A conservative strategy of risk stratification and a more selective use of procedures may be more cost-effective with revascularization less frequently performed and targeted to those who would most benefit from it.

Recently, the Veterans Affairs Non-Q-Wave Infarction Strategies In Hospital Trial (VANQWISH) (821) has shed important light on the question of intervention in patients with non-Q-wave infarction. The VANQWISH Trial evaluated a somewhat different population than the Thrombolysis in Myocardial Infarction (TIMI-3B) Trial. VANQWISH investigators randomly assigned to an invasive or conservative strategy 920 patients who did not have a major complication within 24 to 72 hours of onset of symptoms. The ECG criteria required the absence of new Q waves; therefore, the trial included patients with and without ST-segment elevation on admission. The aggressive strategy called for routine cardiac catheterization with revascularization of significant lesions, whereas the conservative strategy used intensive medical therapy; angioplasty was used only in patients with recurrent ischemia or hemodynamic compromise. In this trial of management of non-Q-wave MI, there was a 28% rate of cardiac
events during follow-up of 12 to 44 months but no early or late clinical benefit with routine invasive management. There was no difference in the primary end point of combined death or nonfatal MI during the average follow-up of 23 months (138 patients assigned to the invasive strategy versus 123 patients assigned to the conservative strategy, \(P=0.35\)). There was a significantly higher rate of death among patients assigned to invasive treatment both at hospital discharge (21 versus 6, \(P=0.007\)) and at 1 year (58 versus 36, \(P=0.025\)). Concern has been raised about the operative mortality rate observed in the trial (7.7% for the composite group and 11.6% for those assigned to the invasive strategy); however, it has been demonstrated that the centers enrolling patients in the trial had operative mortality rates within the expected range for all centers in the United States.

Although the TIMI-3B and VANQWISH trials did not involve identical populations, both studies failed to support the notion that an aggressive approach to revascularization in non–ST-segment elevation ACS reduces the risk of death or nonfatal MI. A contrary view was expressed in the preliminary report of the Fragmin During Instability in Coronary Artery Disease (FRISC) Trial II presented on March 7, 1999, at the 48th Scientific Sessions of the American College of Cardiology, in New Orleans, La. The FRISC report indicated that, when combined with an early invasive strategy, the LMWH dalteparin may reduce early events in patients with unstable coronary artery disease. In the open acute phase of the trial, 2267 patients with unstable angina or non–Q-wave MI received dalteparin, 120 IU/kg every 12 hours during the first 5 to 7 days. In the subsequent double-blind phase, 2015 of these patients were randomly assigned to receive subcutaneous dalteparin 5000 to 7500 IU/kg twice daily or placebo for 3 months. Results at 90 days showed no significant difference between the dalteparin and placebo groups in terms of the primary end point (death or MI); however, during the first 45 days, there was a significant reduction in the primary end point among those receiving dalteparin compared with those receiving placebo (3.7% versus 6.5%, respectively; \(P=0.003\)). During the prolonged treatment phase, the incidence of bleeding events was 26% with dalteparin and 10% with placebo. In addition to being randomly assigned to receive dalteparin or placebo, patients enrolled in FRISC II were assigned within 48 hours to invasive or noninvasive early management. The invasive strategy consisted of early coronary angiography (within 2 to 7 days), whereas the noninvasive strategy consisted of exercise testing with referral to coronary angiography if the test was positive or further events warranted it. At 6 months the rate of death or MI in the invasive group was 9.5% versus 12% in a noninvasive group (\(P=0.045\)). According to subgroup analyses, men particularly benefited from an early invasive strategy, with the rate of death or MI among invasive versus noninvasive groups at 9.1% versus 13.9%; \(P=0.002\).

It will be interesting to learn whether other antithrombotic/antiplatelet therapies will produce an environment in which medical therapy alone will be sufficient or whether it will foster improved results with aggressive interventions, which is being addressed in ongoing clinical trials (822).

More recent data from the TIMI-IIIB study (154) suggest that patients with unstable angina or non–Q-wave MI who have elevations of cTnI on admission have an increased risk of death or
nonfatal MI at 6 weeks. Clearly more studies are needed in this area before a guideline for optimal care can be suggested. In general, the outcome of patients with ischemic-type chest discomfort and isolated T wave or other minor abnormalities is favorable, and the relative role of interventions in this group is much less clear.

Glucose-Insulin-Potassium Infusion

Metabolic modulation of AMI patients, originally proposed by Sodi-Pallares (823) in 1962, was recently evaluated in a pilot trial by the Estudios Cardiologicos Latinoamerica (ECLA) Collaborative Group (824) in South America. In this recently reported study, 407 patients admitted within 24 hours of onset of symptoms of a suspected MI, regardless of age or ECG findings, were randomly assigned to either a high-dose infusion of glucose-insulin-potassium (GIK) (25% glucose, 50 IU/L soluble insulin, and 80 mmol/L KCl at a rate of 1.5 mL · kg⁻¹ · hr⁻¹ for 24 hours) or a low-dose infusion (10% glucose, 20 IU/L soluble insulin, and 50 mmol/L KCl at a rate of 1 mL · kg⁻¹ · hr⁻¹ for 24 hours) or usual care. A significant reduction in the composite end point of death, nonfatal severe heart failure (greater than Killip class 2), and nonfatal ventricular fibrillation was observed for the overall study population as well as the 252 patients (62%) who also were treated with reperfusion strategies. This latter group also showed a statistically significant reduction in mortality rate (relative risk [RR]=0.34; CI=0.78 to 0.1; 2 \( P=0.008 \)). A strong relationship was also found between the time from symptom onset and impact of infusion. A significant reduction in mortality rate was observed in patients treated ≤12 hours after symptom onset (RR=0.43; 95% CI=0.2 to 0.9; \( P=0.021 \)). Because these results show that a metabolic modulating strategy is feasible in the early hours of an AMI with a GIK infusion in contemporary practice, it is hoped that an appropriately sized clinical trial will get under way soon. The results may have strong implications for incorporating this rather simple and inexpensive therapy for the routine care of AMI patients worldwide.
IV. Hospital Management

Early, General Measures

Recommendations

Class I
1. Selection of electrocardiographic monitoring leads based on infarct location and rhythm.
2. Bed rest with bedside commode privileges for initial 12 hours in hemodynamically stable patients free of ischemic-type chest discomfort.
3. Avoidance of Valsalva.
4. Careful attention to maximum pain relief.

Class IIb
1. Routine use of anxiolytics.

Class III
1. Prolonged bed rest (>12 to 24 hours) in stable patients without complications.

Monitoring for Adverse Events

Early general measures focus on monitoring for adverse events, preventing such events through protective measures, and treating adverse events when they do occur. Electrocardiographic monitoring is an essential role of CCU staff, who must be adept at rhythm interpretation, lead selection based on infarct location and rhythm, (82) as well as lead placement for detection of right ventricular involvement (155). Computer algorithms have proved superior to medical personnel for detection of arrhythmias (156). However, the choice of lead placement and application technique (ie, skin preparation and use of conducting gels) remain essential human skills.

Blood pressure should be measured repeatedly; actual frequency will depend on the severity of the illness. Although invasive arterial monitoring (discussed in "Hospital Management") is preferred in the hypotensive patient, noninvasive monitoring is adequate for most patients. Monitoring with an automatic device that inflates and deflates at programmed intervals is useful, but it must be recognized that measurements may be inaccurate because of inappropriate cuff size or muscle contractions; marked peripheral vasoconstriction can result in falsely low readings. Furthermore, many patients report that the device is irritating and disrupts rest. Pulse oximetry is now routine for continuous monitoring of oxygen saturation and extremely helpful for providing early warning of hypoxemia.

Level of Activity

Protection against adverse events involves a variety of measures aimed at minimizing myocardial damage by maintaining a balance of oxygen supply and demand. If oxygen and aspirin therapy have not been initiated in the ED, they should be administered immediately (see "Initial Recognition and Management in the Emergency Department" for dosing), and the need for nitroglycerin should be determined (see "Rationale and Approach to Pharmacotherapy" for dosing). All healthcare providers should communicate quiet confidence.
Limiting early physical exertion and minimizing sympathetic stimulation (eg, acute ischemic-type chest discomfort and anxiety) are methods of minimizing myocardial oxygen demand that increases the area of myocardial damage when coronary blood flow is limited (157). In an earlier era the duration of bed rest was extended to several weeks until it was known that prolonged immobility is harmful because of the physiological deconditioning that occurs after even 6 hours in the supine position,(158) Preload decreases because of plasma volume losses that occur early in the bed rest period. Shifts in ventricular filling activate the body's compensatory mechanisms to buffer pressure and volume alterations. Cardiovascular dysfunction after bed rest may be more a function of these fluid shifts than deconditioning from physical inactivity (159)

A short period (=12 hours) of bed rest seems prudent for most patients with AMI with allowances for bedside commode use. Prolonged bed rest is unnecessary except for patients with AMI who are hemodynamically unstable. Low-level activities such as toileting, assisted bathing, and light ambulation should be used to prevent physiological deconditioning. Sample admitting orders are presented in Table 5.

**Table 5. Sample Admitting Orders**

| Condition: | Sericsus |
| IV: | NS or D5W to keep vein open |
| Vital signs: | q1/2 h until stable, then q 4 h and p.r.n. Notify if HR <60 or >110; BP <90 or >150; RR <8 or >22. Pulse oximetry x24 h. |
| Activity: | Bed rest with bedside commode and progress as tolerated after approximately 12 h |
| Diet: | NPO until pain free, then clear liquids. Progress to a heart-healthy diet (complex carbohydrates=50-55% of kilocalories, monounsaturated and unsaturated fats ≤30% of kilocalories), including foods high in potassium (eg, fruits, vegetables, whole grains, dairy products), magnesium (eg, green leafy vegetables, whole grains, beans, seafood), and fiber (eg, fresh fruits and vegetables, whole-grain breads, cereals). |
| Medications: | • Nasal O2 2 L/min × 3 h |
| | • Enteric-coated ASA daily (165 mg) |
| | • Stool softener daily |
| | • β-adrenoceptor blockers? |
| | • Consider need for analgesics, nitroglycerin, anxiolytics |

"Coronary precautions," designed to limit physical exertion and sympathetic stimulation, became the standard of care in the 1960s. Iced and hot fluids were restricted as were stimulant beverages, rectal temperature measurements and examinations, and vigorous back rubs; assistance with eating was common, and enforced bed rest was the norm. A recent national survey demonstrates that coronary precautions are still in practice across the United States despite the fact that research does not support their use (160)
Avoidance of the Valsalva maneuver is the only coronary precaution of universal significance. Forced expiration against a closed glottis causes sudden and intense changes in systolic blood pressure and heart rate. Changes in ventricular loading during the Valsalva maneuver may influence regional endocardial repolarization and predispose the patient to ventricular arrhythmias (161,162). Age attenuates autonomic cardiovascular responsiveness(161,163-165), so avoiding use of the Valsalva maneuver may be especially important in persons <45 years old. Stool softeners should be prescribed routinely, and a bedside commode rather than a bedpan should be used by all but the most unstable patients.

Blood pressure increases after caffeine intake (166), but the increase is not clinically significant until 400 mg of caffeine (ie, 2 to 4 cups of coffee, depending on strength and brewing method) is ingested (167). People who drink caffeinated beverages regularly develop a tolerance after 1 to 4 days (168,169), regardless of dose. Withdrawal of caffeine is associated with headache (170,171) and increases in heart rate (172). Routine caffeine drinkers can safely drink several cups of coffee daily even while in the CCU (173).

**Proper Analgesia (Use of Morphine, Anxiolytics, and the Role of Education)**

Patients with AMI typically exhibit overactivity of the sympathetic nervous system, which adversely increases myocardial oxygen demands through acceleration of heart rate, elevation of arterial pressure, augmentation of cardiac contractility, and a heightened tendency to occurrence of ventricular tachyarrhythmias (97,174). Because this sympathetic drive arises from a combination of ischemic-type chest discomfort and anxiety, a primary objective of therapy is administration of sufficient doses of an analgesic such as morphine sulfate to relieve what many patients have described as a feeling of impending doom. Morphine sulfate can be administered intravenously at a rate of 2 to 4 mg every 5 minutes, with some patients requiring as much as 25 to 30 mg before pain relief is adequate (97,175). The current practice of administering morphine in small increments to avoid paradoxic augmentation of sympathetic nervous system tone and respiratory depression may have a tendency to result in too low a cumulative dose being administered. Fear of inducing hypotension also tends to restrict the amount of morphine sulfate administered. It is important to realize that morphine-induced hypotension typically occurs in volume-depleted, orthostatic patients and is not a particular threat to supine patients (97). It may be more prudent to avoid concomitant use of other vasodilators such as intravenous nitroglycerin in patients with severe unremitting pain. Patients should be instructed to notify the nurse immediately when discomfort occurs and describe its severity using a numeric scale (eg, 1 to 10).

The depressant effect of morphine on ventilation is centrally mediated and widely appreciated. Fortunately, in the setting of AMI respiratory depression is usually not a significant clinical problem because of the sympathetic discharge associated with severe ischemic-type chest discomfort or pulmonary edema. Administration of 0.4 mg naloxone IV at up to 3-minute intervals to a maximum of 3 doses may be used to relieve morphine-induced respiratory depression, should it occur.
Patient education effectively decreases emotional distress (176), increases knowledge (177), and changes behavior following AMI. Patients want information about risk factors (178) and self-management techniques (eg, how to treat ischemic-type chest discomfort) rather than information about disease pathophysiology (eg, causes of ischemic-type chest discomfort) (179). Effective educational techniques focus on concrete, objective information before procedures are performed (180). Following are some examples of sensory information that are helpful to patients before they undergo cardiac catheterization:

- "The room will be dimly lit and may feel cool."
- "You will hear us tell you to take a deep breath and hold it."
- "The dye will make you feel hot and flushed for about 15 seconds."

Materials written at a sixth-grade reading level or below are best (181).

The decreasing length of hospital stays has raised concern about adequate opportunity for appropriate patient education (182) although short educational sequences have been shown to produce outcomes comparable to lengthy sessions (178). Innovative presentation styles (eg, programmed instruction, audiovisual techniques, health education television programs) can produce benefits comparable to individual educational sessions (177,183). All patients may not be ready to learn during hospitalization, and methods of accommodating them until they are ready are greatly needed. Responsibility for some education can be delegated to healthcare professionals who see the patient after discharge (eg, cardiac rehabilitation, home health, or office nurse). Use of a single repository for all educational materials (eg, a binder that travels with the patient) may provide consistency, document material taught, and identify goals that remain. Self-education through personal computer software or videotapes warrants further study. Inclusion of spouses in teaching also increases learning and retention over time (184).

It is important to note that 80% of all sudden cardiac deaths occur in persons with known cardiovascular disease (185). Accordingly, family members of AMI patients should be taught CPR (186), because most episodes of cardiac arrest occur within 18 months of hospital discharge (187).

Symptoms of nicotine withdrawal, anxiety, insomnia, depression, difficulty concentrating, irritability, anger, restlessness, and slowed heart rate (188) may occur in hospitalized smokers. Pharmacological therapy can be of benefit to patients experiencing nicotine withdrawal. The proper use of anxiolytics, however, is dependent on a thorough understanding of their pharmacokinetics and pharmacodynamic properties (29). Agitation and delirium are not uncommon in the CCU, particularly in patients with complicated AMI and protracted stays in the intensive care setting. In addition, a number of drugs frequently used in the CCU, such as lidocaine, mexiletine, procainamide, atropine, cimetidine, and meperidine, are capable of inducing delirium. Intravenous haloperidol is a rapidly acting neuroleptic that can be given safely and effectively to cardiac patients with agitation. It rarely produces hypotension or requires assisted ventilation. In selected patients the use of anxiolytics may prove beneficial.
Usually, however, routine use of pharmacological anxiolytics is neither necessary nor recommended. Dixon and colleagues (189) have demonstrated that anxiety, blood pressure, heart rate, and ischemic-type chest discomfort were no different in patients treated with diazepam compared with those treated with placebo. Conversely, psychological support provided during hospitalization has been shown to decrease anxiety and depression immediately and for up to 6 months after AMI (184). Liberalized visiting rules for patients in critical care can be helpful; several studies have demonstrated no harmful physiological effects attributable to unrestricted visiting policies (190,191).

**Treatment of Adverse Events**

Although the use of prophylactic antiarrhythmic agents in the first 24 hours after MI is not recommended, the availability of atropine, lidocaine, pacing paddles or a pacemaker, a defibrillator, and epinephrine remains prudent for treating important rhythm disorders.* Lidocaine in a dose of 1.0 to 1.5 mg/kg IV may be used for first-line treatment of sustained ventricular tachycardia (VT) associated with hemodynamic instability. See "Rationale and Approach to Pharmacology" for further recommendations.

Epinephrine plays a prominent role in advanced life support following a circulatory arrest associated with VF, asystole, or electromechanical dissociation (192). Although it is known to have an adverse effect on cardiac rhythm and increases myocardial oxygen demand, it does support the peripheral vascular tree and thus enhances circulation during external chest compression.

**Identification and Treatment of the Patient at Low Risk**

Several methods have been proposed to reduce the cost of caring for AMI patients: (1) identify true infarcts early; (2) provide early aggressive reperfusion; and (3) streamline the in-hospital phase of management using clinical guidelines and critical pathways, stratifying patients based on risk, and reducing length of CCU stay and total length of stay in hospital.

The ready availability of serum cardiac marker measurements in most hospitals, coupled with significant advances in techniques for rapidly measuring markers that rise into the abnormal range in <6 hours (eg, myoglobin [64,65], CK-MB isoforms [59], cardiac specific troponin T and I [56,61]) now enable clinicians to diagnose or exclude MI in uncertain cases within 8 to 12 hours from onset of chest discomfort. Use of such rapid biochemical techniques has been shown to reduce length of stay in CCUs, and clinicians are encouraged to assess their current laboratory testing protocols with a goal of more accelerated decision making (193).

*The committee strongly recommends that physicians and nurses maintain expertise in the correct differentiation of accelerated idioventricular rhythm, BBB, and monomorphic and polymorphic ventricular tachycardia.

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Several reports in the literature suggest that reperfusion protocols with thrombolytic agents or PTCA can significantly reduce hospital stay (194-197). Important independent predictors of freedom from late major complications include absence of early sustained VT or VF, absence of early sustained hypotension or cardiogenic shock, the presence of only 1 or 2 coronary arteries with significant (75%) stenosis, and a preserved LV ejection fraction (>40%) (196).

Using clinical variables at presentation, clinicians can estimate a patient's risk of mortality before administering thrombolytic therapy (102,198). Although considerable controversy centers around the relative merits of one thrombolytic agent over another, it is important to realize that several clinical variables have a greater influence on a given patient's mortality risk than the exact thrombolytic agent prescribed. A recent analysis from the contemporary reperfusion era provides useful information by summarizing the independent influence of clinical characteristics on 30-day mortality in patients with ST elevation treated with thrombolysis (199) (Figure 9).

**Figure 9.** Influence of clinical characteristics on 30-day mortality after myocardial infarction in patients treated with thrombolytic agents based on experience from the GUSTO (Global Utilization of Streptokinase and TPA for Occluded Arteries) trial. Although considerable attention has been paid to optimizing thrombolytic regimens—indeed, the small absolute differences in mortality observed with different thrombolytic regimens are controversial—it should be emphasized that the choice of the agent is far less important than are certain clinical variables with respect to mortality. This pyramid depicts the importance of such clinical characteristics as calculated from a regression analysis in the GUSTO trial. Numbers in parentheses indicate the proportion of risk of 30-day mortality associated with particular characteristics; shaded blocks indicate variables that constitute 90% of mortality seen in post-MI patients with ST elevation receiving thrombolytic therapy. tPA indicates tissue-type plasminogen activator; US Hosp, patients treated in a US hospital; CVD, cardiovascular disease; CABG, coronary artery bypass graft; DM, diabetes mellitus; AMI, acute myocardial infarction; BP, blood pressure. From Lee KL. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation. 1995;91:1659-1668. Reproduced with permission. Also modified from Management of Acute Myocardial Infarction (Julian D, Braunwald E, eds). Antman EM. Medical therapy for acute coronary syndromes: an overview. In: Califf RM, ed. Acute Myocardial Infarction and Other Acute Ischemic Syndromes. p 54, 1994, by permission of the publisher, WB Saunders Co Ltd, London.

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Triage of Patients With Acute Myocardial Infarction and Other Coronary Syndromes

The premium on cardiac intensive care beds makes it imperative that alternatives to the CCU be developed for patients for whom an MI is excluded and MI patients with a low-risk profile. Persons who are considered at very low risk and who are expected to derive little benefit from thrombolytic therapy (eg, lack of ST-segment displacement on ECG, constellation of clinical features suggesting less impact of thrombolysis on mortality) should nevertheless remain in the hospital to receive other medical interventions, including rest, antiplatelet therapy, antithrombin therapy, and β-adrenoceptor blockers.

Data compiled from multiple studies (largely before the reperfusion era) suggest that patients admitted to the CCU for observation and treatment of suspected MI can be triaged to a low-risk category (102,200-203). Although extensive data have not been recompiled in this era of reperfusion therapy for MI, clinical experience suggests that patients can be transferred safely out of the CCU as early as 24 to 36 hours after admission if they do not have a history of previous infarction, persistent ischemic pain, CHF, hypotension, heart block, or hemodynamically compromising ventricular arrhythmias. It is unlikely that such patients will require transfer back to the CCU or will die in the hospital (204).

One of the most important determinants of resource use for management of MI patients is diagnostic testing—an expenditure that may not be necessary in low-risk MI patients and that may prolong hospital stay (205). Considerable variation exists among countries in management of MI (206) across and within geographic regions in the United States (207), across medical specialties (205), among patients of differing race and gender (208), and between young and old patients with MI (209). Even after adjusting for baseline determinants of risk, part of this variation in practice patterns cannot be explained by medical issues, highlighting the need for contemporary guidelines for clinical practice and regular updating of local hospital protocols and critical pathway maps.

Two trends in nursing care have been developed to reduce costs: (1) the use of personnel with less training or without licenses in place of registered nurses and (2) changes in staff-patient ratios. Although patients identified as low risk may be able to be safely managed following such changes, few data are available to document the safety and quality implications of these trends. There is concern that reduction in staffing ratios has not only curtailed time available for in-patient education but has increased the level of stress experienced by critical-care nurses today. Additionally there are data to suggest that alterations in staffing may negatively influence patient recovery rates and treatment success. When mortality rates of hospitals documented to attract high-quality nurses were compared with a matched sample of hospitals that failed to attract such staff, the magnet hospitals had a 4.6% lower mortality rate after adjusting for differences in predicted mortality (P=126). Superior outcomes could not be attributed to patients, organizational, or physician characteristics although flexibility in staffing patterns is desirable to respond to the frequent fluctuations in levels of acuity, more data are required before a general recommendation can be made about changes in nurse staffing patterns.
Two large studies have been published that support these concerns (210,825). A survey of 7560 nurses from across the United States suggests that nurses are caring for increasing numbers of patients and are required to cross-train for more responsibilities; 74% report having less time to teach patients and families, and 69% report less time to provide basic nursing care. Forty-nine percent reported that registered nurses working on a part-time or temporary basis have replaced full-time staff, and 36% reported an increase in nonlicensed assistive personnel. Staffing and perceived quality of care were significantly lower in the Pacific and northeastern regions of the country, where managed care is prevalent (210).

Objective data on quality outcomes were obtained from the American Nurses’ Association (825) from a recent study of 502 hospitals in California, Massachusetts, and New York. These data demonstrated that adverse outcomes (ie, pressure ulcers, pneumonia [not community acquired], urinary-tract infections, and postoperative infections) and hospital lengths of stay were associated with RN staffing levels. Adverse events were higher in institutions with lower RN staffing levels. As RN staffing levels decreased, patient length of stay increased, presumably because of adverse events.

A recent report on the adequacy of staffing from the Institute of Medicine (826) concluded that there was sufficient evidence from several studies using different types of quality measures to conclude that there is a positive relationship between nursing-staff levels and the quality of care in nursing homes. The evidence is not sufficient, however, to conclude that such a relationship exists in hospitals. It has been suggested that patient variables (eg, severity of illness) contribute significantly to the variance in outcome and that adverse events may be a more sensitive marker of differences in organizational quality (ie, collaboration, leadership, organizational culture, job satisfaction) than staffing ratios (827,828). Taken together, the research in this area suggests that adverse events are not simply the result of changes in staffing levels but more a function of fundamental changes in institutions as a result of reorganization and restructuring. If so, quality-monitoring activities in hospitals will be essential as the current trend in managed care penetrates the rest of the country.

Summary of Identification and Treatment of the Patient at Low Risk
Clinicians should strive to identify patients with an acute coronary syndrome who have not sustained an MI ideally within 8 to 12 hours of onset of symptoms. This can be accomplished by serial sampling of serum cardiac markers and use of 12-lead ECGs and their interpretation in the context of the number of hours that have elapsed since onset of the patient's symptoms rather than adherence to a rigid protocol that requires a specified number of samples be drawn in the hospital. For example, to exclude an MI in a patient presenting to the ED within 4 hours of onset of ischemic-type chest discomfort, blood specimens might be drawn at admission and 8 hours later. A patient presenting 12 hours after onset of discomfort who has a normal ECG and normal serum cardiac marker levels in the ED need not be admitted to the CCU.

The mortality risk of patients who do sustain an MI can be evaluated using an integrated assessment of demographic and clinical variables according to the scheme shown in Figure 9.
Low-risk patients include those without a history of previous infarction and who do not experience persistent ischemic pain, CHF, hypotension, heart block, or hemodynamically compromising ventricular arrhythmias. Such patients can be safely transferred out of the CCU within 24 to 36 hours of admission and, provided they remain asymptomatic and without complications, constitute a group of patients who can be considered for early discharge in another 24 to 48 hours.

Identification and Treatment of the Patient at High Risk

Recommendations for Management of Recurrent Chest Discomfort

Class I
1. Aspirin for pericarditis.
2. β-Adrenoceptor blockers intravenously, then orally for ischemic-type chest discomfort.
3. (Re)administration of thrombolytic therapy (alteplase) for patients with recurrent ST elevation.
4. Coronary arteriography for ischemic-type chest discomfort recurring after hours to days of initial therapy and associated with objective evidence of ischemia in patients who are candidates for revascularization.

Class IIa
1. Nitroglycerin intravenously for 24 hours, then topically or orally for ischemic-type chest discomfort.

Class IIb
1. Corticosteroids for pericarditis.
2. Indomethacin for pericarditis.

Recurrent Chest Pain in the Post-MI Patient: Pericarditis and Ischemia

Recurrent chest pain in the patient still hospitalized after MI requires an evaluation of the cause of the pain while initiating therapy to resolve it, if possible.

The 2 most common cardiac causes of recurrent chest pain are acute pericarditis and ischemia, with the latter being the more common and potentially more serious. An ECG taken during the recurrent pain and compared with the initial one is clinically helpful. (38). Usually, recurrent pain within the first 12 hours after onset of infarction is considered to be related to the original infarction itself. Pericarditis is probably not responsible for significant chest discomfort in the first 24 hours.

Pericarditis in AMI occurs with extension of myocardial necrosis throughout the wall to the epicardium. The Multicenter Investigation of the Limitation of Infarct Size (MILIS) study (211) found that pericarditis (defined as the presence of a pericardial friction rub) occurred in 20% of 703 patients following AMI. Postinfarction pericarditis occurs in ≈25% of patients with acute transmural MI not treated with thrombolytic therapy when typical symptoms or a pericardial friction rub are accepted as indicative of pericarditis, whereas the average incidence is only 14% when the presence of a friction rub is required for the diagnosis (212). Patients with pericarditis...
have larger infarcts (defined by CK-MB), lower ejection fraction (measured with radionuclide ventriculography), and a higher incidence of CHF (211,213). Pericarditis may appear up to several weeks after AMI. Anterior chest discomfort mimicking ischemia can occur with pericarditis. However, pericardial pain usually has distinguishing characteristics such as pleuritic or positional discomfort, radiation to the left shoulder, scapula or trapezius muscle and a pericardial rub, electrocardiographic J-point elevation with concave upward ST-segment elevation and PR depression. Pericardial effusion is evident echocardiographically in >40% of cases(214) but is rarely of hemodynamic consequence. A small effusion is not diagnostic of pericarditis as it can be demonstrated in the majority of patients with AMI (87a).

Focal pericarditis can be diagnosed electrocardiographically by either persistently positive T waves or reversal of initially inverted T waves during the first week after acute transmural MI. However, similar T-wave alterations have also been observed when postinfarction pericardial effusion exists in the absence of clinically recognized pericarditis (215) Pericarditis is not associated with re-elevation of CK-MB, and there are data to suggest its incidence has decreased in the reperfusion era (216-218). Interestingly, Dressler syndrome (post-MI syndrome), an autoimmune-type carditis, has essentially disappeared (219) in the reperfusion era.

Aspirin (160 to 325 mg daily) is the treatment of choice, but high doses (650 mg every 4 to 6 hours) may be required (220,221). Indomethacin provides effective relief of symptoms; however, 1 study has presented data that suggest it may cause increased coronary vascular resistance (222) and experimentally causes thinning of developing scar (223) Ibuprofen and corticosteroids, also efficacious for pain relief, exert a tendency for thinning of scar and myocardial rupture (224,225). The risk-benefit ratio of continuing antithrombotic therapy such as heparin in the presence of acute pericarditis is always a clinical challenge. Usually such therapy can be continued safely but requires added vigilance for the detection of enlarging pericardial effusion or signs of hemodynamic instability. Any evidence of impending cardiac tamponade is an indication for prompt termination of antithrombotic therapy.

It is important to differentiate between pain due to pericarditis and that due to ischemia. The latter is more likely when the chest pain is similar to the initial ischemic-type chest discomfort, occurring at rest or with limited activity during hospitalization. This may or may not be associated with re-elevation of the CK-MB, ST-segment depression or elevation, or pseudonormalization of inverted T waves (T-wave inversion on baseline ECG becoming upright during ischemia) (214) Early recurrent angina, especially after successful reperfusion, may occur in up to 58% of patients (226).

Reinfarction has been reported to occur in ≈10% of patients during the first 10 days but only in up to 3% to 4% of patients who have undergone thrombolytic therapy and received aspirin (97,227-230) Reinfarction is associated with re-elevation of serum CK-MB after the initial peak of the index infarction. Diagnosis of reinfarction within 18 hours after initiation of thrombolytic therapy should be based on recurrence of severe ischemic-type chest discomfort lasting at least 30 minutes, usually, but not always, accompanied by recurrent ST-segment elevation of ≥0.1 mV.
in ≥2 contiguous ECG leads and re-elevation of CK-MB to more than the upper limit of normal or increased by ≥50% over the previous value (97). Pathological findings of reinfarction show areas of healing myocardium along with the more recent necrosis usually in the same vascular risk region of myocardial tissue perfused by the original infarct-related artery. Death, severe CHF, and arrhythmias are early complications of reinfarction, and there is an increased incidence of cardiogenic shock or cardiac arrest (227,231).

With recurrent suspected ischemic-type chest discomfort, coronary arteriography often clarifies the cause of chest discomfort with demonstration of a high-grade coronary obstruction. Prompt reperfusion using PTCA (if available and the lesion is suitable) or additional thrombolysis is appropriate, especially if a thrombus is present. If multiple high-grade lesions are present, more complete revascularization by CABG is appropriate.

Cardiac rupture may account for recurrent pain and occurs in 1% to 4% of all patients admitted with AMI (230,232-234). Left ventricular free wall rupture is typically heralded by chest pain and electrocardiographic ST-T wave changes with rapid progression to hemodynamic collapse and electromechanical dissociation. The frequency of cardiac rupture has 2 peaks: an early peak within 24 hours and a late one from 4 to 7 days after AMI. Early rupture is related to the initial evolution of infarction before significant collagen deposition, and late rupture is related to expansion of the infarct-related ventricular wall (90,232). Cardiac rupture is observed most frequently in patients with the first MI, those with anterior infarction, the elderly, and women. Other risk factors include hypertension during the acute phase of MI, lack of previous angina or MI, lack of collateral blood flow, Q waves on the ECG, use of corticosteroids or nonsteroidal anti-inflammatory drugs, and use of thrombolytic therapy >14 hours after onset (90,234). However, thrombolytic therapy early after AMI, ie, within 14 hours, decreases risk of cardiac rupture (91,233) The most important determinants in preventing rupture are successful early reperfusion and the presence of collateral circulation (232,233) Pseudoaneurysm is a serious complication representing rupture of the free wall. Clot forms in the pericardial space, and an aneurysmal wall containing clot and pericardium prevents exsanguination. The echocardiogram characteristically shows a small neck opening into the body of the aneurysm (87a). Surgical correction is always indicated.

Pericardiocentesis for relief of tamponade and emergency surgical repair may be lifesaving (235,236) Transesophageal echocardiography is valuable in the diagnosis of free wall rupture and pseudoaneurysm, but for relief of tamponade in this setting, rapid fluid replacement is essential. Ideally the patient should be in the operating room and fully prepared for or already on cardiopulmonary bypass to prevent hemodynamic collapse.

Heart Failure and Low-Output Syndromes

Left Ventricular Dysfunction

Pump failure due to AMI is manifested clinically by a weak pulse, poor peripheral perfusion with cool and cyanotic limbs, obtundation, and oliguria. Blood pressure (taken by cuff) is usually low, and there are variable degrees of pulmonary congestion. A third heart sound may be audible.
The treatment of LV dysfunction is determined by the specific hemodynamic derangements that are present, most importantly (1) pulmonary capillary wedge pressure, (2) cardiac output (measured with a balloon flotation catheter), and (3) systemic arterial pressure (preferably measured with an intra-arterial cannula). Often the patient has a cardiac index <2.5 L/min/m², a modestly elevated left-sided filling pressure (>18 mm Hg), and a systolic arterial pressure ≥100 mm Hg. Although this subject has evidence of LV dysfunction, systemic arterial pressure is adequate to allow for (1) modest diuresis (best accomplished with intravenous furosemide) in combination with (2) afterload and preload reduction, using nitroglycerin. Nitroglycerin offers a greater degree of venodilation than sodium nitroprusside and relieves ischemia by dilating epicardial coronary arteries. In the early hours of acute infarction, when ischemia often contributes substantially to LV dysfunction, nitroglycerin is the more appropriate agent. Its intravenous infusion should be initiated at 5 μg/min and increased gradually until mean systolic arterial pressure falls by 10% to 15% but not below 90 mm Hg. The institution of ACE inhibitor therapy is also appropriate in this setting.

The patient with more severe LV dysfunction has a depressed cardiac output, an abnormally high left-sided filling pressure, and systolic arterial pressure <90 mm Hg; this patient has, or is rapidly approaching, cardiogenic shock. If the patient is markedly hypotensive, intravenous norepinephrine should be administered until systolic arterial pressure rises to ≥80 mm Hg, at which time a change to dopamine may be attempted, beginning at 5 to 15 μg/kg per minute. Once arterial pressure is brought to ≥90 mm Hg, intravenous dobutamine may be given simultaneously in an attempt to reduce the magnitude of the dopamine infusion. In addition, consideration should be given to initiating intra-aortic balloon counterpulsation.

Recent nonrandomized and retrospective studies have suggested that mechanical reperfusion by PTCA or CABG of occluded coronary arteries may improve survival in patients with MI and cardiogenic shock. In large clinical trials such patients have an in-hospital survival rate ranging from 20% to 50% when treated with intravenous thrombolytic therapy (237-240). In other case series mechanical reperfusion with PTCA has been reported to result in hospital survival rates as high as 70%, but selection bias may have influenced these findings. A multicenter, prospective, randomized study recently confirmed this general approach (241).

In the setting of cardiogenic shock complicating AMI, emergency CABG has been used when other interventions have failed or not been indicated. A multicenter trial of surgically controlled reperfusion using total vented cardiopulmonary bypass and substrate-enhanced blood cardioplegia in patients with acute non-PTCA-related coronary occlusion noted 3.4% mortality overall with 9% mortality in patients with preoperative shock (242,243). Data from the SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock?) Registry suggest that, in some patients, emergency CABG (without specific recommendations regarding intraoperative myocardial protection strategies) is associated with lower mortality (19%) than emergency PTCA (60%) for patients with cardiogenic shock complicating AMI (241). In other
nonrandomized studies surgical mortality ranged from 12% (244) to 42% (245) but is generally superior to other treatment modalities. The efficacy of emergency CABG in patients with cardiogenic shock may be better defined by an ongoing clinical trial is more clearly defined in the recently reported SHOCK randomized trial (241).

On the basis of these earlier studies, emergency CABG should be considered for AMI patients with severe, diffuse, multivessel disease or cardiogenic shock and who are not candidates for or who have undergone unsuccessful thrombolytic therapy and/or PTCA, and who are within 4 to 6 hours of onset of MI. In the case of patients with cardiogenic shock whose coronary anatomy is unsuitable for PTCA, this time window can extend to 18 hours from the onset of shock.

**Right Ventricular Infarction and Dysfunction**

Right ventricular (RV) infarction encompasses a spectrum of disease states ranging from asymptomatic mild right ventricular dysfunction through cardiogenic shock. Most patients demonstrate a return of normal RV function over a period of weeks to months, suggesting RV stunning has occurred rather than irreversible necrosis. In this sense RV ischemia can be demonstrated in up to half of all inferior MIs, although only 10% to 15% of patients show classical hemodynamic abnormalities (246,247).

Right ventricular infarction accompanying inferior MIs is associated with a significantly higher mortality (25% to 30%) and thus identifies a high-risk subgroup of patients with inferior MIs (6%) who should be considered high-priority candidates for reperfusion (246). One group of investigators recently reported a 31% in-hospital mortality rate in patients with inferior MIs complicated by RV infarction compared with 6% in patients who had an inferior MI without RV involvement (246). The treatment of patients with RV ischemia is different and occasionally diametrically opposed to management of LV dysfunction.

**Anatomic and Pathophysiological Considerations**

The right coronary artery usually supplies most of the RV myocardium; thus, occlusion of this artery proximal to the RV branches will lead to RV ischemia (248). Hemodynamically significant RV infarctions occur almost exclusively in the setting of inferior AMIs (249). Because the right ventricle has a much smaller muscle mass than the left ventricle, due to the lower vascular resistance of the pulmonary circuit, myocardial oxygen demand is significantly less than that of the left ventricle (250) Coronary perfusion of the right ventricle occurs in both systole and diastole (250). The right ventricle also has a more favorable oxygen supply-demand ratio than the left ventricle, because of the more extensive collateral flow from left to right (251,252) These factors likely explain the absence of hemodynamically significant RV ischemia in most patients with proximal right coronary artery occlusions, as well as improvement in RV function observed in the majority of patients following RV ischemia (253).

The severity of the hemodynamic derangements associated with RV ischemia is related to (1) the extent of ischemia and subsequent RV dysfunction, (2) the restraining effect of the surrounding pericardium, and (3) interventricular dependence related to the shared interventricular septum.
When the right ventricle becomes ischemic, it acutely dilates, resulting in an increased intrapericardial pressure caused by the restraining forces of the pericardium. As a consequence, there is a reduction in RV systolic pressure and output, decreased LV preload, a reduction in LV end-diastolic dimension and stroke volume, and a shifting of the interventricular septum toward the left ventricle (254). Because of this RV systolic and diastolic dysfunction, the pressure gradient between the right and left atria becomes an important driving force for pulmonary perfusion. Factors that reduce preload (volume depletion, diuretics, nitrates) or diminish augmented right atrial contraction (concomitant atrial infarction, loss of AV synchrony), as well as factors that increase RV afterload (concomitant LV dysfunction), are likely to have profoundly adverse hemodynamic effects (255-257). Goldstein and coworkers (256) have demonstrated the importance of a paradoxical interventricular septal motion that bulges in pistonlike fashion into the right ventricle, generating systolic force, which allows pulmonary perfusion. The loss of this compensatory mechanism with concomitant septal infarction may result in further deterioration in patients with RV ischemia.

**Clinical Diagnosis**

Evidence of RV ischemia should be sought in all patients with acute inferior MI. The clinical triad of hypotension, clear lung fields, and elevated jugular venous pressure in the setting of an inferior MI is characteristic of RV ischemia. Although specific, this triad has a sensitivity of <25% (258). Distended neck veins alone or the presence of Kussmaul's sign (distention of the jugular vein on inspiration) are both sensitive and specific for RV ischemia in patients with an inferior MI (259). These findings may be masked in the setting of volume depletion and may only become evident after adequate volume loading. A right atrial pressure $\geq 10$ mm Hg and $>80\%$ of pulmonary wedge pressure is a relatively sensitive and specific finding in patients with RV ischemia (260).

Demonstration of 1 mm ST-segment elevation in the right precordial lead V4R is the single most predictive electrocardiographic finding in patients with RV ischemia (261). The finding may be transient; half of patients show resolution of ST elevation within 10 hours of onset of symptoms (262). It is important for physicians to ensure that hospital personnel (house officer, nurse, technician) recording the ECG in this setting know how to properly record lead V4R, especially in view of the variety of multilead recording systems available. All patients with inferior infarctions should be screened initially for this finding at the time of admission. Critical-care staff should be encouraged to choose routine monitoring leads based on infarct site. Echocardiography can be helpful in patients with suspicious but nondiagnostic findings (87a). It can show RV dilation and asynergy, abnormal interventricular and interatrial septal motion, and even right to left shunting through a patent foramen ovale (263-265). This latter finding is unique to RV ischemia and should be suspected when persistent hypoxia is not responsive to supplemental oxygen (265).

**Management of Right Ventricular Ischemia/Infarction**

Treatment of RV infarction includes early maintenance of RV preload, reduction of RV afterload, inotropic support of the dysfunctional right ventricle, and early reperfusion (73) (Table 6).
Because of their influence on preload, drugs routinely used in management of LV infarctions, such as nitrates and diuretics, may reduce cardiac output and produce severe hypotension when the right ventricle is ischemic. Indeed, a common clinical presentation for RV infarction is profound hypotension following administration of sublingual nitroglycerin, with the degree of hypotension often out of proportion to the electrocardiographic severity of the infarct. Volume loading with normal saline alone often resolves accompanying hypotension and improves cardiac output. Volume loading is a critical first step in the management of hypotension associated with RV ischemia; inotropic support (in particular, dobutamine hydrochloride) should be initiated promptly if cardiac output fails to improve after 0.5 to 1 L to 2 L of fluid has been given.

Another important factor for sustaining adequate RV preload is maintenance of AV synchrony. High-degree heart block is common, occurring in as many as half of these patients (268). Atrioventricular sequential pacing leads to a significant increase in cardiac output and reversal of shock, even when ventricular pacing alone has not been of benefit (269). Atrial fibrillation occurs in up to one third of patients with RV ischemia (270) and has profound hemodynamic effects. Prompt cardioversion from atrial fibrillation should be considered at the earliest sign of hemodynamic compromise. When LV dysfunction accompanies RV ischemia, the right ventricle is further compromised because of increased RV afterload and reduction in stroke volume (271). In such circumstances, the use of afterload-reducing agents such as sodium nitroprusside or an intra-aortic counterpulsation device is often necessary to "unload" the left and subsequently the right ventricle.

**Table 6. Treatment Strategy for Right Ventricular Ischemia/Infarction**

<table>
<thead>
<tr>
<th>Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintain right ventricular preload</td>
</tr>
<tr>
<td>Volume loading (IV normal saline)</td>
</tr>
<tr>
<td>Avoid use of nitrates and diuretics</td>
</tr>
<tr>
<td>Maintain AV synchrony</td>
</tr>
<tr>
<td>AV sequential pacing for symptomatic high-degree heart block unresponsive to atropine</td>
</tr>
<tr>
<td>Prompt cardioversion for hemodynamically significant SVT</td>
</tr>
<tr>
<td>Inotropic support</td>
</tr>
<tr>
<td>Dobutamine (if cardiac output fails to increase after volume loading)</td>
</tr>
<tr>
<td>Reduce right ventricular preload with left ventricular dysfunction</td>
</tr>
<tr>
<td>Intra-aortic balloon pump</td>
</tr>
<tr>
<td>Arterial vasodilators (sodium nitroprusside, hydralazine)</td>
</tr>
<tr>
<td>ACE inhibitors</td>
</tr>
<tr>
<td>Reperfusion</td>
</tr>
<tr>
<td>Thrombolytic agents</td>
</tr>
<tr>
<td>Primary PTCA</td>
</tr>
<tr>
<td>CABG (in selected patients with multivessel disease)</td>
</tr>
</tbody>
</table>

IV indicates intravenous; AV, atrioventricular; SVT, supraventricular tachycardia; ACE, angiotensin converting enzyme; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft.
Fibrinolytic therapy and primary PTCA with subsequent reperfusion have been shown to improve RV ejection fraction (272) and reduce the incidence of complete heart block (272-274).

**Prognosis**
The mere presence of RV ischemia evident by noninvasive criteria is associated with significantly increased short-term morbidity and mortality and may also influence long-term outcome (246,275,276). Clinical and hemodynamic recovery eventually occur even in patients with RV dysfunction (259,277-279) that persists for weeks or months. This return to normal may be due to improvement of concomitant LV dysfunction, resulting in a reduction in RV afterload, or to a gradual stretching of the pericardium with amelioration of its restraining effect (277).

**Hemodynamic Monitoring**
**Recommendations for Balloon Flotation Right-Heart Catheter Monitoring**

**Class I**
1. Severe or progressive CHF or pulmonary edema.
2. Cardiogenic shock or progressive hypotension.
3. Suspected mechanical complications of acute infarction, ie, VSD, papillary muscle rupture, or pericardial tamponade.

**Class IIa**
1. Hypotension that does not respond promptly to fluid administration in a patient without pulmonary congestion.

**Class III**
1. Patients with acute infarction without evidence of cardiac or pulmonary complications.

The balloon flotation catheter is often very helpful in management of AMI and concomitant hemodynamic instability, including low cardiac output, hypotension, persistent tachycardia, pulmonary edema, and apparent cardiogenic shock. In the patient with hypotension and tachycardia, the balloon flotation catheter allows quick and easy differentiation of (1) inadequate intravascular volume, with a resultant low left-sided filling pressure, and (2) adequate intravascular volume and a high left-sided filling pressure due to extensive LV dysfunction. Treatment of the former is prompt expansion of intravascular volume (with normal saline), whereas management of the latter often includes diuresis, inotropic support, afterload reduction, and/or other supportive measures. In those with extensive LV dysfunction, a balloon flotation catheter in the right side of the heart can be used to monitor therapeutic efforts to adjust the left-sided filling pressure so as to maximize cardiac output at the lowest possible filling pressure. These sophisticated manipulations of intracardiac pressures and cardiac output are usually made considerably easier with information provided by a flotation catheter.

Although the balloon flotation catheter is quite safe when used by experienced operators, its use has a recognized association with adverse events, including ventricular tachyarrhythmias (during its manipulation) and pulmonary hemorrhage or infarction. In addition, it causes some patient discomfort and requires that the patient be relatively immobile. Because the pressure waveform recorded from the catheter tip may be distorted, the clinician should routinely examine the actual
waveform rather than rely on the digital display of pressure. Because of the risk of infection, balloon flotation catheters generally should not remain in the same site for >5 days.

Recommendations for Intra-arterial Pressure Monitoring

Class I
1. Patients with severe hypotension (systolic arterial pressure <80 mm Hg) and/or cardiogenic shock.
2. Patients receiving vasopressor agents.

Class IIa
1. Patients receiving intravenous sodium nitroprusside or other potent vasodilators.

Class IIb
1. Hemodynamically stable patients receiving intravenous nitroglycerin for myocardial ischemia.
2. Patients receiving intravenous inotropic agents.

Class III
1. Patients with acute infarction who are hemodynamically stable.

All CCUs should have the equipment and personnel to monitor intra-arterial pressure. Such monitoring is useful in all hypotensive patients, particularly those with cardiogenic shock. Long-term monitoring is best accomplished through the radial artery, although the brachial or femoral arteries may be used as alternatives. Perfusion of the limb or hand distal to the catheter site must be carefully and periodically examined for evidence of ischemia. Because of risk of arterial thrombosis and infection, intra-arterial catheters generally should not remain in the same arterial site for prolonged periods of time, certainly no longer than 72 hours. Intra-arterial and central catheters can be left in place for this amount of time only if carefully inserted and properly cared for with a sterile occlusive dressing. Before insertion, the site should be adequately prepared under sterile conditions. Antibacterial ointments are no longer recommended (280).

Recommendations for Intra-aortic Balloon Counterpulsation

Class I
1. Cardiogenic shock not quickly reversed with pharmacological therapy as a stabilizing measure for angiography and prompt revascularization.
2. Acute mitral regurgitation or VSD complicating MI as a stabilizing therapy for angiography and repair/revascularization.
3. Recurrent intractable ventricular arrhythmias with hemodynamic instability.
4. Refractory post-MI angina as a bridge to angiography and revascularization.

Class IIa
1. Signs of hemodynamic instability, poor LV function, or persistent ischemia in patients with large areas of myocardium at risk.

Class IIb
1. In patients with successful PTCA after failed thrombolysis or those with 3-vessel coronary disease to prevent reocclusion.
2. **In patients known to have large areas of myocardium at risk with or without active ischemia.**

Since its introduction in the late 1960s, intra-aortic balloon counterpulsation has been recognized as an effective treatment for patients with unstable ischemic syndromes and cardiogenic shock (281-286). Reduction of LV afterload by rapid deflation of the balloon in end diastole appears to be the predominant mechanism of the balloon's effect (287,288). By inflating in diastole, the balloon also raises diastolic coronary and systemic perfusion. Studies on the effects of this increased perfusion pressure on coronary blood flow and myocardial oxygen consumption have yielded conflicting results (289,290) Recently Kern et al(291), using Doppler flow velocity measurements, were able to show a nearly 2-fold increase in proximal coronary flow velocity. This combination of decreased myocardial oxygen demand and maintained or improved coronary flow make intra-aortic balloon pumping a powerful tool for patients with cardiogenic shock or acute ischemic syndromes.

Counterpulsation was first used as a stand-alone modality to treat patients with post-MI cardiogenic shock (281). Counterpulsation stabilized most patients, but in-hospital mortality remained a dismal 83% (281). In virtually all shock-management strategies in which counterpulsation is used today, it acts as a stabilizing device or bridge to facilitate diagnostic angiography and revascularization or repair. In selected patient populations survival rates for cardiogenic shock treated in the first 16 to 24 hours with intra-aortic balloon pumping and surgical and angioplasty revascularization range between 60% and 75% (284,292). Similarly, intra-aortic balloon pumping and early repair for acute VSD and mitral regurgitation show survival rates of 60% or sometimes higher (285). Patients with severe recurrent ischemia after MI can be stabilized with an intra-aortic balloon pump so that they can undergo angiography and emergency revascularization with PTCA or CABG (240).

Several early studies, before reperfusion therapy, showed that routine prophylactic use of intra-aortic balloon pumping in AMI (282,293) did not affect infarct size. A retrospective review of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials suggested that placement of an intra-aortic balloon pump after reperfusion with either thromolytic therapy or PTCA reduced the incidence of reocclusion (294). In a subsequent randomized trial, patients with rescue PTCA at 90 minutes or those with 3-vessel CAD(295) showed a reduction of reocclusion events from 21% to 8% after intra-aortic balloon pumping. In a second randomized trial of the use of prophylactic placement of these devices in high-risk patients (age >70, ejection fraction <45%, 3-vessel disease, suboptimal PTCA, saphenous graft occlusion, ventricular arrhythmias) undergoing primary PTCA, 437 patients were studied to determine the effect of balloon pumping on resulting LV function and a composite clinical end point (death, reocclusion, reinfarction, CHF, and stroke). There was no significant difference in clinical outcome, including rate of reocclusion (6.2% versus 8.0%), nor did it influence global or regional LV function (296). However, there was a reduction in the incidence of recurrent ischemia, including the need for repeat angiography and PTCA of the infarct-related artery. In summary, for patients without LV dysfunction, the prophylactic and routine use of intra-aortic balloon pumping following either reperfusion strategy cannot be recommended.
Rhythm Disturbances

Atrial Fibrillation

Recommendations

Class I

1. Electrical cardioversion for patients with severe hemodynamic compromise or intractable ischemia.
2. Rapid digitalization to slow a rapid ventricular response and improve LV function.
3. Intravenous β-adrenoceptor blockers to slow a rapid ventricular response in patients without clinical LV dysfunction, bronchospastic disease, or AV block.
4. Heparin should be given.

Class IIa

1. Either diltiazem or verapamil intravenously to slow a rapid ventricular response if β-adrenoceptor blocking agents are contraindicated or ineffective.

Atrial fibrillation (AF) associated with AMI most often occurs within the first 24 hours and is usually transient but may recur. The incidence of AF in AMI ranges from 10% to 16% (297,298), whereas atrial flutter or supraventricular tachycardia is much less frequent. The consequences and acute treatment of all 3 conditions may be considered together, recognizing that in atrial flutter and supraventricular tachycardia, atrial pacing may be effective in terminating the tachycardia (299-305). The incidence of AF increases with age, occurring in 4.2% of patients aged ≤59 years and in 16% of patients aged ≥70. Atrial fibrillation occurs more often in patients with larger infarcts, those anterior in location, and in patients whose hospital course is complicated by CHF, complex ventricular arrhythmias, advanced AV block, atrial infarction, or pericarditis. Atrial fibrillation may also occur in patients with inferior MI secondary to proximal right coronary artery occlusion due to involvement of the sinoatrial nodal artery, which provides the major blood supply to the atria.

The incidence of AF after AMI is decreased in patients receiving thrombolytic therapy (300,306), and in the GUSTO trial patients treated with accelerated alteplase and intravenous heparin had a significantly lower incidence of AF and atrial flutter compared with other fibrinolytic therapies (228). The occurrence of AF is also associated with excess catecholamine release, hypokalemia, hypomagnesemia, hypoxia, underlying chronic lung disease, and ischemia of the sinus node or left atrial circumflex arteries (270,297,300,307-310).

Systemic embolization is more frequent in patients with paroxysmal AF (1.7%) compared with those without (0.6%), with one half of embolic events occurring on the first day of hospitalization and >90% occurring by the fourth day (298). Because AF can be associated with pericarditis, the development of PR-segment displacement on serial ECGs may predict risk of developing AF during hospitalization(306).
When hemodynamic compromise occurs due to rapid ventricular rate or loss of atrial contraction, immediate cardioversion is indicated, beginning with 100 J, then 200 to 300 J, then 360 J if lower energies fail. In the conscious patient, support with brief anesthesia is essential.

In the absence of CHF or severe pulmonary disease, one of the most effective means of slowing the ventricular rate in AF is the use of intravenous β-adrenoceptor blocking agents such as atenolol (2.5 to 5.0 mg over 2 minutes to a total of 10 mg in 10 to 15 minutes) or metoprolol (2.5 to 5.0 mg every 2 to 5 minutes to a total of 15 mg over 10 to 15 minutes). Heart rate, blood pressure, and the ECG should be monitored, and treatment should be halted when therapeutic efficacy is achieved or if systolic blood pressure falls below 100 mm Hg or heart rate below 50 bpm during treatment.

Rapid administration of digitalis to achieve rate slowing may be accomplished by giving intravenous digoxin (8 to 15 µg/kg [0.6 to 1.0 mg in a person weighing 70 kg]) with half the dose administered initially and the additional increment in 4 hours. This method provides a slower response than intravenous β-adrenoceptor blockade; however, some effect on rate slowing may be detectable in one half to 2 hours.

Rate slowing may also be achieved by intravenous verapamil (5 to 10 mg [0.075 to 0.15 mg/kg]) given over 2 minutes with a repeat dose 30 minutes later or similarly by intravenous bolus administration of diltiazem (20 mg [0.25 mg/kg]) over 2 minutes followed by an infusion of 10 mg/h. If rate response is inadequate, a second dose of diltiazem (25 mg [0.35 mg/kg]) may be given over 2 minutes after an interval of 15 minutes. A subsequent infusion is given at a rate of 10 to 15 mg/h. Because of their negative inotropic effect and newer concerns regarding the use of calcium channel blockers in AMI, these agents are not recommended as first-line drugs despite their effectiveness in slowing heart rate, especially if given to patients also receiving β-blocking agents. Although AF after AMI is usually transient, heparin therapy should be given to patients not already receiving it.

Guidelines for use of Class I and Class III antiarrhythmic agents and electric shock for converting persistent AF have not been formulated. It is not clear whether antiarrhythmic agents should be used for prevention of AF if it recurs during hospitalization, although its recurrence portends a worse prognosis. For this reason it has become common practice to use antiarrhythmic agents such as quinidine, procainamide, or, preferably, amiodarone or sotalol (312) Transient AF does not obligate the patient to receive long-term anticoagulation or antiarrhythmic agents, but if such treatment is elected, it is appropriate to limit their use to 6 weeks if sinus rhythm has been restored.

**Ventricular Tachycardia/Ventricular Fibrillation**

**Recommendations**

**Class I**
1. Ventricular fibrillation should be treated with an unsynchronized electric shock with an initial energy of 200 J; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.

2. Sustained (>30 seconds or causing hemodynamic collapse) polymorphic VT should be treated with an unsynchronized electric shock using an initial energy of 200 J; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.

3. Episodes of sustained monomorphic VT associated with angina, pulmonary edema, or hypotension (blood pressure <90 mm Hg) should be treated with a synchronized electric shock of 100 J initial energy. Increasing energies may be used if not initially successful.

4. Sustained monomorphic VT not associated with angina, pulmonary edema, or hypotension (blood pressure <90 mm Hg) should be treated with one of the following regimens:
   a. Lidocaine: bolus 1.0 to 1.5 mg/kg. Supplemental boluses of 0.5 to 0.75 mg/kg every 5 to 10 minutes to a maximum of 3 mg/kg total loading dose may be given as needed. Loading is followed by infusion of 2 to 4 mg/min (30 to 50 µg/kg per minute).
   b. Procainamide: 20 to 30 mg/min loading infusion, up to 12 to 17 mg/kg. This may be followed by an infusion of 1 to 4 mg/min.
   c. Amiodarone: 150 mg infused over 10 minutes followed by a constant infusion of 1.0 mg/min for 6 hours and then a maintenance infusion of 0.5 mg/min.
   d. Synchronized electrical cardioversion starting at 50 J (brief anesthesia is necessary).

Comment: Knowledge of the pharmacokinetics of these agents is important because dosing varies considerably, depending on age, weight, and hepatic and renal function.

Class IIa
1. Infusions of antiarrhythmic drugs may be used after an episode of VT/VF but should be discontinued after 6 to 24 hours and the need for further arrhythmia management assessed.

2. Electrolyte and acid-base disturbances should be corrected to prevent recurrent episodes of VF when an initial episode of VF has been treated.

Class IIb
1. Drug-refractory polymorphic VT should be managed by aggressive attempts to reduce myocardial ischemia, including therapies such as β-adrenoceptor blockade, intra-aortic balloon pumping, and emergency PTCA/CABG surgery. Amiodarone, 150 mg infused over 10 minutes followed by a constant infusion of 1.0 mg/min for up to 6 hours and then a maintenance infusion at 0.5 mg/min, may also be helpful.

Class III
1. Treatment of isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained VT.

2. Prophylactic administration of antiarrhythmic therapy when using thrombolytic agents.
Ventricular Fibrillation—Background
Disturbances of cardiac rhythm are common during AMI. Early-phase arrhythmias are probably largely a result of micro reentry. Although other electrophysiological mechanisms such as enhanced automaticity and triggered activity have been proposed in experimental models of MI, convincing evidence of their role in human MI is not yet established (313). Important contributory factors include heightened adrenergic nervous system tone, hypokalemia, hypomagnesemia, intracellular hypercalcemia, acidosis, free fatty acid production from lipolysis, and free radical production from reperfusion of ischemic myocardium (313-315). The relative importance of each of these factors in the pathogenesis of arrhythmias during AMI has not been established, nor has it been clearly shown that aggressive measures specifically targeted at 1 or more of these mechanisms can be relied on clinically to reduce arrhythmia frequency in AMI.

Primary VF should be distinguished from secondary VF, the latter occurring in the presence of severe CHF or cardiogenic shock (316). Late VF develops >48 hours after onset of infarction. The incidence of primary VF is highest (around 3% to 5%) in the first 4 hours after MI and declines markedly thereafter (317). Epidemiological data suggest that the incidence of primary VF in AMI may be decreasing in the current era, possibly due to aggressive attempts at infarct-size reduction, correction of electrolyte deficits, and a greater use of β-adrenoceptor blocking agents (318). Contrary to prior belief, primary VF appears to be associated with a significantly higher in-hospital mortality, but those persons who survive to hospital discharge have the same long-term prognosis as patients who do not experience primary VF (319).

Management Strategies for Ventricular Fibrillation
Prophylaxis
Primary VF remains an important contributor to risk of mortality during the first 24 hours after MI. Therefore, a reliable method for its prediction and prevention remains desirable but has not been established despite extensive clinical investigation. Classification of ventricular arrhythmias in ascending order of risk of primary VF ("warning arrhythmias") was proposed, but this approach lacks appropriate specificity and sensitivity (320-322).

Accelerated idioventricular rhythm occurs frequently during the first 12 hours of infarction. Data from the prereperfusion era do not support development of accelerated idioventricular rhythm as a risk factor for development of VF (321,323). In patients receiving thrombolysis or undergoing primary PTCA, accelerated idioventricular rhythm may be a reperfusion arrhythmia and does not indicate an increased risk of VF (324). Thus, it is best managed by observation and should not trigger initiation of antiarrhythmic prophylaxis against VF.

Meta-analysis of randomized trials of prophylaxis with lidocaine has shown a reduction in the incidence of primary VF by \( \approx 33\% \), but this was offset by a trend toward increased mortality, probably from fatal episodes of bradycardia and asystole (325). The prior practice of routine ("prophylactic") administration of lidocaine to all patients with known or suspected MI has been largely abandoned in most contemporary CCU protocols because of an unfavorable risk-benefit
ratio and a decreased incidence of the target arrhythmia. Thus, its routine use is not recommended, with the possible exception being situations in which a defibrillator is unavailable, provided there is a skilled professional always available who can initiate CPR if asystole occurs. Prophylactic regimens with other antiarrhythmic drugs have not been evaluated as extensively as lidocaine, and no other agents, even including the close structural analogues mexiletine and tocainide, have been shown to decrease the incidence of primary VF when given on a prophylactic basis.

Routine administration of intravenous β-adrenoceptor blockers to patients without hemodynamic or electrical (AV block) contraindications is associated with a reduction in incidence of early VF. Intravenous followed by oral β-adrenoceptor blockers should be given in the absence of contraindications. Suitable regimens include intravenous metoprolol (5 mg every 2 minutes for 3 doses, if tolerated, followed by 50 mg orally twice a day for ≥24 hours and then increased to 100 mg twice a day). An alternative regimen is atenolol (5 to 10 mg intravenously followed by 100 mg orally on a daily basis).

Clinical experience as well as observational data from CCU populations has identified hypokalemia as an arrhythmogenic risk factor for VF. Low serum levels of magnesium have not been clearly shown to be associated with an increased risk of VF, although tissue depletion of magnesium remains a potential risk factor. Although randomized clinical trial data do not exist to confirm the benefits of repletion of potassium and magnesium deficits in preventing VF, it is sound clinical practice to maintain serum potassium levels at >4.0 mEq/L and magnesium levels at >2.0 mEq/L in patients with AMI.

**Treatment**

Ventricular fibrillation should be treated with an unsynchronized electric shock using an initial energy of 200 J. If this is unsuccessful, a second shock using 200 to 300 J and, if necessary, a third shock using 360 J is indicated. Ventricular fibrillation that is not easily converted by defibrillation may be treated with additional adjunctive measures. No rigorous scientific support exists to favor one pharmacological treatment program over another or even to confirm that they improve the likelihood of resuscitation over repeated shocks given alone. The ACLS protocol recommends adjunctive therapy in the following hierarchy, as needed, for resistant VF: (1) epinephrine (1 mg IV push); (2) lidocaine (1.5 mg/kg); (3) bretylium (5 to 10 mg/kg). Intravenous amiodarone (150 mg bolus), now available, also may be used.

There are no firm data to help define an optimal management strategy for prevention of recurrent VF in patients who have sustained an initial episode of VF in the setting of MI. It seems prudent to correct any electrolyte and acid-base disturbances and administer β-adrenoceptor-blocking agents to inhibit increased sympathetic nervous system tone and prevent ischemia. If infusion of an antiarrhythmic drug is initiated (eg, lidocaine 2 mg/min), it should probably be maintained for only 6 to 24 hours and then discontinued so that the patient's ongoing need for antiarrhythmic treatment can be reassessed.
**Ventricular Tachycardia—Background**

Several definitions have been used for VT in the setting of AMI. Nonsustained VT lasts <30 seconds, whereas sustained VT lasts >30 seconds and/or causes earlier hemodynamic compromise requiring immediate intervention. Based on electrocardiographic appearance, VT has also been categorized as monomorphic or polymorphic. While short bursts (<5 beats) of nonsustained VT of either monomorphic or polymorphic configuration may be seen frequently, contemporary epidemiological data do not suggest that they are associated with a sufficiently increased risk of sustained VT or VF to warrant a recommendation of prophylactic therapy.

The vast majority of post-MI VT and VF occur within the first 48 hours of MI (317). Sustained VT or VF occurring outside of this time frame deserves careful evaluation, including consideration of electrophysiology studies. In addition, monomorphic VT at rates <170 bpm are unusual as a post-MI arrhythmia and suggests a more chronic (mature) arrhythmogenic substrate (327-330).

**Management Strategies for Ventricular Tachycardia**

1. Only for episodes of sustained hemodynamically compromising VT is treatment always indicated (313). In the absence of clinical evidence of effective perfusion, urgent electrical conversion of VT is indicated. Rapid, polymorphic-appearing VT should be considered similar to VF and managed with an unsynchronized discharge of 200 J, while monomorphic VT with rates >150 bpm can usually be treated with a 100-J synchronized discharge (326). If the patient is hemodynamically stable, brief trials of medications (lidocaine or procainamide) may be given first. Immediate cardioversion is generally not needed for rates <150 bpm.

2. Episodes of sustained VT that are somewhat better tolerated hemodynamically may initially be treated with one of the following drug regimens:
   a. **Lidocaine**: bolus 1.0 to 1.5 mg/kg. Supplemental boluses of 0.5 to 0.75 mg/kg every 5 to 10 minutes to a maximum of 3 mg/kg total loading dose may be given as needed. Loading is followed by infusion of 2 to 4 mg/min (30 to 50 μg/kg per minute). In older patients and those with CHF or hepatic dysfunction, infusion rates should be reduced to avoid lidocaine toxicity.
   b. **Procainamide**: 20 to 30 mg/min loading infusion, up to 12 to 17 mg/kg. This may be followed by an infusion of 1 to 4 mg/min. Infusion rates should be lower in the presence of renal dysfunction.
   c. **Amiodarone**: 150 mg infused over 10 minutes followed by a constant infusion of 1.0 mg/min for 6 hours and then a maintenance infusion at 0.5 mg/min.

3. Rare episodes of drug-refractory sustained polymorphic VT ("electrical storm") have been reported in cases of AMI. Anecdotal evidence suggests that these may be related to uncontrolled ischemia and increased sympathetic tone and are best treated by intravenous β-adrenoceptor blockade (331), intravenous amiodarone (332), intra-aortic balloon pumping, or emergency revascularization.

**Bradyarrhythmias and Heart Block**
Background, Epidemiology, and Importance
Sinus bradycardia occurs frequently (in 30% to 40% of patients) with AMI, especially within the first hour of inferior MI and with reperfusion of the right coronary artery (Bezold-Jarisch reflex), a result of increased parasympathetic activity (vagal tone) (97). Heart block may develop in ≈6% to 14% of patients with AMI and predicts an increased risk of in-hospital mortality but is a poor predictor of long-term mortality in those surviving to discharge (333-335). Intraventricular conduction delay has been reported in ≈10% to 20% of patients with AMI in past reviews (336). Of AMI patients entered in recent thrombolysis trials, BBB was present on admission in only 4% but predicted a substantially increased in-hospital mortality. (27)

The increased mortality associated with heart block and intraventricular conduction delay is related more to extensive myocardial damage than to heart block as such. Indeed, pacing has not been clearly shown to reduce mortality associated with AV block or intraventricular conduction delay (334,337). The difficulty in showing benefit may reflect the overriding impact on mortality of extensive infarction that may obscure benefit in a fraction of these patients (337,338). Thus, pacing to protect against sudden hypotension, acute ischemia, and precipitation of ventricular arrhythmias associated with sudden heart block is still recommended in selected high-risk patients.

Prognosis
Prognosis in AV block is related to the site of infarction (anterior versus inferior), the site of block (intranodal [proximal]-above the His bundle-versus infranodal [distal]-below the His bundle), the nature of the escape rhythm, and the hemodynamic consequences (221,337-339).

The risk of developing heart block with AMI is increased when 1 or more of the following are present: first-degree AV block, Mobitz type I AV block, Mobitz type II AV block, left anterior hemiblock, left posterior hemiblock, right bundle branch block (RBBB), and LBBB.

Treatment
Recommendations for Atropine (also see "Initial Recognition and Management in the Emergency Department" for early use)

Class I
1. Symptomatic sinus bradycardia (generally, heart rate <50 bpm associated with hypotension, ischemia, or escape ventricular arrhythmia).
2. Ventricular asystole.
3. Symptomatic AV block occurring at the AV nodal level (second-degree type I or third-degree with a narrow-complex escape rhythm)

Class IIa
None.

Class III
1. Atrioventricular block occurring at an infranodal level (usually associated with anterior MI with a wide-complex escape rhythm).
2. Asymptomatic sinus bradycardia.
Atropine reverses decreases in heart rate, systemic vascular resistance, and blood pressure mediated by parasympathetic (cholinergic) activity. Atropine is useful for treating symptomatic sinus bradycardia, and may be beneficial in the presence of AV block at the AV node level or for ventricular asystole (326). Atropine is most effective for sinus bradycardia occurring within 6 hours of onset of symptoms of AMI (336). Sinus bradycardia at this time may be related to ischemia, reperfusion (Bezold-Jarisch reflex), ischemic-type chest discomfort, or morphine or nitroglycerin therapy. Atropine is also effective for profound sinus bradycardia with hypotension associated with thrombolytic therapy (especially of the right coronary artery) (340). Atropine should be used with caution in the setting of AMI because of the protective effect of parasympathetic tone against VF and myocardial infarct extension. (326,341). Doses in increments of 0.5 mg, titrated to achieve minimally effective heart rate (for example, about 60 bpm), up to a maximum of 2.0 mg, may be given (342) (Doses <0.5 mg occasionally may elicit a parasympathomimetic response with a paradoxic slowing of heart rate.)

Temporary Pacing
Pacing recommendations in these revised guidelines place more emphasis on transcutaneous pacing (1). The newly available transcutaneous pacemaker systems are suitable for providing standby pacing in AMI, especially for those not requiring immediate pacing and at only moderate risk of progression to AV block, and do not entail the difficulty in application and risk of complications of intravenous systems (343,344). Transcutaneous technology is also well suited to patients receiving thrombolytic therapy, reducing the need for vascular interventions.

Recommendations for Placement of Transcutaneous Patches* and Active (Demand) Transcutaneous Pacing†(326)

Class I
1. Sinus bradycardia (rate <50 bpm) with symptoms of hypotension (systolic blood pressure <80 mm Hg) unresponsive to drug therapy.†
2. Mobitz type II second-degree AV block.†
3. Third-degree heart block.†
4. Bilateral BBB (alternating BBB, or RBBB and alternating left anterior fascicular block [LAFB], left posterior fascicular block [LPFB]) (irrespective of time of onset).*
5. Newly acquired or age indeterminate LBBB, LBBB and LAFBa, RBBB and LPFBa.*
6. RBBB or LBBB and first-degree AV block.*

Class IIa
1. Stable bradycardia (systolic blood pressure >90 mm Hg, no hemodynamic compromise, or compromise responsive to initial drug therapy).*
2. Newly acquired or age-indeterminate RBBB.*

Class IIb
1. Newly acquired or age-indeterminate first-degree AV block.*

Class III
1. Uncomplicated AMI without evidence of conduction system disease.
Transcutaneous patches applied; system may be attached and activated within brief time if needed. Transcutaneous pacing may be very helpful as an urgent expedient. Because it is associated with significant pain, high-risk patients likely to require pacing should receive a temporary pacemaker.

†Apply patches and attach system; system is in either active or standby mode to allow immediate use on demand as required. In facilities in which transvenous pacing or expertise are not available to place an IV system, consideration should be given to transporting the patient to one equipped and competent in placing transvenous systems.

Transcutaneous systems are available that use a single pair of adequately sized, multifunctional electrodes that allow electrogram monitoring, transcutaneous pacing, and defibrillation as needed. These systems may be used in a standby mode in potentially unstable patients. Because transcutaneous pacing may be uncomfortable, especially when prolonged, it is intended to be prophylactic and temporary. A transvenous pacing electrode should be placed in patients who require ongoing pacing and in those with a very high probability of requiring pacing (risk of AV block ≥30%). Thus, transcutaneous pacing systems have allowed both the broadening of the application of standby pacing and the narrowing of the application of transvenous pacing. Technical aspects of transcutaneous pacing are reviewed elsewhere (345). The revised recommendations reflect this change.

## Recommendations for Temporary Transvenous Pacing*

**Class I**

1. **Asystole.**
2. Symptomatic bradycardia (includes sinus bradycardia with hypotension and type I second-degree AV block with hypotension not responsive to atropine).
3. Bilateral BBB (alternating BBB or RBBB with alternating LAFB/LPFB) (any age).
4. New or indeterminate age bifascicular block (RBBB with LAFB or LPFB, or LBBB) with first-degree AV block.
5. Mobitz type II second-degree AV block.

**Class IIa (note also "Recommendations for Transcutaneous Standby Pacing" above)**

1. RBBB and LAFB or LPFB (new or indeterminate).
2. RBBB with first-degree AV block.
3. LBBB, new or indeterminate.
4. Incessant VT, for atrial or ventricular overdrive pacing.
5. Recurrent sinus pauses (>3 seconds) not responsive to atropine

**Class IIb**

1. Bifascicular block of indeterminate age.
2. New or age-indeterminate isolated RBBB.

**Class III**

1. First-degree heart block.
2. Type I second-degree AV block with normal hemodynamics.
3. Accelerated idioventricular rhythm.
4. **BBB or fascicular block known to exist before AMI.**

*It should be noted that in choosing an intravenous pacemaker system, patients with substantially depressed ventricular performance, including RV infarction, may respond better to atrial/AV sequential pacing than ventricular pacing (346,347).*

Transvenous access to the right heart (ie, RV apex) with a catheter for temporary pacing can be achieved percutaneously through the internal (or external) jugular, subclavian, or femoral veins and through the brachial veins, percutaneously or by cutdown (348). Details of pacemaker placement are provided elsewhere (345). Review of the clinical course of 1022 consecutive patients who received a temporary transvenous pacemaker in the CCU during a 5-year period at Mayo Clinic (348) suggests that the preferred routes of insertion, especially if fluoroscopy is not immediately available, are the right internal jugular vein (generally first choice) or left subclavian vein (second choice), provided that the operator is well trained in venous access at these sites. In overall experience, loss of ventricular capture was observed in 18% of patients and complications in 14% (without associated mortality). The highest rates of loss of capture and pacemaker-related complications occurred with brachial venous pacing.

Choosing between ventricular (single-chamber) and sequential, AV (dual-chamber) pacing forms part of the decision-making process when proceeding with transvenous pacing. Because of its greater ease and reliability, ventricular pacing with a single lead is usually chosen. However, selected patients may require AV synchrony to maintain adequate hemodynamic compensation, especially those who are pacemaker dependent. In these cases, an atrial J-lead is also placed and guided to the right atrial appendage fluoroscopically. Alternatively, coronary sinus pacing may be used. Patients with RV infarction and other AMIs with substantially impaired systolic and/or diastolic function are frequently best treated with AV sequential pacing.

Once placed, temporary transvenous pacing may be performed in bipolar or unipolar configurations using a variety of commercially available leads (345). Temporary pacing requires meticulous oversight to ensure safety and efficacy. Temporary pacemaker care is best provided in an intensive care unit setting (generally the CCU). Care includes ensuring sterility of the venous access site and securely attaching the transvenous lead to the skin; attending to appropriate function and settings of the rate, mode, and threshold functions of the external generator box; continuous monitoring to ensure appropriate pacing and sensing functions and absence of dislodgment; and frequent (eg, at least once per shift) testing of pacing thresholds (pacing energy is usually set at >3 times the threshold).

**Permanent Pacing After Acute Myocardial Infarction**

Use of permanent pacemakers after AMI is addressed in the ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices (349). The requirement for temporary pacing in AMI does not by itself constitute an indication for permanent pacing. The unfavorable long-term prognosis of patients with AMI that has caused conduction disturbances...
is related primarily to the extent of associated myocardial injury. Consequently, these patients are at greater risk for death from heart failure and ventricular tachyarrhythmia than from progressive heart block. Indications for permanent pacing after AMI in patients experiencing conduction disturbances are related primarily to the degree and type of AV block and do not necessarily depend on the presence of symptoms.

Recommendations

Class I
1. Persistent second-degree AV block in the His-Purkinje system with bilateral BBB or complete heart block after AMI.
2. Transient advanced (second- or third-degree) AV block and associated BBB.*
3. Symptomatic AV block at any level.

Class IIb
1. Persistent advanced (second- or third-degree) block at the AV node level.

Class III
1. Transient AV conduction disturbances in the absence of intraventricular conduction defects.
2. Transient AV block in the presence of isolated LAFB.
3. Acquired LAFB in the absence of AV block.
4. Persistent first-degree AV block in the presence of BBB that is old or age indeterminate.

*An electrophysiology study should be considered to assess the site and extent of heart block in uncertain cases

Other Surgical Interventions

Recommendations for Emergency or Urgent Cardiac Repair of Mechanical Defects

Class I
1. Papillary muscle rupture with severe acute mitral insufficiency.
2. Postinfarction VSD or free wall rupture and pulmonary edema or cardiogenic shock (emergency or urgent).
3. Postinfarction ventricular aneurysm associated with intractable ventricular tachyarrhythmias and/or pump failure (urgent).

Class III
1. Acute infarctectomy in hemodynamically stable patients.

Clinical Situations Leading to Coronary Artery Bypass Graft Surgery

Evolving Myocardial Infarction
The role of emergency CABG for evolving MI has been discussed in "Initial Recognition and Management in the Emergency Department." The prevailing opinion at this time is that CABG should be limited to patients who have suitable surgical anatomy and who are not candidates for or who have failed thrombolytic therapy/PTCA and who are within 4 to 6 hours of the onset of MI.
In the setting of cardiogenic shock complicating AMI, emergency CABG has been used when other interventions have failed or have not been indicated. This topic has been discussed in "Initial Recognition and Management in the Emergency Department."

**Failed Percutaneous Transluminal Coronary Angioplasty**

Emergency CABG is indicated for most patients with AMI who have persistent angina pectoris or hemodynamic instability following failed PTCA. Coronary artery bypass graft surgery, optimally performed within 2 to 3 hours, can limit myocardial necrosis. However, mortality (3.7% to 12.0%) and morbidity rates exceed those for elective CABG, in particular postoperative hemorrhage, the need for blood products, and perioperative MI (21% to 43% in unstable patients). Operative mortality is increased in patients with unstable hemodynamic status, myocardial ischemia, multivessel disease, and prior CABG (350,351)

**Postthrombolytic Therapy**

For the 3339 patients enrolled in the TIMI-II trial, CABG was used emergently (1.6%) or electively (10% during initial hospitalization), primarily for left main coronary stenosis or coronary anatomy not amenable to PTCA and continuing, recurrent, or exercise-induced ischemia (352) For the 41,021 patients enrolled in the GUSTO trial, CABG was used in 8.6% at a mean of 8.5 days following thrombolytic therapy (353.) Unstable patients undergoing CABG shortly after thrombolytic therapy, primarily for continuing myocardial ischemia, have a higher operative mortality (13% to 17%) and increased use of blood products (352,354,355) than hemodynamically stable patients operated on within 8 hours of thrombolytic therapy, who have a relatively low (2.8%) mortality (356). The only independent predictor of perioperative mortality in TIMI-II was performance of CABG within 24 hours of entry or PTCA. The low 1-year mortality rate (2.2%) noted for operative survivors in this group may support the use of emergency operation for selected patients, however (352). The intraoperative use of aprotinin may reduce hemorrhage related to use of thrombolytic agents (357).

**Recurrent Ischemia**

Urgent CABG should be considered when recurrent ischemia occurs in patients who have sustained an AMI and whose coronary artery anatomy is not suitable for PTCA. Operative mortality in such patients is correlated closely with ejection fraction, and for patients with normal ejection fraction is nearly the same as that of elective CABG (358-360). The survival benefit for patients with reduced LV function supports the use of CABG in this situation.

**Elective Coronary Artery Bypass Graft Surgery After Acute Myocardial Infarction**

Elective CABG would be expected to improve long-term survival in patients with MI who have left main coronary artery stenosis (>50%), 3-vessel disease, 2-vessel disease with proximal left anterior descending coronary artery stenosis, or 2-vessel disease not amenable to PTCA and reduced ejection fraction (128). The optimal timing of surgery has not been established in a randomized controlled trial, although recent retrospective reports have suggested that elective CABG may be carried out 3 to 7 days after MI with operative mortality approaching that for
other elective CABG. Risk of operation is increased for patients with emergency or urgent surgery, older age, and poor ventricular function (360-365).

**Ventricular Tachyarrhythmias**
Ventricular tachyarrhythmia is not an indication for emergency CABG except in rare circumstances when refractory ventricular tachyarrhythmia is thought to be due to ischemia. Intra-aortic balloon pump support has been successful in temporarily reducing the incidence of refractory ventricular tachyarrhythmia in some cases (366).

**Patients With Prior Coronary Artery Bypass Graft Surgery**
Progression of atherosclerosis, particularly in saphenous vein bypass grafts, can result in recurrent myocardial ischemia and the need for reintervention (367). These patients typically have an increased prevalence of unfavorable risk factors, such as previous MI, lower ejection fraction, CHF, and other comorbid conditions as well as risk of atheroembolism from severely diseased bypass grafts, which increase the risk of reoperation in general to 2.0 to 3.5 times the risk of the first operation (244,363,367,368). Emergency reoperative CABG has been reported to have a 17% operative mortality with a high rate of recurrent angina in operative survivors (74% at 24.9 months) (245).

**Patients Undergoing Cardiopulmonary Resuscitation**
Mortality rates in patients who have sustained cardiac arrest in the cardiac catheterization laboratory and who are not responsive to resuscitative measures are reported to be between 43% and 100% (369,370). Rapid institution of extracorporeal cardiopulmonary bypass with adequate decompression of the heart can limit myocardial injury and provide other organ perfusion during the interval between cardiac arrest and myocardial reperfusion (371). The decision to proceed with surgery in such cases requires careful consideration of whether the patient's condition is reversible.

**Intraoperative Myocardial Protection in the Acutely Injured Heart**
Acute ischemia following coronary occlusion results in structural, functional, and metabolic derangements not only in the ischemic myocardium but also in adjacent and remote myocardium. The use of intraoperative myocardial preservation strategies may limit and perhaps reverse ischemic injury in all areas (372). Emergency CABG using substrate-enhanced reperfusate for cardiogenic shock has resulted in reversal of refractory LV dysfunction in 94% (75 of 80 patients)(242) and hospital survival in 91%. Other myocardial protection strategies that have been proposed to provide enhanced myocardial protection include normothermic blood cardioplegia without substrate enhancement (373,374) and hypothermic fibrillatory arrest without aortic cross-clamping and liberal use of preoperative intra-aortic balloon pumping (375,376). The choice of intraoperative myocardial protection strategy should rest with the individual surgeon.

Previous reports of operation in the setting of AMI have stressed the use of saphenous vein bypass grafts that permit antegrade delivery of cardioplegia solutions into the ischemic zone.
The use of retrograde (coronary sinus) cardioplegia that can perfuse the ischemic zone may permit greater use of internal mammary artery bypass grafts (378), with the potential advantage of better long-term patency.

**Management of Mechanical Defects After Acute Myocardial Infarction**

Mechanical defects can occur after AMI and include acute mitral valve regurgitation, postinfarction VSD, LV free wall rupture, and LV aneurysm. Sudden and/or progressive hemodynamic deterioration with low cardiac output and/or pulmonary edema should lead to prompt consideration of these defects and rapid institution of diagnostic and therapeutic measures. The clinical and hemodynamic profiles of the common mechanical defects that occur after AMI are summarized in Table 7.

**Table 7. Clinical Profile of Mechanical Complications of Myocardial Infarction**

<table>
<thead>
<tr>
<th>Variable</th>
<th>VSD</th>
<th>Free Wall Rupture</th>
<th>Papillary Muscle Rupture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, y)</td>
<td>63</td>
<td>69</td>
<td>65</td>
</tr>
<tr>
<td>Days post MI</td>
<td>3–5</td>
<td>3–6</td>
<td>3–5</td>
</tr>
<tr>
<td>Anterior MI</td>
<td>66%</td>
<td>50%</td>
<td>25%</td>
</tr>
<tr>
<td>New murmur</td>
<td>90%</td>
<td>25%</td>
<td>50%</td>
</tr>
<tr>
<td>Palpable thrill</td>
<td>Yes</td>
<td>No</td>
<td>Rare</td>
</tr>
<tr>
<td>Previous MI</td>
<td>25%</td>
<td>25%</td>
<td>30%</td>
</tr>
</tbody>
</table>

Echocardiographic findings

- **Two-dimensional Doppler**
  - Visualize defect
  - May have pericardial effusion
  - Fluid or prolapsing leaflet
  - Regurgitation jet in LA

- **PA catheterization**
  - Oxygen step-up in Hi RV
  - Equalization of diastolic pressure
  - Prominent V wave in PCW tracing


These defects, when they occur, usually present within the first week after AMI. On physical examination, the presence of a new cardiac murmur indicates the possibility of either VSD, mitral regurgitation, or, occasionally, ventricular rupture. A precise diagnosis can usually be established with transthoracic or transesophageal echocardiography.

Use of a balloon flotation catheter is helpful for both diagnosis and monitoring of therapy. With a VSD and left-to-right shunting, oxygen saturation will be higher in the pulmonary artery compared with the right atrium; in this instance, thermodilution cardiac output and pulmonary artery samples for mixed venous oxygen saturation will be falsely elevated. With acute mitral regurgitation, a large V wave will often be evident on the pulmonary artery wedge pressure tracing. With ventricular rupture and pericardial tamponade, equalization of diastolic pressure may be seen.
Coronary angiography can delineate the presence of surgically correctable coronary artery disease and should be done unless the patient is hemodynamically severely unstable from the mechanical defect alone. Cardiac catheterization may better delineate the presence of a mechanical defect if other studies are not clear. Coronary arteriography can delineate the presence of surgically correctable coronary artery disease, and cardiac catheterization may better delineate the presence of a mechanical defect if other studies are not clear. However, the evidence for concomitant CABG associated with surgical repair of an acute VSD is inconclusive (829). Although there is a need to minimize invasive angiographic procedures before early surgical correction of the ruptured septum, initial coronary arteriography to assess the coronary anatomy seems warranted in most cases. Insertion of an intra-aortic balloon pump can help stabilize the patient as noted in "Hospital Management." Surgical consultation should be obtained when a mechanical defect is suspected so that preparations for surgical repair can be optimized. In general, prompt surgical repair is indicated because medical treatment alone is associated with extremely high mortality.

**Acute Mitral Valve Regurgitation**

With total rupture of a papillary muscle, medical treatment alone is associated with 75% mortality within the first 24 hours (379). While emergency surgery is being arranged, the patient should receive nitroprusside to help lower pulmonary capillary pressures and improve peripheral perfusion. Although emergency mitral valve replacement is associated with relatively high mortality (27% to 55%), both overall mortality and subsequent ventricular function are improved, compared with medical therapy alone (380,381). Delay in operation appears to increase the risk of further myocardial injury, other organ injury due to hypoperfusion, and subsequent death (380). Repair of the mitral valve has also been reported in selected circumstances of both acute and chronic ischemic mitral insufficiency with good results (382). When technically possible, the supporting structure of the mitral valve should be retained to more effectively preserve ventricular function.

**Postinfarction Ventricular Septal Defect**

Increased frequency of acute rupture of the interventricular septum (VSD) as well as earlier presentation may be noted in patients who have undergone thrombolytic therapy (383). Although emergency surgical repair was formerly thought to be necessary only in patients with pulmonary edema or cardiogenic shock, it is now recognized as equally important in hemodynamically stable patients (384,385,830). Because all septal perforations are exposed to sheer forces and necrotic tissue removal processes by macrophages, the rupture site can abruptly expand, resulting in sudden hemodynamic collapse even in patients who appear to be clinically stable with normal left ventricular function (830). For this reason, prompt insertion of an intra-aortic balloon pump and referral for emergency operation are recommended for every patient with acute VSD as soon as the septal rupture is diagnosed. Simultaneous CABG, if feasible, seems warranted in patients with extensive coronary artery disease (386).

Emergency surgical repair is indicated when pulmonary edema or cardiogenic shock is present; repair may be deferred in the hemodynamically stable patient. For patients with concomitant
cardiogenic shock, only patients who underwent surgery within 48 hours survived. Operative mortality is related to early operation (34% in the first week after infarction compared with 11% after the first week), but this is related to differences in the case mix: the presence of cardiogenic shock (39% compared with 8% without shock), site of infarction (32% inferior, 12% anterior), and age (25% older than 65 years, 17% for 65 years and younger). Simultaneous CABG, if feasible, is indicated for associated significant coronary disease because long-term survival is improved.

**Left Ventricular Free Wall Rupture**

Surgery includes repair of the ventricle using a direct suture technique or patch to cover the ventricular perforation in addition to CABG as needed. Alternatively, the use of cyanoacrylate glue has been described to hold the patch in place over necrotic myocardium.

**Left Ventricular Aneurysm**

Left ventricular aneurysm may be associated with refractory CHF, VT, or systemic embolization despite therapeutic anticoagulation. Surgical techniques designed to retain ventricular geometry using endoventricular patches may maintain better physiological function with lower mortality than earlier linear repair techniques.

**Mechanical Support of the Failing Heart**

*Intra-aortic balloon pump (IABP) support* improves diastolic coronary blood flow and reduces myocardial work. Its use is covered in detail in "Hospital Management."

*Circulatory support devices* include the use of prosthetic ventricles, the LV turbine (Hemopump), and percutaneous cardiopulmonary bypass circuits. Each has been used in patients with cardiogenic shock after AMI with improvement in other organ perfusion, in many cases as a bridge to definitive revascularization or cardiac transplantation. Total artificial heart implantation has also been used as a bridge to transplantation. Success rates have varied and are generally correlated with the presence of correctable cardiac disease. Survival has been considered fair (from 20% to 33% at best) for this group of patients generally categorized as at very high risk for death if not otherwise treated. None of these devices has been used in a randomized fashion to assess their comparative efficacy in patients.

**Transplantation After Acute Myocardial Infarction**

Cardiac transplantation has been reported for patients who sustained irreversible acute myocardial injury with no correctable lesion and who were otherwise acceptable candidates. Of 15 patients reported, 9 had onset of shock within 3 days of onset of chest pain, and 6 had onset of shock within the first day. Cardiac assist devices were used in 6 patients as a bridge to transplantation. Early posttransplant mortality was 3 of 15 (20%).

**Relation Between Volume of Surgery and Outcome**
Increasing attention is being directed to better quality of surgical outcomes in direct relation to a greater volume of surgical procedures per hospital (399) and per surgeon (400). A retrospective review of 18,986 CABG procedures in 77 California hospitals suggested that higher volume hospitals had lower in-hospital mortality, particularly for "nonscheduled" surgery (401). This suggests that patients with AMI who might require emergency CABG should be directed to hospitals with higher surgical volume and acceptable surgical results.

**Minimum Operative Caseload**

The ACC/AHA guidelines on coronary artery bypass graft surgery (128) suggest a minimum caseload of 200 to 300 open-heart operations per institution and 100 to 150 operations per surgeon, with the majority of operations done for coronary artery disease.

**Case Selection Concerns**

As cardiac surgical programs and individual surgeons come under scrutiny with regard to operative mortality rates, concern has been raised about the possibility that salvageable but high-risk patients may not be offered surgery. The committee believes strongly that patients should be offered surgical treatment if the treating team believes that the benefits outweigh the risks and that meaningful survival of the patient could result. Furthermore, appropriately validated risk-adjusted outcome measures should be used when evaluating the performance of an individual surgeon or surgical program.
V. Rationale and Approach to Pharmacotherapy

**Nitroglycerin**

**Mechanism of Action**

The primary action of nitrates is vasodilation, which is attributable primarily to nitrate-induced relaxation of vascular smooth muscle in veins, arteries, and arterioles. The metabolic conversion of organic nitrates to nitric oxide at or near the plasma membrane of the vascular smooth muscle cell represents the cellular basis for the vasodilatory action of these compounds (402). Believed to be an endothelium-derived relaxing factor (EDRF), nitric oxide is an important endogenous modulator of vascular tone. Nitrate administration has been viewed as a means of providing an exogenous source of nitric oxide that may help replenish or restore the actions of EDRF, which are usually impaired in patients with coronary artery atherosclerosis (403).

The reduction in RV and LV preload resulting from peripheral vasodilation, particularly in the splanchnic and mesenteric circulations, combined with afterload reduction resulting from arterial vasodilation, decreases cardiac work and lowers myocardial oxygen requirements (404). As a consequence, the ratio of myocardial oxygen demand to myocardial oxygen supply improves, and myocardial ischemia is alleviated. Because of their hemodynamic profile, nitrates are particularly useful in patients with impaired LV systolic function or CHF. Additionally, both direct vasodilator effects of nitrates on the coronary bed and drug-induced prevention of episodic coronary artery vasoconstriction can increase global and regional myocardial blood flow, improving the subendocardial-epicardial blood flow ratio (405,406). Enlargement of obstructive atherosclerotic lesions containing intact vascular smooth muscle can increase the caliber of some stenoses, improving coronary flow (407). Nitrates also have been shown to dilate coronary collateral vessels, reverse vasoconstriction of small coronary arteries distal to a coronary obstruction, and reduce platelet aggregation (408).

**Pharmacokinetics and Dosage**

As summarized by Abrams (409), 3 nitrate compounds—nitroglycerin, isosorbide dinitrate (ISDN), and isosorbide-5-mononitrate (ISMN)—are available for clinical use in the United States. Nitroglycerin is characterized by a short half-life of only several minutes. Isosorbide dinitrate is an organic nitrate that is extensively metabolized in the liver to 2 active metabolites, isosorbide-2- and ISMN. The half-life of ISDN ranges from 40 to 90 minutes. Isosorbide-5-mononitrate, the principal active metabolite of ISDN, is a synthetic nitrate approved by the Food and Drug Administration (FDA) in 1991. ISMN does not undergo hepatic metabolism and as a result is 100% bioavailable after oral dosing. Its half-life is 4 to 5 hours. Both ISDN and ISMN are available in sustained-release formulas. Nitroglycerin is the only nitrate available for intravenous use in the United States and the preparation of choice in the management of AMI or unstable angina. Intravenous nitroglycerin can be successfully titrated by frequent measurement of blood pressure and heart rate. Although invasive hemodynamic monitoring is not mandatory, it may be preferable if high doses of vasodilating agents are required, blood pressure instability or hypotension ensues, or there is clinical doubt about the adequacy of LV filling pressure (410).
When titrating intravenous nitroglycerin, begin with a bolus injection of 12.5 to 25.0 μg and a pump-controlled infusion of 10 to 20 μg/min, and increase the dosage by 5 to 10 μg every 5 to 10 minutes while carefully monitoring hemodynamic and clinical responses. Titration end points are control of clinical symptoms or decrease in mean arterial pressure of 10% in normotensive patients or 30% in hypertensive patients (but never a systolic pressure <90 mm Hg), an increase in heart rate >10 bpm (but not exceeding 110 bpm), or a decrease in pulmonary artery end-diastolic pressure of 10% to 30%. Infusions are slowed or temporarily discontinued when mean blood pressure drops below 80 mm Hg or systolic blood pressure drops below 90 mm Hg. Although there is no absolute upper dosage limit, doses >200 μg/min are associated with increased risk of hypotension, and alternative therapy should be considered.

The combination of intravenous nitroglycerin with a β-adrenergic blocking agent in appropriate patients is well tolerated and theoretically attractive because the risk of undesired tachycardia may be reduced. As nitrate tolerance develops, the infusion rate can be increased, but if it becomes necessary to administer >200 μg/min, another vasodilator such as nitroprusside or an ACE inhibitor should be substituted with the knowledge that effectiveness of nitroglycerin usually returns 12 hours after discontinuance.

Limitations and Adverse Effects

In addition to frequently causing headaches, nitroglycerin may also aggravate hypoxemia by increasing ventilation-perfusion mismatch. The most serious side effect is inadvertent systemic hypotension, which may result in reflex tachycardia and worsening myocardial ischemia. Nitroglycerin should be carefully titrated in patients with inferior wall MI because of its frequent association with RV infarction. Such patients are especially dependent on adequate RV preload to maintain cardiac output and can experience profound hypotension during nitrate administration (73). When nitroglycerin administration results in bradycardia and hypotension, discontinuation of the drug, leg elevation, rapid fluid administration, and atropine are appropriate.

Continuation of the anti-ischemic effects of organic nitrates with repeated dosing is the major limitation in use of these drugs. Nitroglycerin tolerance is a complex multifactorial phenomenon that may partially be explained by a relative depletion of sulphydryl groups required for conversion of organic nitrates to nitric oxide (411). More recently it has been suggested that enhanced vascular superoxide production plays an important role in this phenomenon (412). It is now clear that intermittent dosing regimens that allow for a drug-free interval represent the only practical and effective strategy for avoiding nitrate tolerance. When ISDN is used, anti-ischemic activity is more likely to be maintained with a dosing schedule of 2 or 3 times daily. FDA labeling now indicates a dose-free interval of 14 hours is required to avoid tolerance. An asymmetric ISMN dosing regimen, with administration at 8 AM and 3 PM, has been shown to sustain the anti-ischemic effects of the short-acting preparation of this agent (413). When using intravenous nitroglycerin for 24 to 48 hours continuously in the early stages of AMI, it is well to note that drug tolerance is not usually recognized at the bedside. If the desired nitrate effects are lost during this period, it is appropriate to increase the intravenous infusion dose.
Physicians need to be aware of a potential drug interaction between heparin and intravenous nitroglycerin, although as yet unresolved, because these agents are frequently administered at the same time. Several reports have suggested that intravenous nitroglycerin may interfere with the actions of heparin on the activated partial thromboplastin and prothrombin time, thereby decreasing sensitivity to heparin (414-415a). Thus, in addition to requiring increased heparin dosages to achieve a desired anticoagulation end point, patients may be at greater risk for bleeding when nitroglycerin is discontinued and infusion of heparin continues.

**Clinical Trials**
There is experimental and clinical evidence that intravenous nitroglycerin may reduce infarct size and improve regional myocardial function (416,417). It has also been suggested that nitroglycerin may prevent LV remodeling that frequently occurs after a large transmural MI (417). In the preperfusion era a number of small studies demonstrated an improvement in mortality and major cardiovascular morbidity following early administration of intravenous nitroglycerin. A meta-analysis of these earlier trials involving 2042 patients suggested that nitrates reduced the odds of death after AMI by 35% (95% CI, 28% to 49%; \( P < 0.001 \)) (418). Similar analyses involving the use of oral nitrates in fewer patients estimated a treatment effect of ≈20%, but this was not statistically significant, and the greatest reduction in mortality occurred during the first week or so of follow-up (418,419).

The use of nitrate therapy was investigated in the context of routine use of thrombolytic therapy and aspirin with short-term mortality as the primary end point in 2 recently completed large trials. The GISSI-3 trial (420) randomly assigned 19,394 patients to a 24-hour infusion of nitroglycerin (beginning within 24 hours of onset of pain), followed by topical nitroglycerin (10 mg daily) for 6 weeks (with patch removed at bedtime, allowing a 10-hour nitrate-free interval to avoid tolerance), or control. Approximately 50% of patients in the control group received nitrates on the first day or two at the discretion of their physician. There was an insignificant reduction in mortality at 6 weeks in the group randomly assigned to nitrate therapy alone, compared with the control group (6.52% versus 6.92%, respectively). GISSI-3 evaluated lisinopril in a similar fashion; 6-week mortality was reduced slightly. At both 6-week and at 6-month follow-up, the combined use of lisinopril and nitrates led to a greater reduction in mortality when compared with the group that received no nitrate therapy or lisinopril alone. The other large trial, ISIS-4 (421) compared 28-day treatment of controlled-release oral isosorbide mononitrate with placebo control (as well as intravenous magnesium sulfate versus control and the ACE inhibitor captopril versus placebo control) in a 2×2 factorial design in 58,050 patients with suspected MI. Nitrate therapy in ISIS-4 was associated with a small, nonsignificant reduction in 35-day mortality compared with the control group (7.34% versus 7.54%) in the overall comparison. All subgroups examined, including those not receiving short-term nonstudy intravenous or oral nitrates at entry, failed to demonstrate a significant mortality benefit with nitrate use. In both GISSI-3 and ISIS-4, the power to detect potential beneficial effects of routine nitrate therapy was reduced by the extensive early use (>50%) of nontrial nitrate in the control subjects. When data from all randomized control trials of nitrate use in the management of AMI are combined, there is a small...
relative reduction in mortality that is statistically significant (5.5%±2.6%; 2P=0.03) (421), which represents ≈4 lives saved per 1000 treated.

The totality of evidence from all pertinent randomized clinical trials does not support routine use of long-term nitrate therapy in patients with uncomplicated AMI. However, it is prudent to use intravenous nitroglycerin for the first 24 to 48 hours in patients with AMI and recurrent ischemia, CHF, or management of hypertension. It should be continued orally or topically in patients with CHF and large transmural MIs as well. Intravenous administration is recommended in the early stage of AMI because of its onset of action, ease of titration, and the opportunity for prompt termination in the event of side effects.

Aspirin and Other Platelet-Active Drugs
Platelets and thrombosis play important roles in the pathogenesis of acute coronary artery syndromes, and the role of antiplatelet agents has been recently reviewed in 2 publications, the AHA statement "Aspirin as a Therapeutic Agent in Cardiovascular Disease" (422) and the fourth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy (423).

Mechanism of Action of Aspirin
In platelets, aspirin prevents formation of thromboxane A2, a substance that induces platelet aggregation (424-426). Because platelets are unable to generate new cyclo-oxygenase, enzyme inhibition lasts for the life of the cell, or ≈10 days. In vascular endothelial cells aspirin prevents the synthesis of prostacyclin, which inhibits platelet aggregation (427). Endothelial cells can recover cyclo-oxygenase synthesis so that the inhibitory effects of aspirin may be of shorter duration than with platelets (428,429).

Aspirin in Prevention of Thrombotic Complications of Atherosclerosis
As summarized in the fourth ACCP Consensus Conference on Antithrombotic Therapy (423):

- In the recently reported overview of the Antiplatelet Trialists' Collaboration that involved 145 trials, the antiplatelet therapy (mainly aspirin) of 70 000 high-risk patients and 30 000 low-risk patients was found to be protective against vascular events among the following patients: (1) patients with acute MI, 10% versus 14% (at 1 month); (2) a history of MI, 13% versus 17% (2-year follow-up); (3) a history of stroke or transient cerebral ischemia, 18% versus 22% (3-year follow-up); (4) unstable angina, 9% versus 14% (6-month follow-up); and (5) other miscellaneous vascular diseases, 6% versus 8% (1-year follow-up).

When all high-risk patients are considered together, there is about a 30% reduction in nonfatal MI, a 30% reduction in nonfatal stroke, and a 17% reduction in vascular death. For patients with prior infarction or stroke, aspirin is estimated to prevent between 35 and 40 events per 1000 patients treated. In contrast, when used in asymptomatic men, aspirin prevents only 4 events per 1000 subjects treated.

Aspirin: Risk of Hemorrhagic Stroke
A small increase in incidence of stroke in healthy men treated with aspirin was reported in both the American Physician and the British Doctors primary prevention studies (430). However, there has been no evidence of an increased incidence of stroke in studies in which aspirin was
used for secondary prevention of coronary artery disease. These secondary prevention trials clearly indicate that in patients with clinical manifestations of atherosclerotic disease, aspirin reduces risk of stroke. It is likely that as a consequence of its antithrombotic effect, aspirin produces a small increase in risk of cerebral hemorrhage, which is masked by the beneficial effects of aspirin in patients with an increased risk for thromboembolic stroke but becomes manifest in healthy individuals at very low risk for this event.

**Aspirin: Side Effects and Dosage**

The side effects of aspirin are mainly gastrointestinal and dose related. Gastric side effects may also be reduced by administration of diluted solutions of aspirin, treatment with cimetidine, antacids, or use of enteric-coated or buffered aspirin.

Aspirin should be avoided in those with a known hypersensitivity and used cautiously in those with blood dyscrasias or severe hepatic disease. If the patient has a history of bleeding peptic ulcers, rectal aspirin suppositories can be used safely. Another potentially deleterious effect of aspirin is risk of bleeding from surgical sites. Patients who received aspirin in the Veterans Administration Cooperative Study were noted to have significantly increased postoperative chest drainage and reoperation for bleeding. Others have noted that preoperative aspirin use has been associated with increased postoperative chest drainage but not an increased rate of reoperation for bleeding. In another Veterans Administration Cooperative Study, starting aspirin 6 hours after surgery conferred the benefits of improved saphenous vein bypass graft patency without the increased postoperative bleeding seen with preoperative administration of aspirin.

Aspirin is an effective antithrombotic agent in doses between 75 mg and 1.2 g/d. It is also possible that 30 mg/d is effective. There is no evidence that low doses are either more or less effective than high doses when used over the long term, although doses <160 mg/d may not be effective acutely.

**Ticlopidine and Clopidogrel**

Ticlopidine is an antiplatelet drug with a different mechanism of action than aspirin. It inhibits platelet aggregation induced by a variety of agonists, including adenosine diphosphate, possibly by altering the platelet membrane and blocking the interaction between fibrinogen and its membrane glycoprotein receptor, GP IIb/IIIa. The inhibitory effect of ticlopidine is delayed for 24 to 48 hours after its administration; thus, ticlopidine may not be useful when a rapid antiplatelet effect is required.

In 1 trial, ticlopidine has been shown to be more effective than placebo in reducing the occurrence of vascular death or MI at 6 months in patients with unstable angina. Of note, there was no difference in the number of events over the first 7 to 10 days, a finding consistent with the delayed onset of the antiplatelet effect. Ticlopidine has been approved for clinical use in patients with cerebral ischemia when aspirin has failed, cannot be tolerated, or is
contraindicated. However, 2 serious side effects associated with its use have been observed: Reversible neutropenia has been observed when treatment continues for >2 weeks. Ticlopidine can also cause thrombotic thrombocytopenic purpura (TTP). Several cases of TTP have been reported, and in a review of 60 cases, 20% occurred after only 3 to 4 weeks of therapy, but only 3% of patients treated for ≤14 days developed TTP. Furthermore, mortality is high: ≈50% of untreated cases and 25% of treated cases (830a).

Ticlopidine and clopidogrel are ADP-receptor antagonists and quite similar chemically. However, TTP has not been reported with use of clopidogrel, and in the large CAPRIE Trial (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) (831), the incidence of a significant reduction in neutrophils was only 0.10% in the clopidogrel group and actually slightly higher, at 0.17%, in the aspirin group. In that trial, there was a statistically significant relative risk reduction in vascular death, MI, or stroke of 8.7% in favor of clopidogrel. For these reasons, in many catheterization laboratories, ticlopidine has been replaced with clopidogrel combined with aspirin for the prevention of adverse cardiac events after stent implantation. The effectiveness of this regimen, however, is unknown. Clopidogrel is also preferable to ticlopidine for patients who demonstrate aspirin resistance or for whom aspirin is contraindicated because of hypersensitivity.

Ticlopidine has been shown to be more effective than a control therapy in reducing vascular death and MI in patients with unstable angina. 441 The most serious side effect of its use is reversible neutropenia, which has only been observed when treatment is continued for more than 2 weeks. It has been approved for clinical use in patients with cerebral ischemia when aspirin has failed, cannot be tolerated, or is contraindicated.

Rationale for Thrombolytic Therapy

Background

Herrick (442) in the United States and Obrastzow and Straschesko (443) in the Soviet Union first described the clinical features of sudden obstruction of the coronary arteries >80 years ago. However, the pathophysiology of AMI and specifically the role of coronary thrombosis were controversial until the early 1980s. The landmark study of DeWood and colleagues (80), published in 1980, demonstrated complete, presumably thrombotic occlusion of the infarct-related artery in 87% of patients with MI and ST elevation studied angiographically within 4 hours of onset of symptoms and in 65% studied between 12 and 24 hours. The subsequent demonstration of intraluminal thrombus at the time of emergency coronary surgery (80) and the demonstration of infarct-related artery recanalization by intracoronary thrombolytic therapy (443–445) led to the unequivocal role of intracoronary thrombus in acute coronary occlusion. Subsequent pathological and angioscopic observations led to the concept that fissuring or rupture of a vulnerable atherosclerotic plaque was the initiating mechanism of coronary occlusion as a result of coronary spasm, intraplaque hemorrhage, and luminal thrombosis (446–448). A second premise supporting large trials of thrombolytic therapy in AMI was the observation in animal models and early clinical studies that reperfusion could lead to myocardial salvage and improved outcome, but that benefit was time dependent. Reimer, Jennings, and
coworkers (449) showed that coronary artery occlusion in an animal model led to MI that proceeded in a "wavefront" from subendocardium to subepicardium, beginning within 20 minutes and evolving to >70% transmural necrosis in 6 hours, with a small amount of additional necrosis between 6 and 24 hours. Of note, reestablishment of coronary flow within 2 hours resulted in substantial myocardial salvage and functional recovery of the ischemic myocardium, whereas reperfusion as late as 6 hours resulted in limited, subepicardial salvage. Subsequent early controlled clinical trials demonstrated the potential for functional and mortality benefit, but only if therapy was given early and reperfusion resulted (450-453).

Clinical use of intravenous preparations containing streptokinase for AMI dates back 4 decades (454,455). However, contemporary interest in intravenous thrombolytic therapy was reawakened with reports in the mid 1980s of its feasibility and comparability to intracoronary therapy (456-458). Subsequent clinical studies and practical application of thrombolytic therapy has focused on the more broadly and rapidly applicable intravenous application of thrombolytic agents.

**Thrombolytic Agents: General Mechanisms of Action and Pharmacological Properties**

Recognition that acute coronary thrombosis is primary to the pathogenesis of AMI led to the consideration of plasminogen activators as a preferred therapeutic approach to achieving rapid thrombolysis. All of the thrombolytic (fibrinolytic) agents currently available and under investigation are plasminogen activators (459). They all work enzymatically, directly or indirectly, to convert the single-chain plasminogen molecule to the double-chain plasmin (which has potent intrinsic fibrinolytic activity) by splitting a single bond at the arginine 560-valine 561 site, exposing the active enzymatic center of plasmin.

Aside from this similarity, some comparative features of the FDA–approved thrombolytic agents for intravenous therapy (streptokinase, anistreplase, alteplase, and reteplase) are presented in the revised Table 8. Streptokinase and urokinase are approved for intracoronary use, but this route of administration for AMI is now virtually obsolete. In addition, newer agents have been developed (eg, TNK-tissue plasminogen activator [TNK-tPA] and lanoteplase). Recent trials with alteplase have used an accelerated regimen given over 90 minutes. The accelerated regimen leads to the highest patency rate without an increase in ICH and has become the preferred method of administration. The advantage of reteplase is that it can be given by bolus, which is convenient. A recent trial compared the effectiveness and safety of continuous infusion versus double-bolus administration of alteplase (832). The trial was stopped prematurely because of concern about the safety of the double-bolus injection. The rate of hemorrhagic stroke was 1.12% after double-bolus injection of alteplase compared with 0.81% after accelerated infusion of alteplase.
Efficacy of Intravenous Thrombolytic Therapy in Acute Myocardial Infarction

It has now been well established that thrombolytic therapy provides a survival benefit for patients with AMI, based on large, well-controlled clinical trials (459a). Benefit has been shown individually for therapy with streptokinase, anistreplase, and alteplase (28, 29, 460, 461). In an overview of the 9 controlled randomized trials involving >1000 patients, a highly significant \( P < 0.00001 \) 18% proportional reduction in mortality was observed, corresponding to the avoidance of 18 deaths per 1000 patients treated (27). Furthermore, the largest of these studies (ISIS-2, >17,000 patients), showed that when aspirin was combined with streptokinase and treatment was given within 4 hours of onset of symptoms, an odds reduction in mortality of 53% was achieved (control, 13.1%; streptokinase plus aspirin, 6.4%) \( P < 0.0001 \).29 Information from both animal studies as well as clinical trials has provided strong support for the concept that achievement of early, complete, and sustained coronary patency is primarily responsible for benefit of treatment (30). Mechanisms of benefit include favorable effects on myocardial salvage as well as postinfarction remodeling.

Benefits of Thrombolytic Therapy in Specific Patient Subgroups

The overview of thrombolysis trials shows that thrombolytic therapy is clearly beneficial in the vast majority of patients. Differences in outcome in subgroups in clinical trials should be interpreted more cautiously than overall differences in outcome with therapy, given the problems of multiple comparisons and chance deviations from the mean. Sometimes differences in degree (and rarely, direction) of benefit appear among some subgroups, and when these are replicated in independent trials and supported by a clear pathophysiological rationale may reflect valid differences. Implications of overall and subgroup results from the overview of the major randomized, controlled clinical trials (27) for use of thrombolytic therapy in AMI are presented in "Initial Recognition and Management in the Emergency Department."

Comparative Thrombolytic Efficacy

Since publication of the first guidelines for the early management of patients with acute myocardial infarction (1), results of important trials comparing thrombolytic regimens directly have been published, evaluating relative rates of coronary patency, functional benefit, and survival. In 2 large mortality trials (GISSI-2/International (462) and ISIS-3 (463)), mortality rates at 4 to 5 weeks were similar (GISSI-2/International: TPA [duteplase]=8.9%,
streptokinase=8.5%; ISIS-3: alteplase=10.3%, streptokinase=10.6%, anistreplase=10.5%). In these studies conjunctive antithrombotic therapy included aspirin in all patients (160 to 325 mg on admission and daily) and subcutaneous heparin in half (12 500 U twice a day, beginning 4 to 12 hours after thrombolytic therapy). At the time, intravenous heparin was not used in either of these studies because of concerns about increasing the incidence of ICH. The specific failure to use intravenous heparin with TPA in these trials has been the source of some criticism. The GUSTO trial subsequently tested 4 thrombolytic regimens among 41 021 patients (228). Alteplase was given in an accelerated dose regimen to further improve early patency rates and concomitant heparin administered intravenously to maintain patency. Other regimens included streptokinase with subcutaneous or intravenous heparin and a combination of alteplase and streptokinase. Thirty-day mortality was lower with alteplase (6.3%) than streptokinase and subcutaneous heparin (7.2%), streptokinase and intravenous heparin (7.4%), and combined streptokinase and alteplase plus intravenous heparin therapies (7.0%). Differences were highly significant, although proportionately modest, when accelerated alteplase was compared with combined streptokinase groups (14% mortality reduction, \( P=0.001 \)). There was a significant excess of hemorrhagic stroke for accelerated alteplase \( (P=0.03) \) and the combination strategy \( (P<0.001) \), compared with streptokinase only. However, net benefit was still achieved with alteplase compared with streptokinase, with 9 fewer deaths or disabling strokes per 1000 patients treated. Other complications of AMI were generally less frequent with alteplase, including allergic reactions, heart failure, cardiogenic shock, and atrial and ventricular arrhythmias.

Other conclusions drawn from GUSTO are (1) intravenous heparin provides no added benefit over aspirin and subcutaneous heparin when given with streptokinase and in addition increases bleeding risk (the power of this comparison, however, was markedly reduced by the fact that 36% of patients randomly assigned to receive subcutaneous heparin also received intravenous heparin); (2) combination therapy increases bleeding risk (relative to alteplase with intravenous heparin) and provides less benefit; and (3) although the rationale for use of intravenous heparin with alteplase appears sound, other factors, specifically, earlier time to therapy, frontloading alteplase, and requiring ST elevation on entry ECG, likely explain much of the difference in results between GUSTO and ISIS-3 (464). The mechanism of improved benefit with alteplase was assessed in the GUSTO angiographic substudy, which found differences in early (90-minute) patency among regimens (81%, 56%, 61%, 73%) for alteplase, streptokinase-subcutaneous heparin, streptokinase-intravenous heparin, and combination regimens, respectively (465). These differences in patency in the angiographic substudy closely predicted survival outcomes among the 4 strategies when applied to the main trial results (466) and furnish a biological explanation for mortality differences among regimens. The data, coupled with that of additional, independent comparisons showing superior outcomes with accelerated alteplase compared with anistreplases,(467,468) provide a strong impetus for early and complete restoration of infarct artery perfusion as an essential goal of thrombolytic therapy.

Since the initial publication of these guidelines, the Food and Drug Administration has approved the fibrinolytic agent reteplase for use. Reteplase, a mutant of wild-type tPA, has a longer half-life than its parent molecule and has been compared with alteplase in a large clinical trial (833).
An angiographic trial (834) found that 60- and 90-minute TIMI grade 3 flow and coronary patency rates were higher with reteplase than with the accelerated dose of alteplase. When compared with an accelerated infusion of alteplase, reteplase did not provide any additional survival benefit. The mortality rate at 30 days was 7.5% for reteplase and 7.2% for alteplase; and the rates of the combined end point, death or nonfatal MI–disabling stroke, were 7.98% and 7.91%, respectively.

**Considerations in Selecting Thrombolytic Regimens**

GUSTO and other recent studies (467, 468) suggest that accelerated alteplase with intravenous heparin is currently the most effective therapy for achieving early coronary reperfusion and its associated survival benefit but is also substantially more expensive and carries a greater risk of ICH. Thus, the cost-benefit ratio is greatest in patients presenting early after symptom onset with a large area of injury (eg, anterior acute MI) and at low risk of ICH. In groups with a smaller potential for survival benefit and a greater risk for ICH, streptokinase appears to be the agent of choice, particularly in view of the cost. Other promising thrombolytic agents are under investigation (eg, protokinase, reteplase, staphylokinase, TNK-plasminogen activator).

GUSTO-I (228), GUSTO-III (833), and other recent studies (467, 468) suggest that accelerated alteplase and reteplase with intravenous heparin are currently the most effective therapies for achieving early coronary reperfusion, but both are substantially more expensive and carry a slightly greater risk of ICH than streptokinase. Thus, the cost-benefit ratio is greatest in patients presenting early after onset of chest pain or symptoms and in those with a large area of injury (eg, anterior infarction) and at low risk of ICH. Other promising thrombolytic agents under investigation are TNK-tPA and lanetoplase, both of which are mutant forms of wild-type tPA and can be given as a single bolus.

Two equivalence trials comparing these agents with the accelerated infusion of alteplase reported preliminary results in March 1999 at the 48th Scientific Sessions of the American College of Cardiology in New Orleans, Louisiana.

Data from the In TIME-II Study showed the single-bolus thrombolytic lanoteplase (nPA) was as effective in reducing the 30-day mortality rate as tPA in patients with AMI. The trial randomly assigned 15,078 patients within 6 hours of symptom onset to receive single-bolus lanoteplase (120,000 U/kg) or front-loaded alteplase (up to 100 mg). The 30-day mortality rate (primary end point) in the nPA and tPA groups was 6.7% and 6.6%, respectively. At 24 hours, mortality was slightly lower with nPA than with tPA (2.39% versus 2.49%). The nPA group had a significantly higher incidence of ICH than the tPA group (1.13% versus 0.62%; P=0.003).

The ASSENT-2 trial reported preliminary results from TNK-tPA, the other novel thrombolytic agent delivered by single bolus (790). Within 6 hours of symptom onset, 16,950 patients with AMI were randomly assigned to weight-adjusted TNK-tPA or accelerated tPA. The 30-day mortality rate was 6.17% in the TNK-tPA group and 6.18% in the accelerated tPA group. The incidence of total stroke was similar (1.78% versus 1.66%) as was hemorrhagic stroke (0.93%).

©1999 by the American College of Cardiology and the American Heart Association, Inc.
versus 0.94%), and mild to moderate bleeding was observed less often in the TNK-tPA group than in the tPA group (26% versus 28.1%; p<0.002). Although the efficacy of these agents appears to be equivalent to tPA, it will be important to carefully assess the adverse event rates when these studies are published.

There is considerable ongoing investigation of the effectiveness of thrombolytic therapy alone compared with the combination of either direct-acting antithrombins or the GP IIb/IIIa receptor antagonists as a means to improve effectiveness over the currently available regimen. In 2 studies that evaluated the combination of hirudin (desirudin) with alteplase and streptokinase, there was no improvement in mortality rate, and the therapeutic-to-severe bleeding profile appeared to be very close (TIMI-9 and GUSTO-IIb trials).

Over the past few years, there has been an increase in the number of patients who undergo primary angioplasty for treatment of AMI in hospitals with tertiary cardiac facilities. This has been driven to a large extent by the observed higher patency in TIMI-3 flow rates associated with coronary angioplasty as well as the desire of cardiologists to assess coronary anatomy and ventricular function early in patient management. Still, however, this represents only a small portion of patients with AMI, and thrombolytic therapy remains the major means of reperfusion.

A number of proposals for selection of thrombolytic regimens after GUSTO have been suggested (96,469-471). Additional considerations include avoiding reuse of streptokinase or anistreplase for at least 2 years (preferably indefinitely) because of a high prevalence of potentially neutralizing antibody titers. Alternatively, Simoons (470) has proposed considering primary PTCA for those at highest risk (about 10% of patients), alteplase for those at moderate to high risk (40%), streptokinase for those at low to moderate risk (40%), and no lytic therapy for those at lowest risk (10%). All of these recommendations await prospective testing.

Current Use Rates for Thrombolytic Therapy

The industry-sponsored National Registry of Myocardial Infarction tracks the use of thrombolytic therapy in the United States and has enrolled 220,171 patients treated at 1,370 US hospitals during its second phase (NRMI 2) from June 1994 through December 1995. Overall, 37.2% received reperfusion therapy (83% thrombolysis, 15.4% primary angioplasty, 1.4% immediate CABG) (written communication, W. J. Rogers, June 1996). Among a subset of patients presenting with ST elevation or LBBB within 12 hours of symptom onset (n=64,211), the use of reperfusion therapy was 70%, with 8.2% of the cohort receiving primary PTCA.472

Because many patients have contraindications or other exclusions for fibrinolytic agents, it has been difficult to ascertain the proportion of patients with ST elevation who fail to receive fibrinolytic therapy that actually should have received such therapy (472). Critical to any such assessment of appropriateness of care, however, is whether the diagnosis of AMI was suspected on entry into the healthcare system or was an "outcomes" diagnosis made after 12 to 24 hours in the hospital or some time before hospital discharge. Experience to date suggests that in patients
<65 years old, overall usage of thrombolytic therapy ranges between 40% and 50% (as high as 70% to 75% for patients with ST-elevation MI). In those older than 65, the overall use rate is below 20% and should be higher. Some increase in use rates probably can be achieved, but contraindications prohibit a vast increase in use rates.

The industry-sponsored NRMI tracks the use of thrombolytic therapy in the United States and has enrolled 330,928 patients treated at 1470 US hospitals during its second phase (NRMI-2) from June 1994 through July 1996. Barron et al (789) recently reported an analysis of this database, attempting to determine what proportion of patients with an MI who are eligible for reperfusion therapy do not receive this proven treatment. Barron used a conservative definition of thrombolytic eligibility (diagnostic changes on ECG or LBBB ≤ 6 hours after onset of symptoms and no contraindication to thrombolytic therapy indicated); investigators found that 31% of their cohort were eligible for reperfusion therapy; 25% had nondiagnostic initial ECGs; 41% presented >6 hours from onset of symptoms, and 3% had contraindications to thrombolytic therapy.

Of those who were eligible for thrombolytic therapy, 24% did not receive any form of reperfusion therapy (7.5% of all patients). Multivariate analysis revealed that the independent predictors for eligible patients not being given reperfusion therapy were the presence of LBBB, the disappearance of chest pain at the time of presentation, age >75 years, female gender, and various preexisting cardiovascular conditions. Perhaps most disconcerting was the finding that patients with the highest risk of death from AMI were the least likely to receive reperfusion therapy (e.g., patients with a history of congestive heart failure or the presence of LBBB). Both groups had an in-hospital mortality rate of ≈20%, well above the mortality rate of 7.9%, yet the presence of LBBB made it 78% less likely that a patient would receive reperfusion therapy than patients who presented with ST-segment elevation.

Antithrombotics/Anticoagulants
Once fissuring of an atherosclerotic plaque has occurred, whether an epicardial coronary vessel becomes totally occluded, develops a more severe, flow-limiting stenosis, or heals without incident depends to a large extent on the degree to which thrombus propagates in the vessel lumen. As previously discussed, platelet activation and aggregation are crucial elements of the process, but the balance between activation of the coagulation cascade and its inhibition is also critical. The process by which a thrombus is formed is complex, and our understanding of it continues to evolve (473), but much of the therapeutic effort has focused on inhibiting thrombin and thereby preventing conversion of fibrinogen to fibrin. In addition to having a primary role in this initial process of coronary thrombosis, thrombin also is an important platelet activator; activation of platelets by thrombin is not inhibited by aspirin. Another reason that thrombin is considered critical is that active thrombin becomes bound to a developing clot, and as the clot lyses, either pharmacologically or through endogenous means, the "clot-bound" thrombin can convert fibrinogen to fibrin as it is exposed to the circulating blood.

Unfractionated Heparin

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Recommendations

Class I
1. **Patients undergoing percutaneous or surgical revascularization. Comment:** For PTCA, monitoring of activated clotting time (ACT) is recommended, with a goal of 300 to 350 seconds during the procedure.

Class IIa
1. **Intravenously in patients undergoing reperfusion therapy with alteplase.**
   
   **Comment:** The recommended regimen is 70 U/kg as a bolus at initiation of alteplase infusion, then an initial maintenance dose of = 15 U/kg per hour (with a maximum of 4000 U bolus and 1000 U/h infusion for patients weighing >70 kg), adjusted to maintain aPTT at 1.5 to 2.0 times control (50 to 70 seconds) for 48 hours (Table 9).

   Continuation of heparin infusion beyond 48 hours should be restricted in patients at high risk for systemic or venous thromboembolism.

2. **Intravenous UFH or LMWH subcutaneously for patients with non-ST elevation MI.**

3. **Subcutaneously UFH (eg, 7500 U b.i.d.) or LMWH (eg, enoxaparin 1 mg/kg b.i.d.) (7500 U twice daily)** (intravenous heparin is an acceptable alternative) in all patients not treated with thrombolytic therapy who do not have a contraindication to heparin. In patients who are at high risk for systemic emboli (large or anterior MI, AF, previous embolus, or known LV thrombus), intravenous heparin is preferred.

4. **Intravenously in patients treated with nonselective thrombolytic agents** (streptokinase, anistreplase, urokinase) who are at high risk for systemic emboli (large or anterior MI, AF, previous embolus, or known LV thrombus). **Comment:** It is recommended that heparin be withheld for 4-6 hours and that aPTT testing begin at that time. Heparin should be started when aPTT returns to <2 times control (»70 seconds), then infused to keep aPTT 1.5 to 2.0 times control (initial infusion rate about 1000 U/h). After 48 hours, a change to subcutaneous heparin, warfarin, or aspirin alone should be considered.

Class IIb
1. **Patients treated with nonselective thrombolytic agents, not at high risk, subcutaneous heparin, 7500 U to 12500 U twice a day until completely ambulatory.**

Class III
1. **Routine intravenous heparin within 6 hours to patients receiving a nonselective fibrinolytic agent (streptokinase, anistreplase, urokinase) who are not at high risk for systemic embolism.**

Heparin has been available as an anticoagulant for many years; it was initially described in 1916. The pharmacological entity consists of a mixture of molecules with molecular weights varying between 5000 and 20 000, with different-size molecules having different effects on the coagulation system. After forming a complex with antithrombin III (AT-III), the heparin-AT-III complex has the ability to inactivate both thrombin and activated factor X. When a dose of heparin is given, the actual measured effect on coagulation is modulated by a number of factors, including the particular admixture of heparin molecules in the dose, circulating levels of AT-III, availability of platelet factor IV and other plasma proteins that inactivate heparin, and the ability
of heparin to reach thrombin bound to clot. The heparin-AT-III complex is quite large and generally does not appear to be effective against clot-bound thrombin.

In patients who will not be given thrombolytic therapy, there is little evidence about the benefit of heparin in the modern era, in which aspirin, β-adrenoceptor blockers, nitrates, and ACE inhibitors are routinely available. Nevertheless, the best available data emanate from a series of randomized clinical trials performed before the reperfusion era. A systematic overview of these studies demonstrated a 17% reduction in mortality and a 22% reduction in risk of reinfarction with heparin (474). The control groups in these trials were not treated with other therapies, particularly aspirin, that are now considered routine. Notwithstanding, it is primarily these randomized data from an earlier era that support the recommendation to use heparin in patients not treated with thrombolytic therapy.

In patients who are treated with thrombolytic therapy, recommendations for heparin therapy depend on the thrombolytic agent chosen. Streptokinase, anistreplase, and urokinase are nonspecific fibrinolytic agents that produce systemic breakdown of the coagulation system, including depletion of factors V and VIII and massive production of fibrin(ogen) degradation products, themselves anticoagulants. From this perspective, the need for conjunctive systemic anticoagulation with these agents is conceptually less. In comparison, relatively fibrin-specific agents, including alteplase and newer agents such as reteplase, produce a variable effect on the systemic coagulation system, and in many patients very little breakdown of fibrinogen or depletion of coagulation factors is evident (475,476).

More than 60 000 patients were enrolled in the randomized ISIS-3 (463) and GISSI-2/International (477) trials comparing subcutaneous heparin with no routine heparin in conjunction with streptokinase, anistreplase, and alteplase. During the period in which heparin was given, a small reduction in mortality (4 to 5 lives per 1000 treated) was observed in ISIS-3; however, by 30 days the 2 to 3 lives saved per 1000 treated was no longer statistically significant. A small excess rate of hemorrhagic stroke (1 to 2 per 1000 treated patients) was observed together with a larger excess in systemic bleeding (3 to 5 per 1000 patients), although total stroke rate was not significantly increased. In the GUSTO-I trial (228), >20 000 patients treated with streptokinase were randomly assigned to routine intravenous heparin versus routine subcutaneous heparin. No significant differences were observed in death, reinfarction, or nonhemorrhagic stroke rates, while excess rates of systemic bleeding and hemorrhagic strokes (trend) were observed in the intravenous heparin group.

Several angiographic studies have evaluated coronary perfusion as a function of heparin therapy (228,478,479) Two trials have shown more rapid resolution of ST-segment elevation in patients treated with intravenous heparin immediately at the time of streptokinase infusion compared with intravenous heparin started at a later time (478,479). The OSIRIS study, however, showed no difference in perfusion at 24 hours or in clinical outcomes in the 2 groups. In the GUSTO-I angiographic substudy, patients treated with intravenous heparin had an 88% patency rate at 5 to 7 days compared with 72% in patients treated with subcutaneous heparin (P<0.05), although less
reinfarction occurred in the subcutaneous heparin group (3.4% versus 4.0%, \( P < 0.05 \)). A small group of patients were randomly assigned to anistreplase with or without intravenous heparin in the DUCCS-1 study (480), and no differences in clinical end points were observed, other than a higher rate of bleeding in heparin-treated patients. Viewing these studies as a whole, intravenous heparin appears to have no advantage over subcutaneous heparin when used with a nonspecific thrombolytic agent, and the evidence for use of subcutaneous heparin is equivocal (481).

The occurrence of a large, anterior infarction, documentation of thrombus in the left ventricle by echocardiography, history of a previous embolic event, and AF have been associated with a high risk of embolic stroke. Although no randomized trial evidence exists to demonstrate a definite benefit specific to this group, some empirical evidence exists that the risk of systemic emboli in the general population of MI patients can be reduced by early initiation of heparin (482). In the SCATI trial patients were randomly assigned to a 2000 IU bolus of heparin followed by 12500 IU subcutaneously twice a day or to placebo. In the subgroup also treated with streptokinase, aspirin was withheld. In-hospital mortality was 4.6% in the heparin group and 8.8% in the control group, and a reduction in stroke was observed. Therefore, heparin is recommended for these patients at high risk of systemic arterial emboli, regardless of the thrombolytic agent given.

When alteplase is chosen as the thrombolytic agent, the empirical information to confirm the pathophysiological reasoning discussed above is primarily inferential. In a series of angiographic trials (483-485), intravenous heparin has been shown to lead to higher rates of infarct-related artery perfusion in conjunction with alteplase. When aPTT has been evaluated, a direct relation between duration of aPTT and the likelihood of infarct-related artery perfusion has been observed (484,485). A recent overview (486) points out, however, that the effects of intravenous heparin on clinical outcomes from these studies are not as convincing; a significant increase in the rate of bleeding and nonsignificant increases in rates of reinfarction and hemorrhagic and nonhemorrhagic stroke are evident (486). These negative findings are tempered by a point estimate of an 18% reduction in mortality with broad confidence limits. Until the uncertainty is resolved, it seems judicious to use heparin for \( \geq 48 \) hours with alteplase and to target the aPTT to a 50- to 70-second range.

When primary angioplasty is chosen as the route of reperfusion, high-dose heparin therapy is recommended. This recommendation does not come specifically from empirical data in the AMI setting but from general observations in the setting of angioplasty that an ACT of \( \geq 300 \) to 350 seconds is associated with a lower rate of complications than lower ACT values (487,488).

Very recently abciximab, a Fab fragment of humanized monoclonal antibody to the glycoprotein IIb/IIIa receptor on the platelet surface, has been demonstrated to reduce the risk of adverse outcomes significantly, both at 30 days (489) and at 6 months (490) after high-risk percutaneous intervention (489,491). Benefit, however, was accomplished at the price of an increase in major bleeding from 13% to 24%. Abciximab, like experimental IIb/IIIa antagonists, increases the ACT measurement with a given dose of heparin by an average of 35 seconds (491). A recent trial with abciximab compared this agent with placebo in the context of standard heparin dosing in the
placebo group and 2 heparin regimens with abciximab: a weight-adjusted standard dose and a lower dose aimed at achieving an ACT of 150 to 300 seconds during routine as well as high-risk percutaneous procedures (492). The trial was terminated early when an interim analysis showed a combined rate of death and nonfatal MI of 8.1% in the placebo group, 3.6% in the weight-adjusted heparin arm, and 2.6% in the low-dose heparin arm. A trend toward less bleeding in the low-dose heparin arm compared with the placebo arm was also reported. A third trial evaluating abciximab in the treatment of refractory unstable angina also was stopped early because of a 40% reduction in the composite end point of death, MI, or need for repeat revascularization (492,493).

The dose of heparin in the thrombolytic-treated patient remains somewhat controversial. Based on the infarct-related artery perfusion results described above, it would be reasonable to recommend an aPTT value >3-fold higher than the median control value. However, recent information strongly supports a lower aPTT because death, stroke, reinfarction, and bleeding were found to be lowest in the aPTT range of 50 to 75 seconds or =1.5 to 2.0 times the control value (494). Because of the clear evidence that the measured effect of heparin on the aPTT is important for patient outcome and that the predominant variable mediating the effect of a given dose of heparin is weight (494), it is important to administer the initial doses of heparin as a weight-adjusted bolus (481). A 70 U/kg bolus followed by a maintenance infusion of 12 U/kg per hour (with a maximum of 4000 U bolus and 1000 U/h infusion for patients weighing >70 kg) has been useful, although other mitigating factors including age and gender, require careful aPTT measurement and dose adjustment. More recent information for both heparin and the novel antithrombin agent hirudin indicate that when used with thrombolytic therapy, an aPTT goal of 60 to 90 seconds is associated with an unacceptably high rate of ICH (495,496). The current recommendation is an aPTT of 50 to 70 seconds, based on the GUSTO trials, TIMI 9a, and the recently reported TIMI 10B trial (790).

An algorithm for heparin dosing in the setting of thrombolytic therapy or treatment of non-ST-segment elevation is provided in Table 9. It is important to check the aPTT 4 to 6 hours after initiating therapy or changing dose, given the information about increased risk with a high aPTT. Considering the substantial delay in reporting aPTT values in many hospitals, the use of bedside coagulation monitoring (497), if reliably performed, may be helpful.
The previous ACC/AHA guidelines on AMI recommended low-dose subcutaneous heparin (5000 U every 12 hours for 24 to 48 hours) in all MI patients without contraindication who were not otherwise being treated with heparin for another reason. Current recommendations call for 7500 U twice a day (ACCP guidelines) (423). The empirical basis for this recommendation was the demonstration that deep venous thrombosis was reduced from 12% to 4% in an overview of 3 randomized controlled trials (498). Continued adherence to this standard is reasonable, although routine earlier mobilization and use of aspirin may make this treatment unnecessary.

Once heparin has been started, the appropriate duration of therapy is uncertain. Based on the evidence for disruption of the atherosclerotic plaque and the concept that a healed endothelial surface would be salutary, a duration of 3 to 5 days has been standard. The only randomized trial to address this issue found, however, that discontinuation of heparin after 24 hours following thrombolytic therapy with alteplase resulted in no measurable increase in ischemic events (499), although this study did not have adequate power to detect modest differences. A reasonable approach is to use intravenous heparin for 48 hours and then to use heparin according to the clinical characteristics of the patients. Heparin may be discontinued in low-risk patients, given subcutaneously in patients at high risk of systemic embolization, and intravenously in patients at high risk for coronary reocclusion.

Concern is mounting that when heparin is discontinued abruptly, the patient undergoes a high-risk period for recurrent thrombosis (500,501). Despite this concern, no specific policy has been tested to attempt to reduce this clinical "rebound" effect. Several ongoing studies, however, are reducing heparin infusions in a gradual fashion (eg, by one half within 6 hours, then discontinuing over the subsequent 12 hours).

Table 9. Heparin Adjustment Nomogram for Standard Laboratory Reagents With a Mean Control aPTT of 26–36 s

<table>
<thead>
<tr>
<th>aPTT (s)</th>
<th>Bolus Dose (U)</th>
<th>Step Infusion (min)</th>
<th>Rate Change (mL/h)</th>
<th>Repeat aPTT</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>3000</td>
<td>0</td>
<td>+2</td>
<td>6 h</td>
</tr>
<tr>
<td>40–49</td>
<td>0</td>
<td>0</td>
<td>+1</td>
<td>6 h</td>
</tr>
<tr>
<td>50–75</td>
<td>0</td>
<td>0</td>
<td>0 (no change)</td>
<td>Next AM</td>
</tr>
<tr>
<td>76–85</td>
<td>0</td>
<td>0</td>
<td>−1</td>
<td>Next AM</td>
</tr>
<tr>
<td>86–100</td>
<td>0</td>
<td>30</td>
<td>−2</td>
<td>6 h</td>
</tr>
<tr>
<td>101–150</td>
<td>0</td>
<td>60</td>
<td>−3</td>
<td>6 h</td>
</tr>
<tr>
<td>&gt;150</td>
<td>0</td>
<td>60</td>
<td>−6</td>
<td>6 h</td>
</tr>
</tbody>
</table>

aPTT indicates activated partial thromboplastin time. Heparin infusion concentration = 50 U/mL. Target aPTT = 50–70 s. For aPTTs obtained before 12 h after initiation of thrombolytic therapy: 1. Do not discontinue or decrease infusion unless significant bleeding or aPTT >150 s. 2. Adjust infusion upward if aPTT <50 s. For aPTTs obtained ≥12 h after initiation of thrombolytic therapy, use entire nomogram. Deliver bolus, step infusion, and/or change rate of infusion based on aPTT, as noted on appropriate line of nomogram. Adapted with permission from Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Pillar L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108:2585-275S.
Platelet counts should be monitored daily in patients on heparin. Recent evidence suggests the incidence of heparin-induced thrombocytopenia is 3% and is associated with a substantial risk of prothrombotic events (502). If the platelet count drops below 100 000, a test for heparin-induced thrombocytopenia should be obtained, and the clinician should be vigilant for thrombotic complications as the prognosis in patients with thrombocytopenia is substantially worse (503).

The deficiencies of heparin as an antithrombotic agent have been discussed in detail (504). Fractionated heparins have been developed with variable effects on inhibition of thrombin and factor Xa. Although UFH and LMWH both catalyze the inhibition of thrombin by AT-III at clinically administered doses, the higher ratio of anti-Xa:anti--IIa activity of LMWHs offers the potential advantage of inhibiting the coagulation cascade at a more proximal step, leading to reduction in the generation of thrombin (505). The addition of a low molecular weight heparin preparation to a regimen of aspirin, b-adrenoceptor blockers, and nitrates in patients with unstable angina/non Q wave MI is superior to placebo for reducing the risk of death and nonfatal MI in hospital, 506 although this effect was lessened in longer-term follow up. Some evidence exists that subcutaneous administration of a low molecular weight heparin appears to be superior to infusion of unfractionated heparin for reducing episodes of recurrent ischemia in patients with unstable angina. 507 These agents are superior in many forms of venous thrombosis, 508 but their relative value in coronary arterial thrombosis has not been established.

**Low Molecular Weight Heparins**

LMWH preparations are formed by controlled enzymatic or chemical depolymerization-producing saccharide chains of varying length but with a mean molecular weight of \( \approx 5000 \) (835). A critical chain length of 18 saccharides is required to form the ternary complex consisting of a heparin fragment, antithrombin, and thrombin. In addition to the critical pentasaccharide sequence discussed above and required for attachment of a heparin fragment to antithrombin, an additional 13 saccharide residues are necessary to allow the heparin fragment to simultaneously attach to the heparin-binding domain of thrombin and create the ternary complex (836). Creation of short-chain or LMWH fragments <18 saccharides in length retain the critical pentasaccharide sequence but are of insufficient length to permit attachment to the heparin-binding domain of thrombin, and therefore thrombin is not inhibited by such short-chain fragments. However, only the critical pentasaccharide sequence is required for binding to antithrombin and inhibition of factor Xa. Thus, through the creation of a mixture of short- and long-chain heparin fragments, preparations of varying antiXa:antiIIa activity may be developed. Additional features of LMWHs of particular clinical relevance are a decreased sensitivity to platelet factor IV, a more stable, reliable anticoagulant effect, and lower rates of thrombocytopenia and heparin-induced thrombocytopenia syndrome. Thus, LMWHs are clinically attractive because of better bioavailability, ease of administration via the subcutaneous route, and enriched anti-Xa activity (837). Higher anti-Xa activity is important because of the multiplier effect, in which 1 molecule of factor Xa leads to production of many molecules of thrombin.

Gurfinkel and colleagues (507) compared placebo treatment, UFH, and the LMWH nadroparin in 219 patients with unstable angina who were also treated with aspirin. Combination therapy with
aspirin plus nadroparin significantly reduced the number of patients with an adverse end point event (combined death, MI, and recurrent angina) during the study period, from 59% in the aspirin group and 63% in the aspirin-plus-heparin group to 22% in the aspirin-plus-nadroparin group ($P<0.0001$ for comparisons of the nadroparin group with each of the other 2 groups).

The FRISC Trial (506) was designed to determine whether subcutaneous administration of the LMWH dalteparin (Fragmin) would reduce ischemic events during the acute in-hospital period after an episode of unstable angina/non–Q-wave MI. A secondary goal was to determine whether long-term anticoagulation therapy would provide additional benefit compared with anticoagulation restricted only to the acute phase (the first few days after hospitalization) of an acute coronary syndrome. Patients presenting ≤72 hours after onset of unstable angina/non–Q-wave MI were randomly assigned to receive either dalteparin (120 IU/kg subcutaneously twice daily for 6 days followed by daily subcutaneous injections of 7500 IU for an additional 35 to 45 days; $n=746$) or placebo ($n=760$). All patients received aspirin. Compared with the placebo group, dalteparin-treated patients experienced a 63% reduction in death and nonfatal MI at the 6-day evaluation (4.8% in the placebo group compared with 1.8% in the dalteparin group, $P=0.001$). However, with longer-term follow-up, event rates for the 2 groups began to converge, and a nonsignificant trend toward improved outcome was observed in the dalteparin group (10.7% event rate for the placebo group, compared with 8.0% with dalteparin; RR, 0.75; $P=0.07$) by 40 days. By 150 days, there was no significant difference between the 2 groups.

The Fragmin in Unstable Coronary Heart Disease (FRIC) Study (838) compared dalteparin with IV heparin in patients with unstable angina/non–Q-wave MI presenting ≤72 hours after an episode of ischemic chest pain. During the acute phase (the first 6 days after hospitalization), patients received either subcutaneous dalteparin twice daily or UFH infused intravenously during the first 48 hours; during the chronic phase, subcutaneous dalteparin or placebo was continued until day 45. All patients received aspirin. Compared with the placebo group, dalteparin-treated patients experienced a 63% reduction in death and nonfatal MI at the 6-day evaluation (4.8% in the placebo group compared with 1.8% in the dalteparin group, $P=0.001$). However, with longer-term follow-up, event rates for the 2 groups began to converge, and a nonsignificant trend toward improved outcome was observed in the dalteparin group (10.7% event rate for the placebo group, compared with 8.0% with dalteparin; RR, 0.75; $P=0.07$) by 40 days. By 150 days, there was no significant difference between the 2 groups.

The Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events (ESSENCE) Study (839) examined the effectiveness of enoxaparin in unstable angina/non–Q-wave MI. In this large, multicenter, double-blind trial, 3171 patients were randomly assigned to receive either twice-daily subcutaneous injections of enoxaparin (1 mg/kg) or continuous intravenous infusion of UFH during the acute period (2 to 8 days) after hospitalization for unstable angina/non–Q-wave MI. The primary end point was a composite of death, MI, or recurrent angina was similar for the UFH and dalteparin groups during the 6-day acute period (7.6% versus 9.3% for the UFH and dalteparin groups, respectively). Similarly, after 45 days, the incidence of death, MI, or recurrent angina was 12.3% for both groups.

The FRISC Trial (506) was designed to determine whether subcutaneous administration of the LMWH dalteparin (Fragmin) would reduce ischemic events during the acute in-hospital period after an episode of unstable angina/non–Q-wave MI. A secondary goal was to determine whether long-term anticoagulation therapy would provide additional benefit compared with anticoagulation restricted only to the acute phase (the first few days after hospitalization) of an acute coronary syndrome. Patients presenting ≤72 hours after onset of unstable angina/non–Q-wave MI were randomly assigned to receive either dalteparin (120 IU/kg subcutaneously twice daily for 6 days followed by daily subcutaneous injections of 7500 IU for an additional 35 to 45 days; $n=746$) or placebo ($n=760$). All patients received aspirin. Compared with the placebo group, dalteparin-treated patients experienced a 63% reduction in death and nonfatal MI at the 6-day evaluation (4.8% in the placebo group compared with 1.8% in the dalteparin group, $P=0.001$). However, with longer-term follow-up, event rates for the 2 groups began to converge, and a nonsignificant trend toward improved outcome was observed in the dalteparin group (10.7% event rate for the placebo group, compared with 8.0% with dalteparin; RR, 0.75; $P=0.07$) by 40 days. By 150 days, there was no significant difference between the 2 groups.

The FRISC Trial (506) was designed to determine whether subcutaneous administration of the LMWH dalteparin (Fragmin) would reduce ischemic events during the acute in-hospital period after an episode of unstable angina/non–Q-wave MI. A secondary goal was to determine whether long-term anticoagulation therapy would provide additional benefit compared with anticoagulation restricted only to the acute phase (the first few days after hospitalization) of an acute coronary syndrome. Patients presenting ≤72 hours after onset of unstable angina/non–Q-wave MI were randomly assigned to receive either dalteparin (120 IU/kg subcutaneously twice daily for 6 days followed by daily subcutaneous injections of 7500 IU for an additional 35 to 45 days; $n=746$) or placebo ($n=760$). All patients received aspirin. Compared with the placebo group, dalteparin-treated patients experienced a 63% reduction in death and nonfatal MI at the 6-day evaluation (4.8% in the placebo group compared with 1.8% in the dalteparin group, $P=0.001$). However, with longer-term follow-up, event rates for the 2 groups began to converge, and a nonsignificant trend toward improved outcome was observed in the dalteparin group (10.7% event rate for the placebo group, compared with 8.0% with dalteparin; RR, 0.75; $P=0.07$) by 40 days. By 150 days, there was no significant difference between the 2 groups.
enoxaparin group and 23.3% of the UFH group ($P=0.016$). Patients treated with enoxaparin were also significantly less likely to require revascularization procedures within 30 days (27.0% versus 32.2%; $P=0.001$). A cost-effectiveness analysis showed that despite a small increase in drug cost ($75 per patient), the lower rate of cardiac catheterization and revascularization procedures led to a savings of $1172 per patient if enoxaparin was used instead of UFH.

Although LMWHs share many pharmacological similarities, they also vary in important respects, and it is important to consider each drug individually rather than as members of a class of interchangeable compounds. The varying effectiveness of these drugs in clinical trials may reflect differing anti-Xa:anti-IIa ratios (835). For example, nadroparin and enoxaparin, both of which have been shown to reduce ischemic events after unstable angina or unstable angina/non–Q-wave MI, have in vitro anti-Xa:anti-IIa ratios between 3 and 4; dalteparin, which appeared to be less effective, has an anti-Xa:anti-IIa ratio of ≈2.2. It is not clear to what extent these pharmacological parameters influence the clinical usefulness of the various LMWHs. However, it is also possible that the lack of sustained effect of LMWH in the FRISC and FRIC trials was due to the long patient-enrollment period after the last episode of qualifying chest pain (72 hours in both studies), in contrast to a 24-hour enrollment period used in most other studies.

TIMI-11A (840) was a dose-finding study to assess the safety and tolerability of 2 enoxaparin doses in patients with unstable angina/non–Q-wave MI. The incidence of major hemorrhage was 6.5% in patients who received 1.25 mg/kg enoxaparin subcutaneously every 12 hours for 2 to 8 days but decreased to 1.9% in patients receiving 1.0 mg/kg every 12 hours.

TIMI-11B enrolled 4020 patients with unstable angina/non–Q-wave MI to compare 2 strategies of antithrombotic therapy: UFH during the acute phase followed by placebo subcutaneous injections during the chronic phase versus uninterrupted therapy with subcutaneous enoxaparin during both the acute and chronic phases (840a). The primary efficacy end point is the occurrence through day 43 of the sum of death/nonfatal MI not present at enrollment or severe recurrent ischemia requiring urgent revascularization. The primary safety end point is the development of major hemorrhage or serious adverse event(s) related to study drug.

Kaplan-Meier curves of the primary end point showed a lower rate of events beginning 8 hours after randomization in the enoxaparin-treated patients. At 48 hours there was a statistically significant 24% relative risk reduction from 7.3% in the UFH group to 5.5% in the enoxaparin group. The superiority of enoxaparin was seen in both patients who were treated with UFH and were outside the target aPTT range and patients who were in the target aPTT range. By 14 days, the rate of death/MI/urgent revascularization was 16.7% in the UFH group and 14.2% in the enoxaparin group, a relative risk reduction of 15% ($P=0.03$). All individual elements of the composite end point were reduced in the enoxaparin group.

After treatment in the acute phase, eligible patients entered the long-term phase. Kaplan-Meier curves continued through day 43 showed maintenance of the initial benefit in favor of enoxaparin but no additional relative decrease in events during long-term treatment with enoxaparin.
compared with placebo.

**Conclusion**

Enoxaparin for the acute management of patients with unstable angina/non–Q-wave MI has been shown to be superior to UFH for reducing death and serious cardiac ischemic events. This superiority is achieved without an increase in the rate of either spontaneous or instrumented major hemorrhage. The initial benefit observed with enoxaparin is sustained through day 43; however, no further relative decrease in events was observed in the chronic phase. There was an increase in the rate of major hemorrhage (both spontaneous and instrumented) with long-term enoxaparin treatment.

**Low-Molecular-Weight Heparins as an Adjunct to Thrombolysis**

Another phase II trial in progress, the Hypertension Audit of Risk Factor Therapy (HART-II) Trial, is comparing enoxaparin with UFH as adjunctive antithrombin therapy for patients receiving a front-loaded tPA regimen for ST-segment elevation MI. The primary end point is TIMI-3 flow 90 minutes after initiation of thrombolytic therapy.

Newer direct antithrombin agents are also in an advanced stage of development. The prototypical direct antithrombin agent hirudin was initially isolated from the saliva of the medicinal leech. Now, synthesized by recombinant technology, this compound has several conceptual advantages: it does not require AT-III for its activity, it is not neutralized by plasma proteins, and it is able to inhibit clot-bound thrombin. Its characteristics also yield a stable aPTT value for a given dose, although its predominant renal excretion leads to unpredictable buildup in patients with significant renal dysfunction. After very promising early phase trials in AMI (509,510) and unstable angina (511), large-scale trials were initiated but had to be reconfigured due to an excess rate of ICH in patients treated with thrombolytic agents (495,496). The GUSTO-IIb study comparing hirudin with heparin in conjunction with standard medical therapy in the management of 12 142 patients with acute coronary syndromes recently reported a 30-day death or MI rate (primary end point) of 8.9% for patients randomly assigned to hirudin treatment versus 9.8% for those randomly assigned to heparin ($P=0.058$) (512). The TIMI 9B trial of 3002 patients receiving either TPA or streptokinase for ST-segment elevation MI reported a 30-day rate of death, MI, or severe CHF of 11.9% in patients randomly assigned to heparin compared with 12.9% in patients assigned to hirudin (512a).

**Antiarrhythmics**

Antiarrhythmic therapy plays an important but more limited role in AMI care than in the past, as summarized in "Hospital Management." The use of anticholinergic therapy with atropine for bradyarrhythmias is summarized in "Hospital Management." This section briefly summarizes antiarrhythmic agents in Vaughan-Williams Classes I through III that are appropriate in the acute setting and can be intravenously administered. Use of agents from Classes II ($\beta$-adrenoceptor blockers) and IV (calcium-channel entry blockers) have several other mechanisms of action (anti-ischemic, antihypertensive, etc), and their use is primarily summarized in subsequent
sections. In general, both acute and long-term antiarrhythmic therapy except with β-adrenoceptor blocking agents is indicated only for life-threatening or severely symptomatic arrhythmias and not for risk reduction in patients with non-life-threatening arrhythmias.

**Lidocaine**

Lidocaine is a local anesthetic with antiarrhythmic properties, grouped in Class Ib based on its relatively rapid onset and offset kinetics of membrane sodium channel blockade. Lidocaine is metabolized in the liver; its volume of distribution and rate of clearance are reduced in heart failure (513). Previous randomized studies have shown that it reduces risk for primary VF in both prehospital and early hospital settings (514,515) Despite this fact, mortality is not reduced; indeed, VF deaths are offset by deaths associated with asystole and electromechanical dissociation (325,516).

Lidocaine is the drug of choice in the setting of AMI when treatment is indicated for premature ventricular complexes, VT, or VF. It is generally well tolerated, except in patients with shock. In the most recent adult ACLS protocol (517) lidocaine is recommended as the first antiarrhythmic agent to be used in cardiac arrest patients with persistent VT/VF despite defibrillation and epinephrine, to prevent recurrence, to control unsustained ventricular ectopy requiring therapy, and to treat wide complex tachycardia of uncertain type (518,519)

Lidocaine is the drug of choice in the setting of AMI when treatment is indicated for premature ventricular complexes, VT, or VF. It is generally well tolerated, except in patients with shock. In the most recent adult ACLS protocol (517) lidocaine is recommended as the first antiarrhythmic agent to be used in cardiac arrest patients with persistent VT/VF despite defibrillation and epinephrine, to prevent recurrence, to control unsustained ventricular ectopy requiring therapy, and to treat wide complex tachycardia of uncertain type (518,519)

Lidocaine is given in an initial bolus of 1.0 to 1.5 mg/kg (75 to 100 mg); additional boluses of 0.5 to 0.75 mg/kg (25 to 50 mg) can be given every 5 to 10 minutes if needed up to a total of 3 mg/kg. This is followed by a maintenance infusion of 1 to 4 mg/min, reduced after 24 hours (to 1 to 2 mg/min) or in the setting of altered metabolism (heart failure, hepatic congestion, etc) and as guided by blood level monitoring.

**Bretylium**

Bretylium is a quaternary ammonium compound with both direct (Class III) and indirect (sympathetic neuronal) actions. Its hemodynamic and electrophysiological profile are biphasic, with initial norepinephrine release from adrenergic nerve endings causing hypertension, tachycardia, shortening of AV nodal refractory periods, and subsequent neuronal blockade leading to hypotension (520); clinical Class III effect (refractory period lengthening) also emerges with some (variable) delay. Experimentally and clinically, bretylium has potent antifibrillatory but weak antiarrhythmic effects.

Clinically, bretylium is used in treatment of resistant VF and hemodynamically unstable VT. It is not a first-line agent but is recommended in the current ACLS protocol after defibrillation, epinephrine, and lidocaine have failed to convert VF (or pulseless VT) or after VF has recurred despite epinephrine and lidocaine. It may be used for VT in patients with a pulse, but only after lidocaine and procainamide have failed.

For VF, bretylium is given as a 5 mg/kg bolus; if VF-related cardiac arrest persists, supplemental doses of 10 mg/kg can be given at 5-minute intervals to a maximum dose of 30 to 35 mg/kg. In
stable VT the loading dose is diluted to 50 mL with 5% dextrose and given over 8 to 10 minutes. Bretylium therapy is maintained with an infusion rate of 1 to 2 mg/min.

**Procainamide**

Procainamide is an antiarrhythmic drug grouped in Class Ia because of its intermediate onset and offset kinetics of membrane sodium channel blockade. Procainamide has local anesthetic properties and mild to moderate hypotensive and negative inotropic potential. Its rate of metabolism to N-acetyl-procainamide (NAPA), which has Class III antiarrhythmic activity, is bimodally distributed in the population (fast, slow acetylators).

Procainamide is indicated for life-threatening ventricular arrhythmias but usually not as the drug of first choice. Procainamide suppresses premature ventricular complexes and recurrent VT and may be used when therapy is required when lidocaine has failed or is contraindicated. It may also be used for wide complex tachycardias of uncertain mechanism, although it also is usually not the drug of first choice in this setting. ACLS guidelines list procainamide as potential therapy for VF and pulseless VT refractory to defibrillation and epinephrine after lidocaine, bretylium, and magnesium have been considered (517).

Intravenous procainamide is initiated with a loading infusion of 10 to 15 mg/kg (500 to 1250 mg), given at a rate of 20 mg/min (ie, over 30 to 60 minutes), followed by a maintenance infusion of 1 to 4 mg/min. In responding patients, therapy may be continued orally as needed.

Procainamide may cause proarrhythmia, including torsades de pointes. Patients with renal insufficiency may develop high levels of NAPA and are at increased risk for development of torsades.

**β-Adrenoceptor Blockers**

β-Adrenoceptor blockers such as propranolol, metoprolol, and atenolol have been shown to reduce incidence of VF in patients with AMI in studies preceding the reperfusion era (521). β-Adrenoceptor blockers also may be of particular value early in the management of "electrical storm" (recurrent, polymorphic VT/VF) in the setting of recent MI, which is often unresponsive to standard antiarrhythmic therapy (331). Additional rationale for β-adrenoceptor blocker use in AMI is provided in the following section.

**Amiodarone**

Amiodarone is a complex antiarrhythmic with action in each of the 4 Vaughn-Williams classes. Its mechanisms of action when given over the short term are still poorly defined but may include (1) noncompetitive β-adrenoceptor blockade, (2) calcium channel blockade, (3) blockade of sympathetic efferents, and (4) possible Class Ia effects (522). Short-term (intravenous) amiodarone, unlike long-term (oral) administration may have little Class III effect. Intravenous amiodarone is now approved for treatment and prophylaxis of frequently recurring VF and hemodynamically destabilizing VT. If successful, therapy can be continued orally over the long term. In randomized studies in VF or destabilizing VT refractory to lidocaine, a dose response
was observed between larger (500 to 1000 mg/d) and small (125 mg/d) doses of amiodarone in
time to first VT/VF recurrence, although not in mortality. Amiodarone also was equally as
effective as bretylium in preventing VT/VF recurrence but was better tolerated (less
hypotension) (523).

Because of individual variability, dosing of intravenous amiodarone should be titrated according
to patient response. The recommended starting dose is 500 mg per 24 hours, given in 3 stages: (1)
rapid infusion of 150 mg over 10 minutes, (2) an early maintenance infusion of 1 mg/min for 6
hours, and (3) later maintenance infusion of 0.50 mg/min. Intravenous amiodarone is reasonably
well tolerated, but adverse effects such as hypotension, bradycardia, and AV block may occur.
With greater experience, amiodarone may become a preferred antiarrhythmic agent for
intravenous therapy of life-threatening ventricular tachyarrhythmias in lidocaine failures.

β-Adrenoceptor Blocking Agents
Recommendations for Early Therapy (see also "Predischarge Preparation")

Class I
1. Patients without a contraindication to β-adrenoceptor blocker therapy who can be
treated within 12 hours of onset of infarction, irrespective of administration of
concomitant thrombolytic therapy or performance of primary angioplasty.
2. Patients with continuing or recurrent ischemic pain.
3. Patients with tachyarrhythmias, such as AF with a rapid ventricular response.
4. Non–ST-elevation MI.

Class II
1. Non-Q wave MI.
2. Patients with moderate LV failure (the presence of bibasilar rales without evidence of
low cardiac output) or other contraindications to β-adrenoceptor blocker therapy,
provided they can be monitored closely.

Class III
1. Patients with moderate to severe LV failure or other contraindications to β-
adrenoceptor blocker therapy.

β-Adrenoceptor blocking agents may be given to patients with AMI to reduce morbidity and/or
mortality during (1) the initial hours of evolving infarction and (2) the weeks, months, and years
after completed infarction (secondary prevention).

During the first few hours of infarction, β-adrenoceptor blocking agents may diminish myocardial
oxygen demand by reducing heart rate, systemic arterial pressure, and myocardial contractility. In
addition, prolongation of diastole caused by a reduction in heart rate may augment perfusion to
injured myocardium, particularly the subendocardium. As a result, immediate β-adrenoceptor
blocker therapy appears to reduce (1) the magnitude of infarction and incidence of associated
complications in subjects not receiving concomitant thrombolytic therapy and (2) the rate of
reinfarction in patients receiving thrombolytic therapy.
In subjects not receiving thrombolytic therapy, intravenously administered β-adrenoceptor blocking agents exert a modestly favorable influence on infarct size (524). More important, they diminish short-term mortality. In the First International Study of Infarct Survival (525), in which >16 000 patients with suspected AMI were enrolled within 12 hours of onset of symptoms, immediate intravenous atenolol, 5 to 10 mg, followed by oral atenolol, 100 mg daily, reduced 7-day mortality from 4.3% to 3.7% (P<0.02; 6 lives saved per 1000 treated). The mortality difference between those receiving and not receiving atenolol was evident by the end of day 1 and was sustained subsequently. In the Metoprolol in Acute Myocardial Infarction (MIAMI) trial (526) >5700 subjects with evolving MI were randomly assigned to receive placebo or metoprolol, up to 15 mg intravenously in 3 divided doses followed by 50 mg orally every 6 hours for 48 hours and then 100 mg twice a day thereafter. Fifteen-day mortality was reduced with metoprolol from 4.9% to 4.3%. As in ISIS-1, the mortality difference between those given placebo and those receiving metoprolol was evident by the end of day 1, after which it was sustained.

In subjects receiving concomitant thrombolytic therapy, intravenously administered β-adrenoceptor blocking drugs diminish the incidence of subsequent nonfatal reinfarction and recurrent ischemia; in addition, they may reduce mortality if given particularly early (ie, within 2 hours) after onset of symptoms. In the TIMI-II trial (107), in which all patients received intravenous alteplase, those randomly assigned to receive intravenous metoprolol, 15 mg, followed by oral metoprolol, 50 mg twice a day for 1 day and then 100 mg twice a day thereafter, had a diminished incidence of subsequent nonfatal reinfarction and recurrent ischemia when compared with those begun on oral metoprolol 6 days after the acute event. Among those treated especially early, ie, within 2 hours of symptom onset, the composite end point, death or reinfarction, occurred less often in those given immediate intravenous metoprolol than in those who did not receive it.

If intravenous β-adrenoceptor blockade induces an untoward effect, such as AV block, excessive bradycardia, or hypotension, the condition is quickly reversed by infusion of a β-adrenergic agonist (ie, isoproterenol, 1 to 5 μg/min). The presence of moderate or severe LV failure early in the course of AMI should preclude the use of early IV β-blockade but is a strong indication for the oral use of β-blockade before discharge.

**Contraindications**
The following are relative contraindications to β-adrenoceptor blocker therapy:

- Heart rate <60 bpm
- Systolic arterial pressure <100 mm Hg
- Moderate or severe LV failure
- Signs of peripheral hypoperfusion
- PR interval >0.24 second
- Second- or third-degree AV block
- Severe chronic obstructive pulmonary disease
- History of asthma
Severe peripheral vascular disease
Insulin-dependent diabetes mellitus

Angiotensin-Converting Enzyme Inhibitors

Recommendations

Class I

1. Patients within the first 24 hours of a suspected AMI with ST-segment elevation in 2 or more anterior precordial leads or with clinical heart failure in the absence of significant hypotension (systolic blood pressure <100 mm Hg) or known contraindications to use of ACE inhibitors.

2. Patients with MI and LV ejection fraction <40% or patients with clinical heart failure on the basis of systolic pump dysfunction during and after convalescence from AMI.

Class IIa

1. All other patients within the first 24 hours of a suspected or established AMI provided significant hypotension or other clear-cut contraindications are absent.

2. Asymptomatic patients with mildly impaired LV function (ejection fraction 40% to 50%) and a history of old MI.

Class IIb

1. Patients who have recently recovered from MI but have normal or mildly abnormal global LV function.

A number of large, randomized clinical trials have assessed the role of ACE inhibitors early in the course of AMI. All trials in which only oral ACE inhibitors were used demonstrated a benefit in mortality. The only trial not showing benefit using ACE inhibitors was the Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS) II, in which patients were randomly assigned within the first day to receive either intravenous enalaprilat or placebo followed by increasing oral dosages of either enalapril or placebo. This trial was terminated early by the Safety Committee because of the high probability that a significant beneficial effect of enalapril over placebo was unlikely to be demonstrated with continuation of the trial, as well as a concern over an adverse effect among elderly patients experiencing an early hypotensive reaction (527). The 95% confidence limits ranged from showing a 7% benefit to 29% harm.

Clarification of the role of ACE inhibitors early in the course of MI has more recently resulted from large-scale clinical trials in which oral ACE inhibitors were used. In the ISIS-4 trial 58 000 patients with suspected AMI were randomly assigned within the first 24 hours (median 8 hours) to receive either oral captopril or placebo; a significant 7% proportional reduction was observed in 5-week mortality among those randomly assigned to captopril (421). The largest benefit was among those with an anterior infarction (528). Among the 143 fewer deaths in the group allocated captopril, 44 occurred in days 0 through 1 and 37 in days 2 through 7 (529), demonstrating that early therapy is important. The GISSI-3 trial used oral lisinopril in >19 000 patients with either ST-segment elevation or depression who were randomly assigned to it or open control (420). There was a significant reduction in 6-week mortality (OR 0.88; 95% CI, 0.79 to 0.99); 60% of
the lives were saved during the first 5 days of treatment. The SMILE (Survival of Myocardial Infarction: Long-Term Evaluation) study involved 1556 patients randomly assigned within 24 hours to receive either placebo or zofenopril (530). The patient population was restricted to those with anterior MI who had not received thrombolytic therapy. Use of an early ACE inhibitor in this trial suggested a strong trend of more lives saved in the first 6 weeks (RR 25%, $P=0.19$). A Chinese captopril pilot study involving $>$13600 patients with suspected AMI also revealed an $\approx 0.5\%$ absolute mortality benefit among those who were randomly assigned to the ACE inhibitor compared with the control population (531). A meta-analysis of these major trials along with 11 smaller trials that involve $>$100 000 patients reveals a 6.5% overall odds reduction ($2P=0.006$) with an absolute benefit of 4.6 fewer deaths per 1000 patients treated among those who received the ACE inhibitor (529). These data suggest that ACE inhibitors have a role in early management as well as in the convalescent phase of AMI.

Although detailed subgroup analysis of the ISIS-4 and GISSI-3 trials awaits further publication, it appears that the benefits of ACE inhibitors are greater among those with an anterior infarct or who have evidence of previous infarction, heart failure, and tachycardia, ie, those at highest risk. Nevertheless, all trials with an oral ACE inhibitor have shown benefit from its early use, including those in which entry criteria included all suspected acute infarctions. Data from these trials indicate that ACE inhibitors should generally be started within the first 24 hours, ideally, after thrombolytic therapy has been completed and blood pressure has stabilized. When there are no patient complications and no evidence of symptomatic or asymptomatic LV dysfunction by 4 to 6 weeks, ACE inhibitors can be stopped. ACE inhibitors should not be used if systolic blood pressure is $<$100 mm Hg, if clinically relevant renal failure is present, if there is a history of bilateral stenosis of the renal arteries, or if there is known allergy to ACE inhibitors. ACE inhibitor therapy should start with low-dose oral administration and increase steadily to achieve a full dose within 24 to 48 hours. For example, in ISIS-4 an initial 6.25 mg dose of captopril was given, followed by 12.5 mg 2 hours later, 25 mg 10 to 12 hours later, and then 50 mg twice a day. GISSI patients received 5 mg oral lisinopril at the time of randomization, 5 mg after 24 hours, 10 mg after 48 hours, then 10 mg daily for 6 weeks or open control. Similar graded-dose schedules should be used with other ACE inhibitors, such as ramipril, zofenopril, enalapril, or quinapril. Intravenous enalaprilat should be avoided.

**Calcium Channel Blockers**

**Recommendations**

**Class I**

None.

**Class IIa**

1. Verapamil or diltiazem may be given to patients in whom $\beta$-adrenoceptor blockers are ineffective or contraindicated (ie, bronchospastic disease) for relief of ongoing ischemia or control of a rapid ventricular response with AF after AMI in the absence of CHF, LV dysfunction, or AV block.

**Class IIb**

1. In non-ST-elevation infarction, diltiazem may be given to patients without LV
dysfunction, pulmonary congestion, or CHF. It may be added to standard therapy after the first 24 hours and continued for 1 year.

**Class III**

1. Nifedipine (short acting) is generally contraindicated in routine treatment of AMI because of its negative inotropic effects and the reflex sympathetic activation, tachycardia, and hypotension associated with its use.

2. Diltiazem and verapamil are contraindicated in patients with AMI and associated LV dysfunction or CHF. **Comment:** Calcium channel blocking agents have not been shown to reduce mortality after AMI, and in certain patients with cardiovascular disease there are data to suggest they are harmful (532). It is the consensus of this committee that these agents are still used too frequently84 in patients with AMI and that β-adrenoceptor blocking agents are a more appropriate choice across a broad spectrum of patients with AMI (with exceptions as noted).

**Nifedipine**

In patients with AMI, immediate-release nifedipine does not reduce incidence of reinfarction or mortality when given early (<24 hours) or late after AMI. This lack of benefit is found in all patients, irrespective of gender, overall risk, type of infarction (Q wave versus non-Q wave), and presence or absence of concomitant β-adrenoceptor blocking agents or thrombolytic therapy. Immediate-release nifedipine may be particularly detrimental in patients with hypotension and/or tachycardia; in these patients it may induce a reduction in coronary perfusion pressure, disproportionate dilatation of the coronary arteries adjacent to the ischemic area (so-called "steal"), and/or reflex activation of the sympathetic nervous system, with an increase in myocardial oxygen demands. These findings are based on numerous clinical trials, including the Nifedipine Angina Myocardial Infarction Study (NAMIS) (533), the Norwegian Nifedipine Multicenter Trial (534), the Trial of Early Nifedipine Treatment in Acute Myocardial Infarction (TRENT) (535), and the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) (536,537). These studies were performed using first-generation nonsustained-release nifedipine. Whether the conclusions are valid for the entire class of agents is unknown (311,532,538).

**Verapamil**

Although the overall results of trials with verapamil showed no mortality benefits, subgroup analysis showed that immediate-release verapamil initiated several days after AMI in patients who were not candidates for a β-adrenoceptor blocking agent may be useful in reducing the incidence of the composite end point of reinfarction and death, provided LV function is well preserved with no clinical evidence of heart failure. Verapamil is detrimental to patients with heart failure or bradyarrhythmias during the first 24 to 48 hours after AMI (539-542). One randomized study of 1700 patients, <75 years of age, using verapamil within 2 weeks of AMI showed a 16.7% reduction in major events (death or MI) over 18 months (543).

**Diltiazem**

Data from the Multicenter Diltiazem Postinfarction Trial (MDPIT) (Q-wave and non-Q-wave infarction) (544) and the Diltiazem Reinfarction Study (DRS) (non-Q-wave infarction) (540,541,545,546) suggest that patients with non-Q-wave MI or those with Q-wave infarction,
preserved LV function, and no evidence of heart failure may benefit from immediate-release diltiazem. Diltiazem was begun in MDPIT 3 to 15 days after AMI and in DRS 24 to 72 hours afterward. The results of MDPIT may be confounded by the fact that 53% and 55% of placebo- and diltiazem-treated patients, respectively, received concomitant β-adrenoceptor blocker therapy (544). Also, both the MDPIT and DRS projects were conducted in an era when the use of aspirin was not as prevalent as it is today, raising further uncertainty about the relevance of their findings for contemporary management of AMI. Of particular clinical importance is the detrimental mortality effect of diltiazem in patients with LV dysfunction.

The INTERCEPT trial (Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post Thrombolysis) (diltiazem) will test the hypothesis that use of sustained-release diltiazem in patients receiving thrombolytic therapy for a first MI will decrease mortality, reinfarction, and angina (547).

**Summary of Calcium Channel Blockers**

Calcium channel blockers have not proven beneficial in early treatment or secondary prevention of AMI, and the possibility of harm has been raised. In patients with first non-Q-wave infarction or first inferior infarction without LV dysfunction or pulmonary congestion, verapamil and diltiazem may reduce the incidence of reinfarction, but their benefit beyond that of β-adrenoceptor blockers and aspirin is unclear. Similarly, there are no data to support the use of second-generation dihydropyridines (eg, amlodipine, felodipine) for improving survival in AMI.

**Magnesium**

**Recommendations**

**Class I**

None.

**Class IIa**

1. Correction of documented magnesium (and/or potassium) deficits, especially in patients receiving diuretics before onset of infarction.

2. Episodes of torsades de pointes-type VT associated with a prolonged QT interval should be treated with 1 to 2 g magnesium administered as a bolus over 5 minutes.

**Class IIb**

1. Magnesium bolus and infusion in high-risk patients such as the elderly and/or those for whom reperfusion therapy is not suitable. **Comment:** The available data suggest that mortality reduction may be seen in high-risk patients, provided magnesium therapy is administered soon after onset of symptoms (preferably <6 hours). The optimum dose has not been established, but a bolus of 2 g over 5 to 15 minutes followed by an infusion of 18 g over 24 hours has been used with success.

**Background**

Supplemental administration of magnesium for reducing morbidity and mortality in patients with AMI is a reasonable avenue to pursue because of abundant data relating magnesium to cardiovascular disease (548). It is the second most abundant intracellular cation and is involved in >300 enzymatic processes. Evidence exists that magnesium produces systemic and coronary
vasodilatation, possesses antiplatelet activity, suppresses automaticity in partially depolarized cells, and protects myocytes against calcium overload under conditions of ischemia by inhibiting calcium influx especially at the time of reperfusion (548-552).

Meta-analyses of the 7 randomized trials published between 1984 and 1991 suggest a significant mortality benefit of magnesium (OR 0.44, CI 0.27 to 0.71) (553,554). The Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) trial (555) subsequently reported a 24% reduction in mortality with magnesium treatment ($P<0.04$). The magnesium-treated patients in LIMIT-2 had a 25% lower incidence of CHF in the CCU and a 21% lower rate of ischemic heart disease-related mortality over 4 years, consistent with the hypothesis that magnesium exerts its beneficial effects, at least in part, via a myocardial protective action (555,556).

The results of 1 large trial were negative. The ISIS-4 investigators enrolled 58 050 patients, 29 011 allocated to magnesium and 29 039 to control. There were 2216 deaths (7.64%) by 35 days in the magnesium group and 2103 deaths (7.24%) in the control group (odds ratio 1.06; CI 0.99 to 1.13), suggesting no mortality benefit of magnesium administration and even the possibility of slight harm (421). When ISIS-4 is added to the preceding randomized trials, meta-analysis indicates no beneficial effect of magnesium. Possible sources of heterogeneity that could explain these differences include:

1. The relatively late administration of magnesium in ISIS-4 (557).
2. The control group mortality in ISIS-4 was only 7.2%.

Regression analyses of the available data predict a null effect of magnesium when the control mortality is about 7% and increasing benefit of magnesium for higher control mortality rates (558).

Shechter and colleagues (559) recently reported a randomized trial of 194 patients with AMI unsuitable for thrombolysis. There was a significant reduction in mortality in the magnesium group (4.2% versus 17.3%, $P<0.01$), largely due to a lower incidence of cardiogenic shock and CHF.

An NHLBI-sponsored trial (Magnesium in Coronary Disease [MAGIC]) is planned to further evaluate the role of magnesium in AMI, especially with early administration before thrombolysis in higher-risk patients (557).

**Inotropic Agents**

It is useful clinically to consider inotropic agents in terms of 3 classes (Table 10): inotropic agents with predominant vasoconstrictive properties; catecholamines with predominant inotropic properties with little or no vasoconstriction; and phosphodiesterase inhibitors, inotropic agents with predominant vasodilating properties.
Table 10. A Classification of Inotropic Agents

<table>
<thead>
<tr>
<th>Agent</th>
<th>Mechanism</th>
<th>Isotopic</th>
<th>Vascular Effect</th>
<th>Major Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoproterenol</td>
<td>β-1 receptor</td>
<td>++</td>
<td>Dilation</td>
<td>Hypotension due to bradycardia; no pacing available</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>β-1 receptor</td>
<td>++</td>
<td>Mild dilation</td>
<td>Low output with SBP &gt; 90 mm Hg</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Low dose dopaminergic receptor</td>
<td>++</td>
<td>Renovascular dilation</td>
<td>Hypotension with SBP &lt; 90 mm Hg or ≥ 30 mm Hg below usual value</td>
</tr>
<tr>
<td>Medium dose β-1 receptor</td>
<td></td>
<td></td>
<td>Constriction</td>
<td></td>
</tr>
<tr>
<td>High dose α receptor</td>
<td></td>
<td></td>
<td>Intense constriction</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>α Receptor</td>
<td>++</td>
<td>Intense constriction</td>
<td>Extreme hypotension despite use of dopamine</td>
</tr>
<tr>
<td>Aminine</td>
<td>Phosphodiesterase inhibitor</td>
<td>++</td>
<td>Dilation</td>
<td>Second-tier agent after failure of dopamine/dobutamine</td>
</tr>
<tr>
<td>Milrinone</td>
<td>Phosphodiesterase inhibitor</td>
<td>++</td>
<td>Dilation</td>
<td></td>
</tr>
<tr>
<td>Digitalis</td>
<td>Inhibits Na⁺/K⁺/ATPase pump</td>
<td>+</td>
<td>Variable</td>
<td>Established systolic LV dysfunction and symptoms of heart failure for chronic therapy</td>
</tr>
</tbody>
</table>

SBP indicates systolic blood pressure; LV, left ventricular.

Vasoconstrictor inotropic agents are represented by dopamine and norepinephrine. Contractility and heart rate are increased by dopamine through its direct stimulation of α- and β-adrenergic receptors and through release of norepinephrine from nerve endings. When given in low doses (1 to 3 μg/kg per minute), its major effects are on dopaminergic receptors leading to renovascular dilatation and on β-adrenoceptors modestly stimulating contractility. At a dose of 5 to 10 μg/kg per minute, the β-1 receptor effects are dominant, leading to an increase in contractility and heart rate. At higher doses the α-receptor effects predominate, leading to vasoconstriction. Norepinephrine is almost purely a vasoconstrictive agent with a positive effect on contractility.

The catecholamine inotropic agents that do not cause vasoconstriction are represented by dobutamine. Through its effects on β-1 receptors, it stimulates contractility; the hope that it would produce less tachycardia and fewer arrhythmias than dopamine has not been realized. Isoproterenol produces increased heart rate and contractility while causing vasodilation; therefore, it is not recommended except as an emergency measure when low output is caused by a profound bradycardia and temporary pacing is not available.

Amrinone and milrinone (phosphodiesterase inhibitors) were developed with the hope that their different mechanism of action would lead to improved cardiac output without the risk of arrhythmia engendered by catecholamines. These agents are characterized by both inotropic and vasodilating effects and with a more substantial effect on preload than catecholamines. Excessive mortality when oral milrinone was given long term and unacceptable toxicity of long-term use of amrinone (560) have dampened enthusiasm for long-term use of these drugs. Renal elimination of phosphodiesterase inhibitors is a problem in critically ill patients.

In a patient with perceived low output, the clinician must simultaneously assess the patient for the possible cause and institute life-saving therapy. If volume depletion is a possible cause, an intravascular volume-expanding infusion should be initiated. When blood pressure is low (systolic < 90 mm Hg or 30 points below usual), dopamine is the agent of first choice. If blood
pressure remains low with institution of >20 μg/kg, norepinephrine may be substituted in doses of 2 to 20 μg/kg per minute. In all other situations dobutamine is the agent of first choice. All intravenous catecholamines have the advantage of a very short half-life, enabling titration of the dose in a matter of minutes while observing the clinical effect.

Phosphodiesterase inhibitors are reserved for patients who have not responded to catecholamines or who have significant arrhythmias or ischemia-producing tachycardia on catecholamine therapy. Milrinone is given in a dose of 0.25 to 0.75 μg/kg per minute. Special caution must be advised in patients with renal dysfunction because the drug will accumulate.

In general the current concept is that patients requiring intravenous inotropic support should be maintained on these agents for as short a time as possible. These agents are arrhythmogenic and increase myocardial oxygen demand. The only available empirical information on mortality effects with long-term use are dismal. Whenever possible, afterload reducing agents and intra-aortic balloon pumping should be substituted for inotropic agents.

**Digitalis**

Despite the initial description of the inotropic properties of digitalis in 1785, its role in the post-MI patient remains controversial. Concern about increased mortality associated with long-term use of milrinone has fueled a reexamination of the empirical information about digitalis from previous observational studies. These studies had mixed results, with some suggesting an increase in mortality and others a neutral effect on mortality (561). Recent studies have demonstrated that in patients with definite systolic LV dysfunction, digitalis improves symptomatic status and has a favorable effect on the neurohormonal system (562,563). The Digitalis Investigator Group (DIG) recently reported a study of 7788 patients in CHF (due to ischemic heart disease in 70% of cases) who were in sinus rhythm. Digoxin was compared with placebo for prevention of all-cause mortality (564). More than 90% of patients were also on ACE inhibitors and/or diuretics. Important secondary objectives included hospitalization for CHF, cardiovascular mortality, and death due to CHF. The overall findings of the trial showed no reduction in total mortality with digoxin. However, there were reductions in deaths due to CHF and combined heart failure-related deaths and hospitalizations in digoxin-treated patients. A trend toward increased deaths due to presumed arrhythmia or MI was observed in the digoxin group. Of note, a recent MI was an exclusion criterion for enrollment in the DIG trial. Thus, the current recommendation, based on previous clinical experience, supports the use of digoxin in selected patients recovering from an MI if they have supraventricular arrhythmias or CHF refractory to ACE inhibitors or diuretics. Generally the loading dose is 8 to 15 μg/kg lean body weight, with half the dose given immediately and the remainder given in 25% increments 6 hours apart. A maintenance dose of 0.125 to 0.375 mg/d is given, based on renal function and lean body weight.
VI. Preparation for Discharge From the Hospital
Noninvasive Evaluation of Low-Risk Patients

Recommendations

Class I
1. Stress ECG
   a. Before discharge for prognostic assessment or functional capacity (submaximal at 4 to 6 days or symptom limited at 10 to 14 days).
   b. Early after discharge for prognostic assessment and functional capacity (14 to 21 days).
   c. Late after discharge (3 to 6 weeks) for functional capacity and prognosis if early stress was submaximal.
2. Exercise, vasodilator stress nuclear scintigraphy, or exercise stress echocardiography when baseline abnormalities of the ECG compromise interpretation.*

Class IIa
1. Dipyridamole or adenosine stress perfusion nuclear scintigraphy or dobutamine echocardiography before discharge for prognostic assessment in patients judged to be unable to exercise.
2. Exercise 2-dimensional echocardiography or nuclear scintigraphy (before or early after discharge for prognostic assessment).

Class III
1. Stress testing within 2 to 3 days of AMI.
2. Either exercise or pharmacological stress testing at any time to evaluate patients with unstable postinfarction angina pectoris.
3. At any time to evaluate patients with AMI who have uncompensated CHF, cardiac arrhythmia, or noncardiac conditions that severely limit their ability to exercise.
4. Before discharge to evaluate patients who have already been selected for cardiac catheterization. In this situation an exercise test may be useful after catheterization to evaluate function or identify ischemia in distribution of a coronary lesion of borderline severity.

*Marked abnormalities in the resting ECG such as LBBB, LV hypertrophy with strain, ventricular pre-excitation, or a ventricular paced rhythm render a displacement of the ST segments virtually uninterpretable. For patients taking digoxin or who have <1 mm ST depression on their resting tracing who undergo standard stress electrocardiographic testing, it must be realized that further ST depression with exercise may have minimal diagnostic significance.

Role of Exercise Testing
The role of exercise testing in evaluating patients after MI has been well established (565) and extensively covered in the earlier ACC/AHA guidelines (1,566,567). The basic aims of early exercise testing after MI are to (1) assess functional capacity and the patient's ability to perform...
tasks at home and at work; (2) evaluate the efficacy of the patient's current medical regimen; and (3) risk-stratify the post-MI patient according to the likelihood of a subsequent cardiac event. Numerous studies reported throughout the 1980s provided particularly important information about risk stratification and the development of practical algorithms for further management of the post-MI patient (568-572). The decade of the 1980s also witnessed a dramatic change in treatment of patients with AMI, characterized most notably by the broad use of thrombolytic therapy beginning in 1988. Equally important has been the widespread use of aspirin, β-adrenoceptor blocking agents, vasodilator therapy, common use of ACE inhibitors, and a far more aggressive use of revascularization therapy in patients who have clinical markers of a poor prognosis. It is this constellation of new therapy and not solely the administration of thrombolytic therapy that marks what is generally referred to as the "reperfusion era."

This period has witnessed an impressive reduction in early and 1-year mortality rates for AMI patients, which is particularly striking in patients who have received thrombolytic therapy and revascularization during hospitalization (573).

The improvement in 1-year mortality in patients who have received thrombolytic therapy is multifactorial. Such patients are less likely to have severe 3-vessel coronary artery disease (574). Patients who receive thrombolytic therapy have a smaller infarct size (575). Coronary angiography is frequently performed during hospitalization due to recurrent chest pain, which identifies many patients with severe disease who subsequently undergo revascularization (576). The patient population eligible for predischarge exercise testing in clinical trials of thrombolytic therapy is therefore far different from less selected, historical populations. Their low cardiac event rate following discharge is therefore not surprising and substantially reduces the predictive accuracy of early exercise testing.

The highest-risk subset of patients are those who are unable to exercise (577,578). Although patients with exercise-induced ST depression have a higher 1-year mortality than patients without exercise-induced depression, their absolute mortality remains low (1.7%) by historical standards (578). The duration of exercise is also known to be an important predictor of outcomes and the ability to perform at least 5 metabolic equivalents (METs) without early exercise ST depression and show a normal rise in systolic blood pressure is important in constituting a negative predictive value (579,580).

There is limited evidence on the ability of exercise testing to risk-stratify patients who have not received reperfusion in the current era. Although their subsequent mortality rates are lower because of the constellation of new therapy mentioned earlier, their absolute event rates are higher than in patients who have received thrombolytic therapy, particularly if they have also not undergone revascularization (573). Although the available evidence is limited, exercise testing presumably can still assist in the risk stratification of such patients.

Low-level exercise testing appears to be safe if patients have undergone in-hospital cardiac rehabilitation, including low-level exercise, have had no symptoms of angina or heart failure, and
have a stable baseline ECG 48 to 72 hours before the exercise test. Two different protocols have been used to determine the end points of these very early exercise tests (581-583).

The traditional submaximal exercise test (done at 3 to 5 days in patients without complications) incorporates a series of end points, including a peak heart rate of 120 to 130 bpm or 70% of maximal predicted heart rate for age, a peak work level of 5 METs, or clinical or ECG end points of mild angina or dyspnea, ST-segment depression >2 mm, exertional hypotension, or ≥3 consecutive premature ventricular contractions, whichever end point is reached first. The second protocol is performance of a symptom-limited exercise test (done at 5 days or later) without stopping for target heart rates or MET levels. Although this level appears to be safe and will result in a higher frequency of abnormal exercise tests, the prognostic value of ST depression occurring at higher work levels in deconditioned patients is uncertain and may lead to unnecessary cardiac catheterization.

The optimum time for performing the exercise test after MI remains unresolved. It is argued that a predischarge exercise test provides psychological benefits to the patient and will permit detection of profound ischemia that could be associated with postdischarge cardiac events that might occur before a scheduled 3- to 6-week postdischarge symptom-limited stress test. On the other hand, deferring exercise testing until ≥3 weeks after MI in clinically low-risk patients appears safe and reasonable and enables more optimal assessment of functional capacity. For patients without complications who have not undergone coronary arteriography before discharge, it is the consensus of this committee that patients who might be potential candidates for revascularization procedures should undergo exercise electrocardiography before or just after discharge.

**Supplemental Imaging**

**Exercise Myocardial Perfusion Imaging**

In a number of reports from a decade ago, before the use of thrombolytic therapy, the prognostic value of exercise myocardial perfusion imaging was found to be superior to that of exercise electrocardiographic testing (584-587). Pharmacological stress perfusion imaging (588-590) was also shown to have value for the prediction of postinfarction cardiac events. The key issues are whether these results apply to current patient populations in the reperfusion era and whether myocardial perfusion imaging is worth the additional cost for risk stratification (591). The same issues outlined previously with respect to exercise electrocardiographic testing also apply to this methodology.

In patients with ST elevation who have received thrombolytic therapy, several studies using myocardial perfusion imaging have found that it is less valuable than previously for risk stratification (592-594), primarily because of the low late cardiac event rate.

In patients in the current era who have not received reperfusion therapy, particularly those who have not undergone revascularization, the same considerations regarding subsequent patient outcome that were outlined above for exercise electrocardiographic testing apply. There is evidence that myocardial perfusion imaging is useful for risk stratification in such patients,
despite their better overall prognosis (595). It seems likely that the previously demonstrated superiority of stress myocardial perfusion imaging probably continues to apply to this population, although there is limited evidence on this point. It must be recognized that prospective studies are difficult to conduct because clinicians frequently intervene in patients with abnormal predischarge stress perfusion imaging studies.

Myocardial perfusion imaging with either thallium 201 (596) or technetium 99m sestamibi (597) can assess infarct size. The measurement of infarct size by either one of these techniques is significantly associated with subsequent patient mortality after thrombolytic therapy (596,597). Data are also emerging to suggest that vasodilator stress nuclear scintigraphy is safe and can be used for early (48 to 72 hours) risk stratification.

Recommended strategies for exercise test evaluations soon after MI are presented in Figure 10.

![Figure 10](image)

**Figure 10.** Strategies for exercise test evaluations soon after myocardial infarction (MI). If patients are at high risk for ischemic events, based on clinical criteria, they should undergo invasive evaluation to determine if they are candidates for coronary revascularization procedures (Strategy I). For patients initially deemed to be at low risk at time of discharge after MI, two strategies for performing exercise testing can be used. One is a symptom-limited test at 14 to 21 days (Strategy II). If the patient is on digoxin or if baseline electrocardiogram precludes accurate interpretation of ST-segment changes (eg, baseline left bundle branch block or left ventricular hypertrophy), then an initial exercise imaging study can be performed. Results of exercise testing should be stratified to determine need for additional invasive or exercise perfusion studies. A third strategy is to perform a submaximal exercise test at 5 to 7 days after MI or just before hospital discharge. The exercise test results could be stratified using the guidelines in Strategy I. If exercise test studies are negative, a second symptom-limited exercise test could be repeated at 3 to 6 weeks for patients undergoing vigorous activity during leisure or at work.
Role of Echocardiography
The widespread availability, portability, and relative cost of echocardiography has resulted in its increased use as a practical and reliable means of assessing both global ventricular function and regional wall motion abnormalities. The uses of echocardiography in AMI are discussed in detail in the ACC/AHA guidelines for clinical application of echocardiography (87a).

Risk Stratification After Myocardial Infarction
The incremental value of exercise echocardiography over regular exercise testing after MI has also not been established. The usefulness of exercise echocardiography as a means of assessing myocardial ischemia in patients with coronary artery disease has been well established, with overall sensitivity of 81% and specificity of 89% (598-603). However, its value in predicting cardiac events after MI has not been fully determined. A negative test is, in general, associated with a low risk of cardiac events and death, but it may be higher than that associated with a negative perfusion scan (604-608). The usefulness of pharmacological stress testing with echocardiography or single-photon emission computed tomography (SPECT) imaging using agents such as dipyridamole or dobutamine in predicting cardiac events after AMI is also a subject undergoing intense investigation. A positive dipyridamole echocardiogram after MI is associated with a higher late mortality rate, but a negative test result does not preclude cardiac events in the 2-year follow-up period (609). There are few data regarding the prognostic value of a positive or negative dobutamine stress echocardiogram, but its safety in general and in the 3 to 5 days after MI (610) is acceptably low. This agent, although widely used for pharmacological stress testing, has not been approved for this purpose by the FDA. Like scintigraphy, there is great variation among institutions in expertise and study quality, and it is this local expertise that should determine the choice of test procedures. Exercise echocardiography generally, however, is a less costly procedure than radionuclide perfusion scintigraphy.

Myocardial Viability
A significant development since the previous set of recommendations is related to understanding and identifying myocardial viability. Up to one third of patients who have significant LV dysfunction may improve with revascularization (611). This usually refers to myocardial hibernation (611), in which chronic low flow state is associated with depressed myocardial function. Myocardial stunning (612) is more germane to the situation after MI, when depressed ventricular function is present despite adequate restoration of blood flow. Function will subsequently improve. The therapeutic importance of myocardial stunning is perhaps less than hibernation because identification of the former does not in general initiate a change in management of revascularization. However, identification of extensive reversible LV dysfunction is of prognostic importance and may help to optimize medical management after MI (610).

Several noninvasive imaging modalities have been established as accurate predictors of myocardial viability. These include thallium imaging, positron emission tomography (PET), and dobutamine echocardiography. The choice of which technique to use should be dependent on center and regional expertise. Positron emission tomography scanning is most sensitive in detecting viable
myocardium, but because of the limitations described above and the expense involved, it has little widespread applicability. Thallium imaging has been well established over time, while dobutamine echocardiography seems to have an acceptably high positive predictive accuracy. More important than technique, however, is the question of whether myocardial viability tests should be used in practice until large-scale outcome data can validate the usefulness.

**Left Ventricular Function**

Assessment of LV function after AMI has been demonstrated to be one of the most accurate predictors of future cardiac events in the risk stratification of patients with AMI in both the prereperfusion and the reperfusion eras (614,615). Multiple techniques for assessing LV function of patients after infarction have been shown to have important prognostic value and include such basic principles as clinical estimates based on patients' symptoms (eg, exertional dyspnea, functional status), physical findings (eg, rales, elevated jugular venous pressure, cardiomegaly, S3 gallop), exercise duration (treadmill time) and measurement of ejection fraction by contrast ventriculography, radionuclide ventriculography, and 2-dimensional echocardiography. Zaret and colleagues (614) found that an LV ejection fraction <30% as assessed by radionuclide ventriculography was still predictive of mortality in patients surviving infarction treated with thrombolytic therapy, despite the significantly reduced mortality of these patients compared with those in the prereperfusion era. White and colleagues (616) performed contrast left ventriculography in 605 patients 1 to 2 months after MI. They found postinfarction LV dilation, demonstrated by increased end-systolic volume >130 mL was an even better predictor of mortality after MI than an LV ejection fraction <40% or increased end-diastolic volume. In patients with normal ejection fractions, however, end-systolic volume did not provide any further stratification according to risk.

**Radionuclide Testing for the Diagnosis of Acute Myocardial Infarction**

Guidelines for cardiac radionuclide imaging have been published recently (567) that indicate the clinical use of radionuclide imaging for diagnosis of AMI should be restricted to special limited situations in which the triad of history, electrocardiographic changes, and laboratory measurements is unavailable or less reliable.

In patients who present late (>24 hours and <7 days) without diagnostic electrocardiographic changes and in patients early after coronary artery bypass surgery, myocardial infarct-avid scintigraphy using 99mTc pyrophosphate has moderate sensitivity and specificity for the diagnosis of AMI (617,618). More recently infarct-avid scintigraphy with antimyosin antibody has been described as an alternative to pyrophosphate scintigraphy (619,620) and has just received FDA approval for use in the United States.

In selected patients with RV infarction, radionuclide imaging may also have a role in diagnosis by demonstrating a reduced RV ejection fraction and RV asynergy (621).

Localized perfusion defects occur in a high percentage of patients with acute LV infarction associated with coronary occlusion (622). However, such perfusion defects do not distinguish...
between acute ischemia, acute infarction, or previous infarction. Serial changes on follow-up perfusion images with either $^{201}$Tl or $^{99m}$Tc sestamibi suggest an acute process but still do not distinguish between ischemia or infarction.

Measurement of Infarct Size

Technetium 99m sestamibi is uniquely suited to accurate measurement of myocardium at risk in clinical infarction. Because there is minimal redistribution of the radiopharmaceutical over time, imaging can be delayed for several hours after injection and still provide accurate information about myocardial perfusion at the time of injection. The validity and feasibility of this approach has been well established in animal and clinical studies (623-626).

As mentioned previously, myocardium at risk is a major determinant of final infarct size. However, final infarct size may be considerably smaller than the initial myocardium at risk, reflecting the effects of reperfusion therapy, spontaneous reperfusion, and collateral blood flow (627) Clinical data have demonstrated the importance of final infarct size as a major determinant of subsequent patient survival and quality of life. Radionuclide techniques are clearly useful for this purpose. In patients who have not received reperfusion therapy, measurement of rest ejection fraction and end-systolic volume index before hospital discharge by equilibrium-gated radionuclide angiography is highly associated with subsequent patient outcome (613,628) In patients who have received reperfusion therapy, the postdischarge rest ejection fraction by equilibrium radionuclide angiography after resolution of myocardial stunning and compensatory hyperkinesia is highly associated with subsequent patient outcome (596,629,630).

Myocardial perfusion imaging with $^{201}$Tl and $^{99m}$Tc sestamibi can also be used to assess infarct size(596,631,632). Most recently $^{99m}$Tc sestamibi has been used with tomographic imaging for this purpose (633,634) Measurement of infarct size with $^{99m}$Tc sestamibi has been closely correlated with other measurements of infarct size, including ejection fraction (635) regional wall motion score (635), creatine kinase release (626), and $^{201}$Tl defect size (632). Two studies have now shown an association between infarct size and patient outcome (596,597). Table 11 summarizes the uses for radionuclide testing in AMI.
Summary of Stress Testing After Acute Myocardial Infarction

It is the consensus of the task force that the current approach to risk stratification of patients after MI requires little change from the recommendations outlined in the original ACC/AHA task force report "Early Management of Patients With Acute Myocardial Infarction." Patients who have clinically declared themselves to be at high risk should have coronary arteriography to identify those who are candidates for revascularization (97). Patients without clinical complications after infarction should have a submaximal exercise stress test before discharge or, alternatively, a symptom-limited stress test 3 weeks after discharge. Patients who can achieve at least 5 METs are treated medically. If there are signs of severe ischemia at a low level of exercise, such as marked ST-segment change or inability to complete stage I, failure to achieve 3 to 4 METs, or if blood pressure falls during exercise, the patient should undergo coronary arteriography.

It must be acknowledged, however, that the positive predictive value of virtually all noninvasive tests has declined as late prognosis improves, particularly those relatively highly selected patients who have received reperfusion therapy. The paradigm for the future will be a new database that examines the benefits, cost-effectiveness, and incremental value of noninvasive tests among lower-risk patients who have received reperfusion therapy.

In patients for whom the resting ECG is uninterpretable because of BBB, major ST-T wave abnormalities, or digitalis therapy, radionuclide myocardial perfusion imaging with exercise or stress echocardiography should be performed, depending on local experience and expertise. In the patient who cannot exercise, pharmacological stress agents can be used with either myocardial perfusion imaging or echocardiography. It is the view of the committee that exercise electrocardiography is a valuable test in assessing prognosis in patients with coronary artery disease. It is generally available, with experienced personnel capable of performing it safely, and it is relatively inexpensive. After uncomplicated MI, patients can be divided into relatively high-
and low-risk groups for subsequent cardiac events if all the information available on the treadmill test is used (Figure 10).

**Ambulatory Electrocardiographic Monitoring for Ischemia**

The value of ambulatory electrocardiographic monitoring in assessing reversible myocardial ischemia and the risk of a subsequent coronary event early after myocardial infarction has been evaluated in a number of studies (636-643). Up to one quarter of patients will show residual ischemia as detected by ambulatory electrocardiographic monitoring. Most episodes of transient myocardial ischemia are silent and occur at rest or during times of low-level physical activity or mental stress (644). During long-term follow-up studies, a number of investigators have reported that the presence of ischemia detected by ambulatory electrocardiographic monitoring in the postinfarction period is predictive of a subsequent poor outcome and increases the risk of cardiac events (636-643). One recent study found that the odds ratio for the patients with, as compared to those without, ambulatory ischemia was 2.3 for death or nonfatal MI at 1 year (643).

Despite the promising initial results with ambulatory electrocardiographic monitoring, the totality of evidence does not support a general statement about its role in all postinfarction patients. Some studies have shown that the results of ambulatory electrocardiographic monitoring could be predicted from exercise test data (638,640), while others have found that additional prognostic information could be obtained by ambulatory electrocardiographic monitoring in postinfarction patients (639). At present a cost-effective strategy has not been developed to identify patients who are at increased risk for ambulatory ischemia and in whom ambulatory electrocardiographic monitoring might be more helpful for stratification into high- and low-risk subgroups for future coronary events.

**Assessment of Ventricular Arrhythmia (Signal-Averaged Electrocardiography, Ambulatory [Holter] Monitoring, Heart Rate Variability)**

**Recommendations for Routine Testing**

**Class I**

None.

**Class IIa**

None.

**Class IIb**

1. Ambulatory (Holter) monitoring, signal-averaged ECG, heart rate variability, baroreflex sensitivity monitoring, alone or in combination with these or other tests, including functional tests (ejection fraction, treadmill testing) for risk assessment after MI, especially in patients at higher perceived risk, when findings might influence management issues, or for clinical research purposes.

The risk of malignant ventricular arrhythmias after hospital discharge is greatest in the first year after AMI (645-649). Recent data suggest that thrombolytic therapy reduces this risk and also confirm that LV dysfunction remains an important, although diminished, predictor of mortality, including sudden death (614,650-653). An open infarct-related artery has emerged as an
important predictor of late outcome in other studies (651). A number of strategies have been used to try to identify patients at high risk for arrhythmic events. Sustained monomorphic VT induced by electrophysiological study is associated with a high arrhythmic event rate (654) but is invasive and has a low specificity. Frequent ventricular premature complexes and higher-grade ventricular ectopy (unsustained VT) on a predischarge Holter monitor also have been associated with a higher mortality among MI survivors, in both the prereperfusion and (less consistently) in the reperfusion eras (645-653).

Recently, newer techniques, including signal-averaged or high-resolution electrocardiography, heart rate variability, and baroreflex sensitivity, have been used to assess patient risk for sudden cardiac death after MI. Signal-averaged electrocardiography identifies delayed, fragmented conduction in the infarct zone in the form of late potentials at the terminus of the QRS complex and represents an anatomic substrate that predisposes the patient to reentrant VT. Kuchar et al (655) reported late potentials to predict an increased incidence of sudden death in the post-MI patient population. Gomes et al (656) found late potentials to be the best single predictor among Holter monitoring and ejection fraction and contributed independently to a combined index, although the positive predictive value of each was poor. The filtered QRS duration was the most predictive feature of signal-averaged electrocardiography in a CAST substudy (657). More recent studies have shown reperfusion therapy to reduce the incidence of late potentials after AMI (658). In the setting of frequent use of thrombolysis, the predictive value of signal-averaged electrocardiography has been variable (650-652).

Heart rate variability, an analysis of the beat-to-beat variation in cycle length, largely reflects the sympathovagal interaction regulating heart rate. Heart rate variability can be quantified in a number of ways, using either time or frequency domain parameters (659). Low heart rate variability, indicative of decreased vagal tone, is a predictor of increased mortality, including sudden death, in patients after MI (659,660) and may add significant prognostic information to other parameters (660). In 1 study decreased heart rate variability was more predictive of arrhythmic events than the presence of late potentials, Holter-derived data, treadmill test results, or ejection fraction; reduced heart rate variability and a late potential by signal-averaged electrocardiography was the strongest combined predictor (652). Standards of measurement, physiological interpretation, and clinical use of heart rate variability have been recently published by a task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (661). The predictive value of heart rate variability after MI, although significant, is modest when used alone. In combination with other techniques its positive predictive accuracy improves. However, the most practical, feasible, and cost-efficient combination of noninvasive predictive tests with heart rate variability remains to be determined.

Baroreceptor sensitivity also quantifies the influence of parasympathetic tone on the heart. Baroreceptor sensitivity is measured as the slope of a regression line relating beat-to-beat heart rate change in response to a change in blood pressure, often accomplished by giving a small bolus of phenylephrine (662). AMI-associated reductions in baroreflex sensitivity have been associated
with an increased susceptibility to arrhythmic events and sudden death in experimental models and initial clinical reports (663-665) and are being further characterized in a multicenter prospective post-MI study (Autonomic Tone and Reflexes After Myocardial Infarction [ATRAMI]).

Summary/Conclusions
Although several investigators have reported an increased likelihood of arrhythmic events in patients when ≥1 noninvasive test is abnormal, 2 important caveats prevent these techniques from being recommended for routine clinical practice at present. First, although the negative predictive value of most of these tests taken in isolation is high (generally >90%), the positive predictive value is unacceptably low (<30%). Second, although the positive predictive value of noninvasive testing for future arrhythmic events can be modestly increased by combining several test results, the therapeutic implications of positive findings are unclear. Insufficient data are available to indicate whether general therapies, such as β-adrenoceptor blockade, ACE inhibition, and revascularization procedures, or specific interventions, such as treatment with amiodarone or an implantable cardioverter-defibrillator, targeted for high-risk patients identified by a combination of noninvasive tests after MI can more favorably impact mortality (666). Moreover, it is difficult to justify the costs of the routine use of these procedures in the absence of therapeutic guidelines or demonstrated clinical benefits associated with a positive test. Until these issues are resolved, use of these tests cannot be recommended in routine management, although they will continue to be of interest as investigational tools for specific risk-assessment protocols.

Invasive Evaluation
Coronary Angiography and Possible Percutaneous Transluminal Coronary Angioplasty After Myocardial Infarction

Recommendations
Class I
1. Patients with spontaneous episodes of myocardial ischemia or episodes of myocardial ischemia provoked by minimal exertion during recovery from infarction.
2. Before definitive therapy of a mechanical complication of infarction such as acute mitral regurgitation, VSD, pseudoaneurysm, or LV aneurysm.
3. Patients with persistent hemodynamic instability.
Class IIa
1. When MI is suspected to have occurred by a mechanism other than thrombotic occlusion at an atherosclerotic plaque. This would include coronary embolism, certain metabolic or hematological diseases, or coronary artery spasm.
2. Survivors of AMI with depressed LV systolic function (LV ejection fraction ≤40%), CHF, prior revascularization, or malignant ventricular arrhythmias.
3. Survivors of AMI who had clinical heart failure during the acute episode but subsequently demonstrated well-preserved LV function.

**Class IIb**

1. Coronary angiography performed in all patients after infarction to find persistently occluded infarct-related arteries in an attempt to revascularize the artery or identify patients with 3-vessel disease.
2. All patients after a non-Q-wave MI.
3. Recurrent VT or VF or both, despite antiarrhythmic therapy in patients without evidence of ongoing myocardial ischemia.

**Class III**

1. Routine use of coronary angiography and subsequent PTCA of the infarct-related artery within days after receiving thrombolytic therapy.
2. Survivors of MI who are thought not to be candidates for coronary revascularization.

This section discusses indications for coronary angiography and possible angioplasty (PTCA) in patients with AMI. The use of emergency angiography and primary PTCA in evolving AMI is considered separately from use of PTCA as an adjunct to thrombolytic therapy (see "Initial Recognition and Management in the Emergency Department").

**Coronary Angiography in the Survivor of Myocardial Infarction Not Receiving Thrombolytic Therapy**

All survivors of MI who are candidates for revascularization therapy (irrespective of whether they were given thrombolytic therapy) with (1) postinfarction angina, (2) objective evidence of ischemia on stress testing, or (3) noninvasive evidence of LV systolic dysfunction should be considered for coronary angiography, because PTCA or CABG may be considered in these patients if they are found to have significant coronary artery disease.

**Coronary Angiography and Possible Percutaneous Transluminal Coronary Angioplasty After Thrombolytic Therapy**

In the immediate period after intravenous administration of thrombolytic therapy, coronary angiography and PTCA have been proposed (1) to restore antegrade coronary flow in the patient in whom thrombolytic therapy is unsuccessful (*adjuvant* PTCA—a term preferred to "rescue") or (2) to reduce the severity of the residual stenosis of the infarct-related artery in the person in whom thrombolytic therapy is successful.

**Adjuvant Percutaneous Transluminal Coronary Angioplasty**

*Immediately After Failed Thrombolysis*

Intravenous thrombolytic therapy successfully restores antegrade coronary flow in 75% to 90% of patients with AMI (667). In those in whom it is unsuccessful, antegrade coronary flow can usually be restored with PTCA. Several studies have demonstrated the marked beneficial effect of infarct-related artery patency (obtained via endogenous, pharmacological, or mechanical recanalization) on survival in patients with AMI (50,668). Survivors of infarction with a patent
infarct-related artery demonstrated at 90 minutes after treatment have an improved long-term outcome when compared with those with an occluded infarct-related artery, even when LV systolic function is similar (669,670). Therefore, in patients in whom thrombolytic therapy fails to restore antegrade coronary flow, recanalization of the infarct-related artery via PTCA has been advocated to (1) establish early infarct-related artery patency, (2) salvage ischemic (but viable) myocardium, and (3) improve long-term survival. Only 1 relatively small randomized trial (671) has assessed the effects of early (performed immediately after identification of failed thrombolysis) adjuvant PTCA on LV function, subsequent cardiac events, or mortality. The results showed a trend favoring better outcomes in those assigned to adjuvant PTCA, but the high mortality rate associated with failed PTCA in this setting and the lack of statistical power of the study argue against its routine use.

A major problem in adopting a strategy of adjuvant PTCA lies in the limitation of accurate identification of patients in whom thrombolytic therapy has not restored antegrade coronary flow. Unless unsuccessful thrombolysis is recognized and corrected quickly (within 3 to 6 hours of onset of symptoms), salvage of ischemic myocardium is unlikely. Unfortunately, clinical markers of reperfusion, such as relief of ischemic-type chest discomfort, resolution of ST-segment elevation, and reperfusion arrhythmias, have limited predictive value in identifying failure of thrombolysis (672) Immediate catheterization of all patients following thrombolytic therapy to identify those with an occluded infarct-related artery is impractical, costly, and often associated with bleeding complications (673,674).

Even in the patient with documented failure of thrombolysis, it is unknown if adjuvant PTCA should be attempted. First, because extensive myocardial necrosis occurs when coronary occlusion has been present for >3 hours (449), PTCA may not salvage a substantial amount of myocardium, considering the time delay associated with presentation of the patient to the hospital after onset of symptoms, infusion of the thrombolytic agent, recognition of failed thrombolysis, and subsequent initiation of PTCA. Second, adjuvant PTCA fails to reestablish antegrade coronary flow in about 10% of patients, and reocclusion of the infarct-related artery occurs in as many as 20% of the remainder (675). Third, unsuccessful salvage PTCA is associated with a high mortality (237,238). Finally, coronary reperfusion occurs over the subsequent hours in many patients with an infarct-related artery that occluded early after thrombolytic therapy. Although infarct-related artery patency is only 65% to 75% 90 minutes after thrombolytic therapy, it rises to 90% by 24 hours (667). Such "late" reperfusion may improve survival without the risk of invasive procedures coupled with thrombolytic therapy.

Recent nonrandomized and retrospective studies have suggested that mechanical reperfusion of occluded coronary arteries may improve survival in patients with MI and cardiogenic shock (238). Such patients have an in-hospital survival rate ranging from 20% to 50% when treated with intravenous thrombolytic therapy (292). Mechanical restoration of antegrade coronary flow via PTCA can be associated with a hospital survival rate ranging from 40% to 70%. Multicenter, prospective, randomized studies are currently under way to objectively test these promising
Observations.

**Hours to Days After Failed Thrombolysis**

Patency of the infarct-related artery is an important predictor of mortality in survivors of MI (668,669). In comparison with those with a patent infarct-related artery, survivors of infarction with an occluded artery have (1) increased LV dilatation (676), (2) a greater incidence of spontaneous and inducible ventricular arrhythmias (677), and (3) a poorer prognosis (678). In survivors of infarction, infarct-related artery patency may favorably influence LV remodeling and electrical stability even if accomplished at a time when salvage of ischemic myocardium is unlikely (ie, hours to days after unsuccessful thrombolysis). The usefulness of PTCA of a persistently occluded infarct-related artery 7 to 48 hours after symptom onset was assessed in a relatively small number of patients (n=71) in the randomized TAMI-6 Study (679). Angiography 6 months later revealed a high incidence of infarct-related artery patency in those who did not receive PTCA as well as a high incidence of reocclusion in those who did, so that infarct-related artery patency was similar in the 2 groups. Not surprisingly, the 2 groups had similar LV ejection fractions, incidence of reinfarction, hospital readmission, and mortality during follow-up. Although other studies in very small numbers of patients (680) suggested that routine PTCA of occluded infarct-related arteries may improve LV performance, there are no convincing data to support the routine use of adjuvant PTCA within 48 hours of failed thrombolysis.

**Routine Coronary Angiography and Percutaneous Transluminal Coronary Angioplasty After Successful Thrombolytic Therapy**

Recommendations

*Class I*

None.

*Class IIa*

None.

*Class III*

1. **Routine PTCA of the stenotic infarct-related artery immediately after thrombolytic therapy.**

2. **Percutaneous transluminal coronary angioplasty of the stenotic infarct-related artery within 48 hours of receiving a thrombolytic agent in asymptomatic patients without evidence of ischemia.**

Occlusive coronary thrombus and subsequent MI occur when platelets and fibrin aggregate at sites of endothelial injury or atherosclerotic plaque rupture. For several days after successful fibrinolysis, platelet aggregation and thrombus formation may recur at the site of arterial injury and lead to reocclusion, especially if a severe residual stenosis is present. Hence, many physicians perform catheterization on all patients who have received thrombolysis with the intention of performing PTCA if a high-grade residual stenosis is present to prevent reocclusion, reinfarction, and death. This rationale has led to strategies that include performing PTCA immediately (within hours), early (within 48 hours), or late (up to 2 weeks) after thrombolytic therapy. A number of important clinical trials have addressed each of these strategies, and their
findings merit special mention and careful consideration.

**Immediately After Successful Thrombolysis**

Three randomized, prospective trials have examined the efficacy and safety of immediate PTCA after thrombolysis. In the TIMI-IIA study (673) 389 patients received r-TPA, after which they were randomly assigned to immediate (within 2 hours) or delayed (18 to 48 hours) PTCA of the infarct-related artery. Left ventricular function, the primary end point of the study, was similar for the 2 groups at hospital discharge and 6 weeks. The incidence of exercise-induced ischemia was similar for both groups. However, those who underwent immediate PTCA had an increased incidence of major adverse events (death, recurrent infarction, emergency CABG surgery, or transfusion). In the TAMI study (674) 197 patients underwent routine PTCA of a stenotic infarct-related artery immediately (90 minutes) or 7 to 10 days after thrombolytic therapy. Left ventricular ejection fraction at 1 week was similar for the 2 groups, as was incidence of reocclusion. Notably, 18% of the patients required a transfusion of ≥2 units of blood as a result of catheterization. A similar outcome was noted in the European Cooperative Study Group VI trial (681), in which 367 patients who received thrombolytic therapy were randomly assigned to immediate PTCA or conservative management, with cardiac catheterization and PTCA only for those with spontaneous or provokable ischemia. Immediate PTCA did not influence LV ejection fraction or the subsequent incidence of reinfarction. However, those who underwent immediate PTCA had a higher incidence of recurrent ischemia (17% versus 3%), bleeding complications (41% versus 23%), and transfusions (10% versus 4%). The study was prematurely terminated because those who underwent immediate PTCA had a higher early (2-week) mortality (7% versus 3%). At 1 year, the differences in outcome persisted.

Taken together, these trials show no benefit of routine PTCA of the stenotic infarct-related artery immediately after thrombolytic therapy. Such a strategy does not appear to salvage myocardium or prevent reinfarction or death, and those subjected to this approach appear to have an increased incidence of adverse events, including bleeding, recurrent ischemia, emergency CABG, and death.

Recent studies have provided insight into why routine PTCA immediately after thrombolysis may be deleterious. In these patients, vascular complications at the site of previous thrombotic occlusion account for most of the excessive bleeding and transfusion requirements. Furthermore, when PTCA is performed after thrombolytic therapy in a patent vessel with some antegrade flow, there is more extensive hemorrhage into the vessel wall than when either treatment is used alone (682). This may further compromise the lumen of the infarct-related artery and promote rethrombosis and reocclusion.

**Hours to Days After Successful Thrombolysis**

It has been suggested that elective PTCA of the stenotic infarct-related artery hours to days after thrombolysis may allow sufficient time for development of a more stable hemostatic milieu at the site of previous thrombotic occlusion. In this setting PTCA would be safer and more effective in reducing the incidence of reocclusion and improving survival. Two large randomized, prospective
trials have tested this hypothesis, with both concluding that (1) there are fewer complications if PTCA is delayed for several days after thrombolytic therapy, and (2) routine PTCA in the absence of spontaneous or provokable ischemia does not improve LV function or survival. In the British SWIFT (Should We Intervene Following Thrombolysis?) Study (683), 800 patients with AMI who received intravenous anistreplase were randomly assigned to PTCA within 2 to 7 days or to conservative management with catheterization and PTCA only for spontaneous or provokable ischemia. There was no difference between the 2 treatment strategies with regard to LV function, incidence of reinfarction, in-hospital survival, or 1-year survival. The TIMI-IIB trial (107) randomly assigned 3262 patients who had received r-TPA to routine catheterization and PTCA within 18 to 48 hours of thrombolysis or conservative management. At the end of the 6-week follow-up period, the 2 groups had a similar mortality (5.2% versus 4.7%, respectively), incidence of nonfatal reinfarction (6.4% versus 5.8%, respectively), and LV ejection fraction (50% versus 50%, respectively). At 1 and 3 years, survival, anginal class, and frequency of bypass surgery were similar in the 2 groups (684,685). Thus, in unselected patients receiving thrombolytic therapy, PTCA of the stenotic infarct-related artery in the absence of evidence of recurrent ischemia within 48 hours does not appear to be beneficial.

It is noteworthy that only recently have data been presented to support the policy of performing catheterization and subsequent revascularization for patients who do have spontaneous or inducible angina after MI. The Danish Acute Myocardial Infarction (DANAMI) Trial (327) randomly assigned 1008 survivors of a first AMI treated with thrombolytic therapy within 12 hours of onset of symptoms to catheterization and subsequent revascularization or standard medical therapy if they showed evidence of spontaneous or inducible angina. Those who underwent revascularization had less unstable angina and fewer nonfatal MIs during a 2-year period of follow-up compared with those patients randomly assigned to medical treatment only (18% and 5.6% versus 30% and 10.5%, respectively).

**Days to Weeks After Successful Thrombolysis**

Continued clot lysis and remodeling of the infarct-related artery stenosis occurs over the days to weeks after successful thrombolysis, making the underlying residual coronary stenosis more stable and less prone to rethrombosis and reocclusion. Thus, delaying PTCA for days to weeks after thrombolysis might improve survival, even though earlier routine PTCA does not. To date there have not been adequately sized trials to evaluate this treatment strategy. Barbash et al (686) randomly assigned 201 patients treated with tissue plasminogen activator to (1) catheterization and PTCA of suitable lesions, including occluded vessels, >72 hours after admission or (2) conservative management with revascularization only for recurrent ischemia. At 10 months the groups had similar LV function, rates of reinfarction, and mortality.

Ellis et al (687) also assessed late PTCA after thrombolytic therapy. Following intravenous thrombolysis, they randomly assigned 87 asymptomatic patients to PTCA at 4 to 14 days or conservative management. Those with postinfarction angina or ischemia with provocative testing were excluded. Although those having PTCA had less angina at 1 year, there was no difference in

©1999 by the American College of Cardiology and the American Heart Association, Inc.
survival in the 2 groups. Procedure-related infarction occurred in 9.5% of patients, which is similar to that observed when mechanical revascularization is attempted earlier in the postinfarction course (688). In short, these relatively small studies have not suggested that routine PTCA in asymptomatic survivors of AMI is beneficial. It remains to be established whether the more widespread use of IIb/IIIa antiplatelet drugs or intracoronary stents will alter this apparent lack of benefit.

**Periprocedural Myocardial Infarction**

A situation meriting special attention is the occurrence of myocardial necrosis in the setting of revascularization procedures. Early surgical literature indicated that although elevation of CK and CK-MB was common during bypass surgery and generally inconsequential, substantial elevations or the development of Q waves (689) have been associated with increased mortality and morbidity. Similarly, elevations of CK-MB are common after percutaneous revascularization procedures. Initial reports indicated no increase in adverse outcomes in patients with elevations <50 IU/L (690), but subsequent reports have indicated a direct relation between CK-MB elevations and both short- and long-term adverse outcomes with no obvious threshold effect (691,692). A commonsense guideline based on currently available data is to treat patients with an increase in CK-MB >5-fold in the same manner as any other patient with an MI. Patients with elevations <3-fold above the upper limit of normal may be discharged from the hospital in a routine manner, although careful follow-up is indicated because of the higher late event rate. Patients with elevations between 3 and 5 times normal are in an uncertain category; especially when the elevation is associated with clinically apparent abrupt closure or side branch occlusion, careful monitoring and routine care for patients with myocardial necrosis would be a conservative route. This area needs considerable further research to determine if enzyme elevations have different meanings as a function of the device used and whether the currently observed adverse prognosis is due to the enzyme elevation itself or the underlying severity of illness of the patients.

**Secondary Prevention**

**Management of Lipids**

**Recommendations**

**Class I**

1. The AHA Step II diet, which is low in saturated fat and cholesterol (<7% of total calories as saturated fat and <200 mg/d cholesterol), should be instituted in all patients after recovery from AMI.

2. Patients with LDL cholesterol levels >125 mg/dL despite the AHA Step II diet should be placed on drug therapy with the goal of reducing LDL to <100 mg/dL.

3. Patients with normal plasma cholesterol levels who have a high-density lipoprotein (HDL) cholesterol level <35 mg/dL should receive nonpharmacological therapy (eg, exercise) designed to raise it.

**Class IIa**
1. Drug therapy may be added to diet in patients with LDL cholesterol levels <130 mg/dL but >100 mg/dL after an appropriate trial of the AHA Step II diet alone.*

2. Patients with normal total cholesterol levels but HDL cholesterol <35 mg/dL despite dietary and other nonpharmacological therapy may be started on drugs such as niacin to raise HDL levels.

Class IIb
1. Drug therapy using either niacin or gemfibrozil may be added to diet regardless of LDL and HDL levels when triglyceride levels are >400 mg/dL—200 mg/dL.

*HMG CoA reductase drugs produce the greatest lowering of LDL cholesterol. Niacin is less effective in lowering LDL, although it is more effective in raising HDL levels. Resins are rarely sufficiently effective to be used alone, but they may be used to supplement lowering LDL with either niacin or HMG CoA reductase drugs. See reference 693.

Approximately 70% of coronary heart disease deaths and 50% of MIs occur in patients who have previously established coronary artery disease (693). It is estimated that the likelihood of fatal and nonfatal MIs is 4 to 7 times higher in patients with apparent coronary disease. Several years ago an overview of secondary prevention trials using both drugs and diet to lower cholesterol demonstrated an approximate 25% reduction in nonfatal and 14% in fatal MIs (693). Recently the Scandinavian Simvastatin Survival Study (694) reported results in 4444 men and women with coronary heart disease and moderate hypercholesterolemia observed over 5.4 years. Coronary heart disease mortality was reduced by 42% and total mortality by 30% among those receiving simvastatin compared with placebo. It is noteworthy that the relative risk reduction seen in this trial was similar among those with the lowest quartile compared with the highest quartile of serum LDL cholesterol. The Cholesterol and Recurrent events (CARE) trial was a similar study in a population of patients who had recovered from an earlier MI and whose total cholesterol (mean 209 mg/dL) and LDL cholesterol (mean 139 mg/dL) were essentially the same as the average for the general population. In this trial 4159 patients were randomly assigned to either 40 mg of pravastatin a day or placebo. After a median follow-up of 5 years, there was a significant 24% reduction in the primary end point of fatal coronary heart disease and nonfatal confirmed MIs in the pravastatin cohort (695).

Recently, the results of the large Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study have been reported. More than 9000 patients are randomly assigned to either placebo or 40 mg pravastatin daily. The trial was carried out in a group of patients with a prior history of MI or unstable angina. It was stopped prematurely because of the efficacy of pravastatin in reducing major cardiovascular events, including a 24% decrease in coronary heart disease deaths, a 23% decrease in the total mortality rate, and a 20% decrease in stroke. Benefit has also been seen in patients with symptomatic coronary disease who were treated with fluvastatin. In the Lescol in Severe Atherosclerosis (LiSA) Study, patients with symptomatic coronary heart disease and hypercholesterolemia who were given fluvastatin had 71% fewer
cardiac events than those in the placebo group. These results firmly establish the desirability of lowering atherogenic serum lipid levels among patients who have recovered from AMI.

The effect of cholesterol lowering combined with low-intensity oral anticoagulation on late saphenous vein graft status was also recently reported (696). In an angiographic trial attempting to reduce atherosclerosis in saphenous vein grafts, post-coronary bypass graft, aggressive lowering of LDL to <100 mg/dL with lovastatin, 80 mg daily, in addition to a Step I AHA diet, achieved a significant 29% reduction in obstructive changes in the vein grafts at 4 to 5 years. There was no additional effect of low-dose warfarin in achieving further reduction.

Approximately 25% of patients who have recovered from an MI demonstrate normal total cholesterol but a low HDL cholesterol fraction on a lipid profile. Low HDL cholesterol is an independent risk factor for development of coronary artery disease (697), and therefore a rationale exists for attempting to raise HDL cholesterol when it is found to be low in the patient with coronary artery disease. The effect of hypertriglyceridemia is more obscure because in many cases the level varies inversely with HDL cholesterol levels. However, if moderate to severe hypertriglyceridemia exists in a patient with established coronary disease, it is probably desirable to attempt to lower triglycerides.

The National Cholesterol Education Panel II has recommended that a complete blood lipid profile be taken in all patients with established coronary heart disease (698). In the infarct patient, this should be done at the time of admission or no later than the first 24 hours; otherwise, there is a minimum 4-week waiting period after onset of the infarct to allow lipid fractions to stabilize and ensure accuracy. During this interim all patients should be treated with a low-cholesterol, low-saturated fat diet such as the AHA Step II diet. If plasma LDL cholesterol concentrations remain >130 mg/dL, drug therapy should be initiated with the goal of achieving an LDL level <100 mg/dL. The drugs available for accomplishing this include HMG CoA reductase inhibitors, nicotinic acid, and bile acid sequestrants. The use of fibrates in patients with established coronary heart disease should be reserved for patients demonstrating moderate to marked elevations in serum triglycerides as well as low HDL cholesterol. In an adjunct study to the Helsinki Primary Prevention Trial, gemfibrozil given to patients with known or suspected coronary artery disease actually resulted in a trend toward more clinical events than in the control group at the end of 5 years (699).

Rehabilitation programs stressing nonpharmacological interventions have been shown to achieve significant reductions in total cholesterol levels and LDL, with increases in HDL levels (700). Exercise, weight management, dietary modification, stress management, and smoking cessation have all been shown to improve blood lipid levels, even without lipid-lowering medications. Because most programs are multifactorial, it is difficult to ascertain which of the treatments are most effective. There are data, however, that demonstrate that exercise and moderate consumption of alcohol can effectively raise HDL levels (701-703).
According to a policy statement on lipids by the Council on Geriatric Cardiology (personal communication, W. Kannel, March 1996):

Diet and drug treatments available for the correction of lipid abnormalities are as effective in the elderly as in the young. Clinical trials have shown that such treatment can reduce total mortality up to age 70-69 and the rate of recurrent coronary events up to the age 75-69. In addition, up to date, there have been no trials to test the value of lipid control in the prevention of initial coronary events in older persons. Such treatment appears reasonable; however, in those elderly who also have other risk factors such as high blood pressure and diabetes, because their risk of a coronary attack is similar to that of persons who have already survived an attack.

Smoking Cessation

Smoking cessation is essential in patients with AMI. Smoking triggers coronary spasm, reduces the anti-ischemic effects of ß-adrenoceptor blockers, and doubles mortality after AMI (704-706). Smoking cessation reduces rates of reinfarction and death within 1 year of quitting, but one third to one half of patients with AMI relapse within 6 to 12 months (707).

Houston-Miller and Taylor (708) advocate a stepped approach to smoking cessation:

- Provide a firm, unequivocal message to quit smoking.
- Determine if the patient is willing to quit.
- Determine the best quitting method.
- Plan for problems associated with withdrawal.
- Set a quit date.
- Help the patient cope with urges to smoke.
- Provide additional help as needed.
- Follow up by telephone call or visit.

Nicotine gum and patches have been shown to mitigate symptoms of nicotine withdrawal in recovering patients (709). These agents are not recommended during hospitalization due to the sympathomimetic effects of the active ingredient, nicotine. However, the dose of nicotine in gum and patches is significantly lower than that found in cigarettes and may be preferable to cigarette smoking if the patient is experiencing acute withdrawal. Clonidine has been shown to be effective in women but not men (710); the reason for this finding is unclear. Lobeline has not been shown to have any advantage over placebo (711-713) but is again under investigation.

A new drug, bupropion, has been shown to help some smokers quit. Nicotine intake is reinforced by activating the central nervous system to release norepinephrine, dopamine, and other neurotransmitters. Bupropion is a weak inhibitor of the neuronal uptake of neurotransmitters. A study of 615 subjects randomly assigned to take placebo or bupropion achieved good initial quit rates with treatment augmented by brief counseling at baseline, weekly during treatment, and intermittently for up to 1 year (841). Seven weeks of treatment with bupropion was associated with a quit rate of 28.8% (100 mg), 38.6% (150 mg), and 44.2% (300 mg/d); 19.6% of subjects assigned to placebo quit (P<0.001). At 1 year, 12.4% of the placebo group and 19.6% (100 mg), 22.9% (150 mg), and 23.1% (300 mg) of the bupropion group remained abstinent. The drug was well tolerated (37 of 462 [8%] stopped treatment prematurely because of headache, insomnia, or dry mouth), although insufficiently powered to detect an incidence of seizures known to occur.
with related medications. It reduced the weight gain common in smokers who quit. Bupropion appears to be another option for patients who need to quit smoking after AMI.

Long-Term Use of Aspirin
The long-term use of aspirin in the postinfarct patient also results in a significant reduction in subsequent mortality. In 6 randomized, placebo-controlled trials in which patients were randomly selected between 1 week and 7 years after the initial infarct, meta-analysis reveals a reduction in vascular mortality of 13% among those randomly assigned to aspirin with a reduction in nonfatal reinfarction of 31% and nonfatal stroke of 42% (714). Although all of these trials involved the use of aspirin in doses ranging from 300 to 1500 mg/d, a recent trial of patients with chronic stable angina pectoris in which aspirin 75 mg/d was used demonstrated a significant reduction of 34% in the primary end point of nonfatal MI and sudden death (715). This suggests long-term use of aspirin in the postinfarction patient in a dose as low as 75 mg/d can be effective, with the likelihood that side effects can be reduced. Other antiplatelet agents such as sulfinpyrazone and dipyridamole have been used in the postinfarct patient, but there is no evidence from these clinical trials that they were any more efficacious than aspirin alone (716,717). Ticlopidine, an antiplatelet agent that has been effectively used in unstable angina and cerebrovascular disease, has not been studied in major clinical trials involving patients with AMI.

Angiotensin-Converting Enzyme Inhibitors
The use of ACE inhibitors early in the acute phase of MI has been described previously. Angiotensin-converting enzyme inhibitors are also of value in selected patients who have recovered from an acute infarction through their ability to interfere with ventricular remodeling and thus attenuating ventricular dilatation over time. The clinical result is a lessened likelihood for development of CHF and death. In addition, the likelihood of a recurrent MI may also be reduced.

The expression of tissue ACE within the heart probably arises from vascular endothelium. In the setting of myocardial necrosis and fibrosis, relatively high concentrations of ACE can be found in the myocardium compared with normal ventricular myocardium (718). These observations, coupled with experience in both the rat model of MI (719) and large randomized clinical trials (720-722) have established that use of ACE inhibitors begun after a patient has recovered from AMI improves long-term survival, provided the infarct was large and anterior in location and results in significant impairment of LV contractility. Specifically, in the Survival and Ventricular Enlargement (SAVE) trial, patients received captopril at a mean 11 days after onset of infarction, resulting in an approximate 20% reduction in mortality (720). The Acute Infarction Ramipril Efficacy (AIRE) trial, in which patients who had been in clinical heart failure during the first day of their infarct and were then randomly assigned an average of 5 days after onset of infarction to either ramipril or placebo, resulted in an approximate risk reduction of 27% in all-cause mortality (721). Similarly, the Trandolapril Cardiac Evaluation (TRACE) trial, in which patients with LV dysfunction on echocardiogram were randomly assigned to receive either trandolapril or placebo a median 4 days after onset of infarction, demonstrated a 22% reduction in mortality (722).
The Studies of Left Ventricular Dysfunction (SOLVD) trial evaluated the ACE inhibitor enalapril in 4228 asymptomatic patients with LV ejection fraction <35%, 80% of whom had experienced a prior MI (723). However, randomization was carried out considerably later on the average than in the SAVE and AIRE trials. This prevention arm of the SOLVD trial revealed a trend toward improved mortality but not a statistically significant difference (724). On the other hand, SOLVD did demonstrate a significant risk reduction of 20% for the combined end points of death or development of CHF requiring hospitalization.

In secondary analyses of the ACE inhibitor trials, the benefit of treatment appears to be primarily in patients with anterior infarctions or LV ejection fraction <40%. Some rationale exists for the use of these drugs in all patients after MI, based on the observation in the SAVE trial that the likelihood of recurrent MI was reduced by ≈25% in treated patients (670) However, this finding is based on posthoc analysis and is currently being studied in prospective trials. There is also preliminary evidence that patients who express a homozygous deletional form of the ACE gene (dd) have an increased circulating ACE level and are more likely to develop MI than those with the II allele ACE gene (725). This reasoning is also supported by recent observations that myocardial levels of ACE are also higher in patients expressing the dd gene (726).

β-Adrenoceptor Blockers

Recommendations for Long-Term Therapy in Survivors of Myocardial Infarction

Class I

1. All but low-risk patients without a clear contraindication to β-adrenoceptor blocker therapy. Treatment should begin within a few days of the event (if not initiated acutely) and continue indefinitely.

Class IIa

1. Low-risk patients without a clear contraindication to β-adrenoceptor blocker therapy.

2. Survivors of non–ST-elevation MI

Class IIb

1. Patients with moderate or severe LV failure or other relative contraindication to β-adrenoceptor blocker therapy, provided they can be monitored closely.

Class III

1. Patients with a contraindication to β-adrenoceptor blocker therapy.

None.

Several placebo-controlled trials, involving a total of >35 000 survivors of MI not receiving thrombolytic therapy, have shown that chronic β-adrenoceptor blocker therapy reduces mortality through a reduction in incidence of sudden and nonsudden cardiac death. Of the available β-adrenoceptor blockers, propranolol (727), timolol (728), and metoprolol (729) have been shown to be efficacious in this regard. For example, in the Norwegian trial of timolol
conducted in the late 1970s in survivors of infarction, mortality was reduced from 9.8% in those given placebo to 7.2% in those receiving timolol, 10 mg twice daily, over an average observation period of 25 months. Interestingly, the beneficial influence of timolol on survival was sustained for ≥6 years after initiation (730). Propranolol, 80 mg 3 times daily, and metoprolol, 100 mg twice daily, reduced mortality by 26% and 36%, respectively, in other studies (727,729).

The salutary effect of long-term β-adrenoceptor blocker therapy is greatest in high-risk patients, ie, those with evidence of large or anterior infarction, and there is continued debate about whether low-risk subjects (ie, those without the following: previous infarction, anterior infarction, advanced age, complex ventricular ectopy, or hemodynamic evidence of LV systolic dysfunction) should be treated with β-adrenoceptor blockers because their long-term prognosis is extremely favorable irrespective of such therapy. Although adverse effects of β-adrenoceptor blockers, such as fatigue, depression, sexual dysfunction, nightmares, and difficulty with recognition of hypoglycemia in diabetics are known to occur, the frequency and severity of these effects are sufficiently low to warrant their use even in low-risk patients. Although no study has determined if long-term β-adrenoceptor blocker therapy should be administered to survivors of MI who subsequently have successfully undergone revascularization, there is no reason to believe that these agents act differently in coronary patients who have undergone revascularization.

Quality Care Alert
Indeed, the data supporting the beneficial effect of the long-term use of β-blocker therapy after AMI is considered so compelling that the Department of Clinical Quality Improvement of the American Medical Association has circulated a document endorsed by the American College of Cardiology, the American Heart Association, the American College of Physicians, the American Academy of Family Practice, and numerous other societies. The document provides a synthesis and consensus for the long-term use of β-blockers after AMI. An expert review panel acknowledged that the data for use of β-blockers after non–ST-segment elevated AMI are limited but generally agreed that the totality of evidence demonstrates the following: use of β-blockers after AMI decreases cardiovascular mortality, decreases reinfarctions, and increases the probability of long-term survival by up to 40%.

Although relative contraindications once may have been thought to preclude the use of β-blockers in some patients, new evidence suggests that the benefits of β-blockers in reducing reinfarctions and mortality may actually outweigh its risks, even in patients with asthma; insulin-dependent diabetes mellitus; chronic obstructive pulmonary disease; severe peripheral vascular disease; PR interval >0.24 second; and moderate LV failure. It is also emphasized that the use of β-blockers in such patients requires careful monitoring of the patient to be certain that adverse events do not occur (842-849).

Antioxidants
Earlier observational data from epidemiological studies suggest that an increased intake of
lipid-soluble antioxidant vitamins (vitamin E and beta carotene) is associated with reduced rates of cardiovascular events, including AMI (731-733). In support of these data, 1 randomized placebo control study of vitamin E treatment in 2002 patients with documented coronary disease indicated a 77% reduction in nonfatal MI but no effect on cardiovascular death or overall mortality (734). However, a mid-study change in the vitamin E dose and some imbalance in the use of β-adrenoceptor blockers in subjects receiving vitamin E make interpretation of that study problematic. A recent prospective cohort study of >34 000 postmenopausal women indicated that an increase in dietary vitamin E but not supplemental vitamin E was associated with decreased cardiovascular risk (735) Regarding beta carotene, several prospective studies have convincingly shown a lack of beneficial effect on cardiovascular disease (736-738), and 2 studies have indicated an increase in lung cancer with beta-carotene treatment (736,737).

There is even less evidence to support the use of water-soluble enzymatic antioxidants for cardiovascular disease. Although 1 study suggested reduced cardiovascular risk in subjects on supplemental vitamin C (739), the majority of other large epidemiological studies have not indicated a benefit (731-733). Thus, routine use of vitamin C cannot be recommended.

Despite promising experimental studies, recombinant superoxide dismutase failed to reduce infarct size in a well-controlled acute PTCA trial (740). One small study showed a trend for reduced restenosis with vitamin E treatment following coronary angioplasty (restenosis rate 35.5% for treatment group versus 47.5% placebo; n=100, \( P=0.06 \)) (741). A larger study evaluating the combination of vitamin E in association with ω-3 fatty acids 2 weeks before elective PTCA showed no impact on the restenosis rate (742).

Thus, there is no convincing evidence to support lipid- or water-soluble antioxidant supplementation in patients after MI or patients with or without established coronary disease. Because these agents are not harmless, the growing practice of recommending antioxidant supplements in these patients should be discouraged until the results of ongoing, well-controlled studies become available and unequivocally indicate a beneficial effect. An extensive review of this subject has been published since these guidelines initially appeared in November 1996 (742a).

### Anticoagulants

#### Recommendations for Long-Term Anticoagulation After Acute Myocardial Infarction

**Class I**

1. For secondary prevention of MI in post-MI patients unable to take daily aspirin.*
2. Post-MI patients in persistent AF.
3. Patients with LV thrombus.

**Class IIa**

1. Post-MI patients with extensive wall motion abnormalities.
2. Patients with paroxysmal AF.

**Class IIb**
1. Post-MI patients with severe LV systolic dysfunction with or without CHF.
*See section III on “Aspirin.”

The indications for long-term anticoagulation after AMI remain controversial. A series of studies comparing warfarin with conventional therapy have demonstrated a reduction in risk of death of 13% and reduction in relative risk of both stroke and reinfarction of 41% (743). The lack of aspirin use in the control groups in these trials has made it difficult to assess the relative merits of aspirin alone versus warfarin alone. Although a cost-effectiveness analysis demonstrates that warfarin compared with standard therapy without aspirin meets the general criteria for cost-effective therapy, the more impressive cost-effectiveness of aspirin (744) makes aspirin alone the current standard antithrombotic regimen for secondary prevention. Although an ample theoretical rationale can be developed for using aspirin and warfarin in combination as a secondary preventive strategy, inadequate empirical information currently exists to recommend it at this time. In a recent report evaluating 160 mg aspirin versus 80 mg aspirin plus 3 mg warfarin versus 80 mg aspirin plus 1 mg warfarin, there was no evidence that combined low-dose aspirin and warfarin reduced subsequent events in 8800 patients after MI. Thromboembolic stroke rates tended to be higher in low-dose warfarin-treated patients as well (745).

The previous ACC/AHA guidelines strongly recommended the use of oral anticoagulants with an International Normalized Ratio (INR) of 2.0 to 3.0 in patients with a ventricular mural thrombus or a large akinetic region of the left ventricle for ≥3 months. Despite a number of small observational studies demonstrating a higher risk of embolic stroke in patients with large anterior infarction and a better outcome in patients treated with warfarin after demonstration of LV mural thrombus by echocardiography (746), randomized controlled trials are not available to support this recommendation. Concern exists that patients at lower risk were treated in the observational studies, so that a firm recommendation based on empirical information cannot be made. Warfarin is indicated in patients with persistent AF after MI, based on results of multiple trials in other patients with AF.

**Calcium Channel Blockers**
Calcium channel blockers are not presently recommended for routine treatment or secondary prevention after AMI. In general, calcium channel blockers should be reserved to treat the subset of patients with angina or hypertension inadequately controlled by other agents. If β-adrenoceptor blockers are contraindicated or poorly tolerated, calcium antagonists that slow heart rate (such as verapamil or diltiazem) may be appropriate as an alternative for secondary prevention in those patients with preserved LV function (230,311,532,538,542,747-755).

**Estrogen Replacement Therapy and Myocardial Infarction**
**Recommendations**

**Class IIa**
4. All postmenopausal patients who have an MI should be carefully counseled about the potential beneficial effects of ERT and offered the option of ERT if they desire it.
1. Hormone replacement therapy (HRT) with estrogen plus progestin for secondary prevention of coronary events should not be given de novo to postmenopausal women after AMI.

2. Postmenopausal women who are already taking HRT with estrogen plus progestin at the time of an AMI can continue this therapy.

The issue of estrogen replacement therapy (ERT) for cardiovascular disease in women is far from clear. Observational studies (756,757) have been interpreted as indicating that oral unopposed estrogen is effective in primary prevention of cardiovascular disease. Confounding factors such as compliance (758) and baseline health in these studies make it difficult to be certain of the effect of ERT.

Recent clinical trials have shown that estrogen given alone or in combination with progestin improves the lipid profile and lowers fibrinogen (759). Favorable effects of estrogen on the lipid profile would, theoretically, be expected to produce a favorable result in preventing coronary atherosclerosis. There is concern that combining estrogen with a progestin (HRT) (760) will ameliorate the potential beneficial effect of estrogen given alone (ERT) on the lipid profile.

In 1993 the American Heart Association and the American Fertility Society sponsored a consensus conference on postmenopausal hormone therapy and the cardiovascular system.761 This conference concluded that the limited data available would indicate that estrogen therapy did reduce mortality in women with moderate and severe coronary disease.

Other factors must be considered in recommending ERT. These include beneficial effects on osteoporosis, sexuality, skin tone, and psychological well-being. These must be weighed against the concern of the possible increase in breast cancer rates, although this is highly controversial.762, 763 A hypothetical population-based analysis by Gorsky et al764 concluded that there was a health benefit of ERT that exceeded any risk.

The first large-scale, randomized, double-blind, placebo-controlled trial that addresses the question of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women was recently published by Hulley et al (791) for the Heart and Estrogen-progestin Replacement Study (HERS) Research Group. Contrary to conventional wisdom and several observational studies (761-764), this trial of 3763 postmenopausal women with established coronary disease and an average age of 66.7 years found no reduction in overall risk for nonfatal MI or coronary death, nor any other cardiovascular outcome, during an average of 4.1 years of follow-up while taking either 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate in 1 tablet daily (n=1380) or placebo (n=1383).

This lack of an overall effect occurred despite a net 11% lower low-density lipoprotein (LDL) cholesterol level and a 10% higher high-density lipoprotein (HDL) cholesterol in the group given hormone therapy compared with the placebo group (P<0.001). There was a statistically significant time trend, however, with more primary coronary events in the hormone therapy group than in the placebo group in year 1 and fewer in years 4 and 5. More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 versus...
This study did not evaluate the cardiovascular effect of treatment with unopposed estrogen, which is commonly used in women who have had a hysterectomy, or other estrogen plus progestin formulations. This study also did not investigate women without coronary disease. Other randomized trials of postmenopausal hormone therapy are likely to answer some of the questions raised by HERS. The Women’s Health Initiative Hormone Replacement Trial (HRT) includes a group of women who have had hysterectomies and received unopposed estrogen as well as women with intact uteruses who receive the same estrogen plus progestin used in HERS. Participants are not required to have coronary heart disease and are generally younger than those in the HERS cohort. The HRT has completed its enrollment of 27,348 women and plans to report the results of the trial in 2005 after 9 years of treatment.

The dose of estrogen for postmenopausal women who have had a hysterectomy is usually 0.625 mg oral conjugated estrogen or its equivalent once a day. In postmenopausal women with a uterus, 2 dosing schedules are commonly used: 0.625 mg conjugated estrogen or its equivalent once a day plus 10 mg progestin (medroxy-progesterone) orally per day for 10 to 14 days each month or 2.5 mg progestin orally every day. Screening procedures for women without a uterus are no different than for the nontreated population. Women who take cyclic progestins and develop bleeding other than at time of withdrawal or women who take continuous progestin and develop either heavy, prolonged, frequent, or intermittent bleeding lasting >10 months after the start of progestin should be evaluated for the bleeding (765).

There is overall uncertainty about the true benefit of ERT after MI in a woman. Therefore, after careful counseling about the risk/benefit issues of HRT, patient preference should be the dominant factor in making any decision. Estrogen replacement therapy is most likely of benefit in both primary and secondary prevention of coronary artery disease.

Antiarrhythmic Agents
Given the risks of traditional (Class I) antiarrhythmic therapy as observed in CAST (2), a study that tested suppressive antiarrhythmic therapy targeted to patients with frequent and complex ventricular ectopy, there is little support at present for the hypothesis that suppression of premature ventricular complexes in post-MI patients will lower mortality. Routine ambulatory (Holter) monitor recordings to identify patients who should receive antiarrhythmic therapy at the time of discharge after an MI is therefore not presently indicated. Amiodarone, a drug with Class
III (as well as Class I, II, and IV action) has shown promise in some but not all post-MI pilot studies (766-768). These potential benefits of empiric therapy with amiodarone after MI were tested recently in 2 moderate-size randomized trials involving post-MI patients at high risk due to LV dysfunction (European Myocardial Infarction Amiodarone Trial [EMIAT]) or ventricular arrhythmias (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial [CAMIAT]). In preliminary reports presented at the 1996 ACC Scientific Session, amiodarone appeared to reduce arrhythmia death and cardiac arrest, but effects on total mortality were not significant. Also, tolerance of long-term amiodarone was poor (40% dropout rate). Thus, amiodarone is safe to use after MI, if necessary for suppression of severe, symptomatic arrhythmias, but β-adrenoceptor blocker therapy is preferred for general prophylaxis.
VII. Long-Term Management

The majority of patients need to modify their lifestyle after AMI. Typical recommendations require a change in previous behavior, including exercise, diet, smoking cessation, stress management, and medication adherence. Achievement of these goals is often complicated by denial of the significance of the event, physical deconditioning that may reflect a lifelong history of sedentary behavior, and emotional distress. Achievement of treatment goals may be facilitated through participation in a formal cardiac rehabilitation program or home rehabilitation if the patient is sufficiently motivated.

Cardiac Rehabilitation

Cardiac rehabilitation combines prescriptive exercise training with education about coronary risk factor modification techniques. Formal rehabilitation programs have been shown to effectively improve functional capacity (769), promote compliance, decrease emotional distress, improve quality of life, reduce cardiovascular mortality (770), mitigate ischemic symptoms (771), promote reversal of atherosclerosis (772), and reduce risk of subsequent coronary events (773). Cardiac rehabilitation may decrease denial, which is known to have a repressive effect and may discourage treatment compliance and recovery after discharge (774).

Despite these benefits, only 15% of qualified patients participate in cardiac rehabilitation, possibly because of lack of physician referral, poor motivation, logistical or financial constraints, or a combination of these factors (775). Home exercise training programs have been shown to be beneficial in certain low-risk patient groups (776). They offer the advantages of convenience and low cost but lack the valuable elements of education and group interaction.

Social integration and social support have been repeatedly shown to influence outcomes after AMI. Social integration refers to existence of social ties (eg, spouse, close family members, or friends) and degree of participation in group activities (eg, family gatherings, religious affiliations). Social support refers to the actual or perceived receipt of information, materials, and/or emotional support.

Mortality from all causes, including ischemic heart disease, is lower in socially integrated individuals (777). Recurrent cardiac events are also significantly lower among persons reporting high levels of social integration when compared with socially isolated persons (778,779).

The most effective social support interventions occur naturally. Family members should be told the importance of their support, including the observation that the need for support has been shown to last longer than most family members realize (780). The quality of the support provided is key; support has been shown to facilitate treatment compliance but only when "policing" is minimized (781). Telephone follow-up, cardiac rehabilitation, or other group events can be effective methods of support for socially isolated individuals (708). Family members should be offered the opportunity to learn CPR because most episodes of cardiac arrest occur ≤18 months after hospital discharge for AMI (187).
Return to Prior Levels of Activity

A significant percentage (14%) of the estimated $56 billion cost to society of coronary artery disease in 1994 was due to lost productivity from temporary or permanent disability (782). Return-to-work rates, which currently range from 63% (783) to 94% (784), are difficult to influence because they are confounded by factors such as job satisfaction, financial stability, and company policies. Return to prior levels of activity is a better outcome indicator than return to paid employment.

The majority of patients who remain asymptomatic after an uncomplicated AMI can very likely return to prior activities safely within 2 weeks, although few data are available to guide this recommendation. In PAMI-II, a study of primary PTCA in low-risk patients with AMI (ie, age <70 years, ejection fraction >45%, 1- or 2-vessel disease, good PTCA result), patients were encouraged to return to work at 2 weeks. The actual timing of return to work was not reported, but no adverse events occurred as a result of this strategy (785). In patients who desire to return to physically demanding activities early, the safety of activity can be determined by comparing performance on a graded exercise test with the MET level required for the desired activity. Table 12 presents energy levels, expressed in METs, required to perform a variety of common activities. This and similar tables can be helpful in translating a patient's performance on a graded exercise test into daily activities that may be undertaken with reasonable safety.
The physician should provide explicit advice about when to return to previous levels of physical activity, sexual activity, and employment. Daily walking can be encouraged immediately (786). In stable patients without complications (Class I), sexual activity with the usual partner can be resumed within 1 week to 10 days. Driving can begin a week after discharge if the patient is judged to be in compliance with individual state laws. Each state’s Department of Motor Vehicles or its equivalent has mandated certain criteria that vary from state to state and must be met before operation of a motor vehicle after serious illness (787). These include such caveats as the need to be accompanied and avoid stressful circumstances such as rush hour, inclement weather, night driving, heavy traffic, and high speeds. Because commercial aircraft are pressurized to only 7500 to 8000 feet (personal communication, Federal Aviation Administration, February 14, 1996), air travel should be undertaken only by stable patients (without a fear of flying) within the first 2 weeks and then only as long as they travel with companions, carry sublingual nitroglycerin, and request airport transportation to avoid rushing.

For patients who have experienced a complicated MI (requiring CPR, accompanied by hypotension, serious arrhythmias, high-degree block, or CHF), driving should be delayed 2 to 3 weeks after symptoms have resolved. Unstable or symptomatic patients or patients with

---

©1999 by the American College of Cardiology and the American Heart Association, Inc.
complications should also be stabilized for ≥2 weeks before commercial air travel because of the lowered oxygen tension experienced above 5000 feet.

Staff

American College of Cardiology
Christine W. McEntee, Executive Vice President
Grace D. Ronan, Associate Director, Document Development & Practice Guidelines
Helene B. Goldstein, MLS, Director, On-Line and Library Services
Gwen C. Pigman, MLS, Assistant Director, On-Line and Library Services

American Heart
Office of Scientific Affairs
Rodman D. Starke, M.D, F.A.C.C.
Kathryn A. Taubert, PhD, Senior Science Consultant

©1999 by the American College of Cardiology and the American Heart Association, Inc.
Updated References


©1999 by the American College of Cardiology and the American Heart Association, Inc.


83. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87:38-52.


113. Brundage BH. Because we can, should we? J Am Coll Cardiol. 1990;15:544-545.


©1999 by the American College of Cardiology and the American Heart Association, Inc.

127. Ellis SG. GUSTO II: primary PTCA versus thrombolysis substudy. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.


186. Dracup K, Moser DK, Guzy PM, Taylor SE, Marsden C. Is cardiopulmonary resuscitation training deleterious for family members of cardiac patients? Am J Public Health. 1994;84:116-118.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


353. Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol. 1995;25(suppl 7):10S-17S.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


492. Lincoff AM. Evaluation of PTCA to improve long-term outcomes by c7E3 glycoprotein IIb/IIIa receptor blockade (EPILOG). Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.

493. Simoons ML. Refractory unstable angina: reduction of events by c-7E3: the CAPTURE Study. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


512. Topol EJ. Global use of strategies to open coronary arteries (GUSTO II): hirudin vs heparin in acute coronary syndromes. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


574. Rogers WJ, Babb JD, Baim DS, et al. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and


©1999 by the American College of Cardiology and the American Heart Association, Inc.


683. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ. 1991;302:555-560.


©1999 by the American College of Cardiology and the American Heart Association, Inc.


696. Domanski MJ, Hunninghake DB, Campeau L. Post CABG trial: effect of cholesterol lowering and low intensity oral anticoagulation on late saphenous vein graft status. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.


745. Fuster V. Low-dose coumadin plus low-dose aspirin following myocardial infarction (CARS Trial). Presented at the American College of Cardiology Scientific Session; March 1996; Orlando, Fla.


1999 Updated ACC/AHA AMI Guideline
(Web Version with changes highlighted)


©1999 by the American College of Cardiology and the American Heart Association, Inc.


807. Yusuf S. Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. JAMA 1997;278:210-211.


810. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb. N


